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Multiple Sclerosis affects around 2 million people worldwide (Kantarci and 
Wingerchuk, 2006; Dutta and Trapp, 2011).  The disease is typified by the destruction 
of the central nervous system neurons’ myelin sheaths, caused by the individual’s own 
immune system (Hauser and Oksenberg, 2006).  This destruction results in the 
inflammation and chronic degeneration of the CNS, causing varying symptoms 
including pain, fatigue, cognitive impairment and paralysis (Costelloe et al., 2008).   
Not only is the life expectancy of individuals with MS 10 years below that of the age-
matched general population (Ragonese et al., 2008), but life quality is often severely 
affected from the start of disease onset (typically around 30 years of age (Hauser and 
Oksenberg, 2006)).  There are several treatments available to aid in the relief of specific 
symptoms; however, the treatment is lifelong which places a burden on healthcare 
services.  Current research looks to expand the available knowledge on the causes of 
MS, to improve preventative measures (such as lifestyle changes to accommodate 
environmental conditions) and targeted treatments (for example, focusing on the 
product of an MS-associated gene variant). 
Of particular interest to MS research are the two population isolates of Orkney and 
Shetland, which together make up the Northern Isles of Scotland.  Shetland has 295 MS 
cases per 100,000 individuals, while Orkney has the highest global prevalence of MS at 
402 cases per 100,000 individuals (Visser et al., 2012).  Orkney, at a lower latitude than 
Shetland, has a significantly higher prevalence than what would be expected.  Multiple 
theories behind the excess of MS cases in Orkney have been investigated, including 
vitamin D deficiency and homozygosity: neither were found to cause the high 
prevalence of MS. It is possible that this excess prevalence may be explained through 
unique genetics.  This thesis sought to better understand these high rates of MS, with 
the aim of passing this knowledge on to the island residents of Orkney and Shetland and 
to contribute the findings to the wider understanding of MS. 
Analyses were conducted using the ORCADES and VIKING datasets.  ORCADES 
contained 2215 individuals from the Orkney islands, including 97 MS cases (some 
recruited because they were cases); VIKING contained 2015 individuals from the 
Shetland islands, including 15 cases.  First, a heritability study was conducted using 
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GCTA to determine the SNP heritability of MS in both Orkney and Shetland and how it 
compared to published estimates of heritability.  The SNP heritability of MS in Orkney 
was estimated at 0.31 (95% CI 0.13, 0.49).  An estimate of SNP heritability for MS in 
Shetland could not be determined due to low case numbers. 
Second, a genome-wide association study was conducted using a combined 
ORCADES/VIKING dataset containing 112 cases and 4223 controls.  The aim of this 
study was to determine if unique common MS risk variants existed in the Northern 
Isles.  Here, 89 SNPs were identified to suggestive significance, mostly within six key 
regions of the genome. Within the literature, only one of these (chromosome 6 SNP 
rs9268154) was associated with Multiple Sclerosis.  Four of the five other regions had 
possible functions within the immune or nervous system.  However, as these did not 
reach genome-wide significance it is likely these results were due to chance; further 
investigation is needed to clarify this. 
Finally, a polygenic risk score study looked at the contribution of common risk variants 
to MS.  The 127 most strongly associated MS SNPs were used to calculate risk scores in 
mainland Scotland, Orkney and Shetland.  These risk scores were compared between 
controls in all three populations to determine if the Northern Isles, by chance, had 
higher frequencies of common risk variants and if this contributed to the excess of 
cases.  These common risk variants explained 3% of variance in MS risk, and had an 
AUC score of 0.69 (95% CI 0.65, 0.74).  However, no difference existed between 
common risk variants in the three populations, aside from one variant: rs9271069, a tag 
SNP for HLA-DRB1*1501.  This SNP was found to have a significantly higher frequency 
in Orkney (RAF = 0.23, p-value = 8 x 10-13) and Shetland (RAF = 0.21, p-value = 2.3 x 
10-6) than mainland Scotland (RAF = 0.17).  This SNP accounted for 6 cases (95% CI 3, 
8) out of 150 observed excess cases per 100,000 individuals in Shetland and 9 cases (95% 
CI 8, 11) of the observed 257 excess cases per 100,000 individuals in Orkney.  
The question of why the Northern Isles have such high rates of MS remains open.  This 
thesis explains a small proportion of this excess. It is hoped that the findings and 
discussions found here will encourage dialogue within the Northern Isles and bring 
awareness to the genetic, environmental and lifestyle factors that contribute to MS 




Multiple Sclerosis is a disease that affects the brain and spinal cord, resulting in pain, 
muscle problems, difficulties with thinking and paralysis.  In a healthy individual, the 
immune system works to protect the body from infections and toxins.  In an individual 
with MS, the body’s immune system attacks itself.  It is not fully understood why this 
happens, although environmental and genetic factors are both thought to influence the 
disease. 
Of particular interest to MS research are the Northern Isles of Scotland, Orkney and 
Shetland.  Orkney has the highest rate of MS in the world, with 402 MS cases per 
100,000 people.  Shetland has a similarly high rate of MS, with 295 MS cases per 
100,000 people.  The number of people affected with MS in the Northern Isles is higher 
than expected. 
So far, studies investigating the rates of MS in the islands have not found the reason for 
the high burden of disease.  This thesis looked to better understand why the rates of MS 
here are so high, and to pass that knowledge on to the island residents of Orkney and 
Shetland and to contribute the findings to the wider understanding of MS. 
First, I looked at how much variation in risk of developing MS was caused by genetics 
(as opposed to the environment).  I found that around one third of differences in the 
risk of developing MS in Orkney was due to differences in genetics between individuals; 
this is similar to previous studies of MS.  This means that although genes are important 
in determining if you are likely to get MS in the Northern Isles, environmental factors 
also play an important role.  I was unable to find an answer to this question for 
Shetland, as there were too few MS cases to answer this question accurately. 
Second, I looked to see if there were any unique genetic variants which exist commonly 
among the populations in the Northern Isles that contributed to MS risk, however it 
does not appear that such a variant is likely to exist.   
Third, I looked at the combined effect of genetic risk variants commonly found in the 
population.  The combination of risk variants each individual has is unique, but it can 
be summarised into a personalised genetic risk score.  When I compared the average 
 xvii 
genetic risk score for people in Orkney and Shetland to the average genetic risk score for 
people in mainland Scotland, I found no difference between the populations. 
Finally, I found the genetic risk variant which has the strongest effect on MS risk is 
more commonly found in the Northern Isles then mainland Scotland.  However, this 
one genetic variant only contributes around 4% to the surplus number of cases that are 
present in the Northern Isles.  This suggests that other factors, either genetic, 
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CHAPTER 1: INTRODUCTION 
1.1 Multiple Sclerosis 
1.1.1 Introduction and Epidemiology 
Multiple Sclerosis (MS) is the most common neurological disability found in young 
adults in the Western world (Tremlett and Rieckmann, 2010).  The disease is 
characterised by the inflammation and chronic degeneration of the central nervous 
system (CNS), a result of the destruction of the myelin sheath surrounding CNS neurons 
by the individual’s immune system (Hauser and Oksenberg, 2006).  There is no 
definitive explanation as to the reason for these immune attacks, with genetic 
susceptibility and environmental factors both contributing to MS risk (Sotgiu et al., 
2004). 
The manifestations of MS’s clinical symptoms are unpredictable (Costelloe et al., 2008).  
As the immune system causes the destruction of the myelin sheath, lesions (or scar 
tissue) form in the damaged regions, interrupting nerve impulses travelling through the 
CNS (Hauser and Oksenberg, 2006).  The location of these regions of damaged myelin 
can result in varying symptoms that are experienced differently in each patient (Miller 
et al., 2008).  The mean age of onset of the disease is 30; within young adults, it is the 
most common reason for diagnosis with a non-traumatic neurological disability 
(Hauser and Oksenberg, 2006).  Although MS has no unique clinical symptoms, some 
symptoms are very distinctive of the disease (Miller et al., 2008).  Among the most 
common are fatigue, vision impairment, poor balance, pain, paralysis and cognitive 
impairment (Miller et al., 2008).  The life expectancy of MS sufferers is also shorter, 
and currently sits at 10 years below the age-matched general population life expectancy 
(Brønnum-Hansen, Koch-Henriksen and Stenager, 2004; Grytten Torkildsen et al., 
2008; Ragonese et al., 2008). 
Symptoms alone cannot be used to diagnose MS; it is essential that evidence of damage 
in at least two distinct regions of the CNS occurring at different time periods is found 
(Polman et al., 2011).  It is also important to rule out other conditions which show 
similar neurological symptoms to MS, for example: CNS infections (also found in Lyme 
disease), CNS inflammatory disorders (systemic lupus erythematosus), structural CNS 
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damage (herniated disc) genetic disorders (hereditary myelopathies), brain tumours 
(lymphoma), deficiencies (copper or vitamin B12) and other non-MS demyelinating 
disorders (neuromyelitis optica) (Magro Checa et al., 2013).  Ruling these conditions 
out requires additional tests above the assessment of a patient’s medical history and 
sensory functions, and magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) 
evaluation and evoked potentials can be used to make a formal diagnosis (Calabresi, 
2004).  MRI scans measure relative water content within tissues; regions in the brain 
where the water-repellent myelin has been degraded hold more water, and so can be 
visibly identified on scans (Polman et al., 2011).  Cerebrospinal fluid, which immerses 
the brain and spinal cord, can be collected via a lumbar puncture and checked for 
elevated IgG antibodies and oligoclonal bands, whose presence indicate an irregular 
immune response (Polman et al., 2011).  Evoked potentials measure brain electrical 
activity in response to stimulation and can identify slower electrical transmission 
caused by demyelination (Polman et al., 2011).  Investigating these criteria in potential 
MS patients often rules out or diagnoses MS (Polman et al., 2011).   
The burden of MS is considerable, with approximately 2 million people worldwide 
affected (Kantarci and Wingerchuk, 2006; Dutta and Trapp, 2011).  In general, 
countries closer to the equator have a lower prevalence of MS, with prevalence 
increasing as you move further north or south away from the equator (Simpson et al., 
2011).  There is a significant association between latitude and MS that persists after 
adjustment for the most strongly associated MS risk allele, HLA-DRB1 (Simpson et al., 
2011), which suggests a strong role of environmental influences that change with 
latitude (Simpson et al., 2011).   
Globally, some of the lowest prevalence rates are found within Africa, where prevalence 
ranges from only occasional cases in sub-Saharan Africa (Poser, 1994) to 10 per 
100,000 in Tunisia (Poser, 1994) and 13 per 100,000 in English-speaking white South 
Africans (Dean, 1967).  A low prevalence of <10 per 100,000 is seen in India, China and 
Japan (Wadia and Bhatia, 1990). 
Higher prevalence rates are found in North America, which has an overall prevalence of 
149 per 100,000 (Dilokthornsakul et al., 2016).  Canada has some of the highest rates of 
MS globally, at 380 per 100,000 (Amankwah et al., 2017). 
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Prevalence in Europe is considerably more varied, with the highest rates found in 
Scotland and Nordic countries (Kingwell et al., 2013).  Scotland has an overall 
prevalence <143 per 100,000 (Kingwell et al., 2013), with island populations such as 
Orkney and Shetland having substantially higher prevalence rates (402 and 295 per 
100,000 respectively) (Visser et al., 2012).  Within the Nordic countries, prevalence is 
typically over 75 per 100,000, with Sweden having the highest prevalence of 253 per 
100,000 (Kingwell et al., 2013). 
In the Southern hemisphere, New Zealand has prevalence rates that range from 23.6 to 
68.5 per 100,000 (Alla et al., 2014), although the indigenous Maori population is lower 
at 24.2 per 100,000 (Taylor et al., 2010).  Australia has a higher prevalence of 95.5 per 
100,000 (Palmer et al., 2013), although this does not include Aboriginal Australians.  A 
2017 study focusing on MS prevalence in Australia failed to identify any Aboriginal 
Australian cases, however they only used data from two out of the 10 Australian 
territories so further research is needed here (McLeod, Hammond and Hallpike, 1994).  
Australia and New Zealand are not the only countries that have groups of individuals 
with significantly different prevalence rates from the general population; there are 
several regions or ethnic groups within countries that have unusually high or low 
prevalence to that expected based on the latitude and prevalence of surrounding 
populations.  For example, although Canada has one of the highest MS prevalence rates 
globally, Native Aboriginals in Manitoba have a prevalence of 40 per 100,000 (Rivera 
and Cabrera, 2001) and First Nations populations in Alberta have a prevalence of 99.9 
per 100,000, lower than the population average (Marrie, Hall and Sadovnick, 2016).  
The Inuit are known to have a much lower prevalence of MS, although no official 
prevalence data has been recorded (Chan, 1977).  The Native Norwegian Sami also have 
a lower than average prevalence of MS of 30 per 100,000 (Lincoln et al., 2009).  
Conversely, populations such as the Italian island of Sardinia have a much higher 
prevalence of MS than expected at 247.6 per 100,000 (Pugliatti, Sotgiu and Rosati, 
2002; Sotgiu et al., 2004).  Within the broadly low-prevalence India, some 
comparatively high pockets of MS prevalence exist: Parsis in Poona, India, who 
migrated to India in the seventeenth century from Persia have prevalence rates of 58 
per 100,000 (Rosati, 2001).  Thus, although MS varies by latitude, the population 
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disparities within regions show that other factors such as genetic differences or 
behavioural-cultural distinctions influence MS risk. 
Woman are more likely than men to develop MS.  The overall incidence rate (the 
number of new cases of MS per year) for MS in Europe, North America, Australia and 
New Zealand is 3.6 and 2.0 cases per 100,000 for women and men respectively (Alonso 
and Hernan, 2008), with the female to male ratio for developing Multiple Sclerosis 
standing at 2:1 (World Health Organization, 2008; Browne et al., 2014).  However, men 
and those with the time of onset occurring at a later age have a worse prognosis and 
faster progression than women and younger individuals diagnosed (Weinshenker et al., 
1991; Confavreux, Vukusic and Adeleine, 2003; Tremlett, Paty and Devonshire, 2006; 
Debouverie et al., 2008).  The reason for women having higher rates of MS is not well 
understood; however, one theory suggests that women have higher levels of a blood 
vessel receptor protein S1PR2.  S1PR2 determines if immune cells successfully cross the 
blood-brain barrier, and they have been found at increased numbers in areas of the 
brain which have been damaged by MS (Cruz-Orengo et al., 2014).   
 
1.1.2 Clinical Course 
MS often first presents itself though a clinically isolated syndrome (CIS) (Efendi, 2015).  
The CIS will show features of inflammatory demyelination, which include optic neuritis 
(when the optic nerve becomes inflamed), brainstem syndromes (a grouping term for 
multiple conditions which affect the brainstem which can cause symptoms including 
pain, paralysis and sensation impairment) or transverse myelitis (inflammation of the 
spinal cord) (Efendi, 2015).  In children, a CIS can appear as symptoms of 
encephalopathy (for example, vomiting, headache or seizure) (Efendi, 2015).  It is not 
until later in the disease course that the type of MS becomes apparent.  Three main 
types of MS exist: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS) 
and secondary progressive MS (SPMS) (Lublin et al., 2014). 
Relapsing-remitting MS 
Between 80-90% of patients with MS are diagnosed as relapsing-remitting MS (RRMS), 
where multiple periods of relapse and remission are experienced (Koch et al., 2008; 
Tremlett and Devonshire, 2008). 
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Relapses, a prominent clinical feature of MS, are defined as the emergence of novel 
symptoms, or the reappearance of earlier symptoms, for a minimum period of 24 hours 
(Scalfari et al., 2010).  Relapses can lead to a temporary or even permanent loss of 
anatomical function (Scalfari et al., 2010).  More than 80% of individuals who 
experience an initial relapse will experience secondary disability progression 
(Weinshenker et al., 1989; Lublin et al., 2014) and early relapse frequency can indicate 
a faster clinical course (Scalfari et al., 2010).  Evidence has suggested that relapses are 
the external expression of recurrent inflammation within the central nervous system 
(Youl et al., 1991) with an average of 10 novel MRI lesions detected for each relapse 
(McDonald, Miller and Thompson, 1994). 
In contrast, remission is a period following a relapse where there no new signs of 
disease activity occur (Tsang and Macdonell, 2011).  The length of a period of remission 
can vary between individuals, but can last for months to years before another relapse is 
experienced (Tsang and Macdonell, 2011).  A relapse before a remission may leave 
problems in around 40% of patients, with the probability of experiencing difficulties 
increasing in individuals who have had MS for a longer period (Tsang and Macdonell, 
2011).  A small subgroup of individuals with RRMS may fully resolve relapse symptoms 
between attacks; in these cases, they are referred to as having benign MS (Sayao, 
Devonshire and Tremlett, 2007; Costelloe et al., 2008). Benign MS symptoms do not 
progress past moderate disability in one functional system (Expanded Disability Status 
Scale stage 3) after 10 years following disease onset (Sayao, Devonshire and Tremlett, 
2007; Costelloe et al., 2008).  From the previous definition, it is possible to group 
approximately 30% of MS patients as benign (Pittock et al., 2004).  Conversely, 
someone is described as having malignant MS if significant disability appears early on 
in disease progression (Gholipour et al., 2011).  This form of disease is unresponsive to 
established treatment methods, although high-dose chemotherapy combined with anti-
thymocyte globulin and an autologous stem cell transplantation have proven effective in 
instigating neurological improvement and improvement on the Expanded Disability 
Status Scale (EDSS) (Kimiskidis et al., 2008). 
The clinical processes of relapses/remissions and chronic worsening are due to specific 
biological mechanisms that can be targeted by drugs to relieve symptoms (Scalfari et al., 
2010).  For example, the drug alemtuzumab is a monoclonal antibody that binds to an 
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antigen expressed on B and T lymphocytes called CD52.  By binding to this antigen, 
circulating lymphocytes are depleted and symptoms of relapses are reduced (NICE, 
2014).  However, although this drug reduces the number of relapses by around 70%, it 
does not delay disease progression (Coles et al., 1999).  Drugs developed for MS tend to 
target specific points in the disease pathway, and so there is not one overall treatment 
that prevents MS in its entirety.  
Primary progressive MS 
Primary progressive MS (PPMS) is diagnosed in 10-20% of individuals with MS (Ebers, 
2004).  Unlike RRMS, symptoms worsen consistently over time, relapses are not 
present and there are few, if any, remissions or improvements in symptoms (Scalfari et 
al., 2010).  Primary-progressive MS is also the form of MS which most often affects late 
onset individuals (where diagnosis occurs after the age of 50) with 55-80% of these 
individuals being diagnosed with this form of MS (Tremlett and Rieckmann, 2010).  
While relapses are considered to be a symptom of CNS inflammation, consistent 
progressive MS is considered to be a symptom of early, chronic axonal loss (Evangelou 
et al., 2000; Filippi et al., 2003).  A PPMS subtype, progressive-relapsing MS (Scalfari 
et al., 2010) exists; this follows the initial pattern of primary-progressive MS, although 
the patient will go on to experience relapses (Tremlett and Rieckmann, 2010).  This is 
the least common form of MS, with approximately 5% of cases being diagnosed with 
progressive-relapsing MS (Tremlett and Rieckmann, 2010).  
Secondary progressive MS 
Secondary progressive MS (SPMS) begins with relapses and remission of symptoms and 
follows on to a progressive phase with no definite period of remission, which may or 
may not have superimposed relapses (Scalfari et al., 2010).   Approximately 65% of 
those who are initially diagnosed with RRMS will develop SPMS (Scalfari et al., 2010).  
Relapses tend to occur less as progression increases, with short remissions or plateaus 
occurring in some cases (Lublin and Reingold, 1996).  However, as milestones of disease 
progression differ between patients it is often difficult to confirm a diagnosis due to the 
high levels of variation (Runmarker and Andersen, 1993; Koch et al., 2008).   
MS Treatment 
Although no cure for MS currently exists, there are several treatment methods 
developed for specific types and stages of MS, with the earlier stages of MS targeted 
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with most success (Rizvi and Agius, 2004). The most current effective treatment for MS 
are disease-modifying therapies (DMT), which can slow the progression of MS by 
reducing the frequency and severity of relapses and novel lesions (Wingerchuk and 
Carter, 2014).  Fifteen DMTs are currently approved by the US Food and Drug 
Administration (FDA) to treat RRMS, PPMS and SPMS (Wingerchuk and Carter, 2014).  
The most recent of these is ocrelizumab, which slows the progression of PPMS by 
decreasing the number of B cells which are CD20-positive (Corboy and Miravalle, 
2010).  Compared with interferon beta-1a, a previously developed MS drug, ocrelizumab 
reduced relapse rates by up to 47% and decreased brain lesions by 95% (Corboy and 
Miravalle, 2010). 
Drugs that have recently been developed or are in the final stages of clinical trials focus 
on regulating the activation of immune cells (for example, alemtuzumab) (Azzopardi, 
Coles and Sklerozda Alemtuzumab, 2011), preventing lymphocytes from departing from 
secondary lymphoid organs (fingolimod and natalizumab, respectively) (Polman et al., 
2006; Kappos et al., 2010) or suppressing CNS inflammation (laquinimod) (Comi et al., 
2012).  Laquinimod works to treat PPMS by reducing the numbers of particular 
cytokines and preventing immune cells from reaching the brain (Comi et al., 2012).  
Another drug currently in development is MD1003, a highly concentrated form of biotin 
or vitamin B7 (10,000 times the recommended daily allowance) (Corboy and Miravalle, 
2010).  This helps to promote the repair of the myelin sheath surrounding CNS neurons 
(Corboy and Miravalle, 2010).  
Autologous haematopoietic stem cell transplantation is currently being investigated as a 
potential solution for MS treatment: haematopoietic (or blood cell producing) stem cells 
are collected from the patient’s bone marrow and stored (Muraro et al., 2017).  The 
patient undergoes aggressive chemotherapy to deplete their immune system, and the 
collected stem cells are used to rebuild the patient’s immune system over 3-6 months 
(Muraro et al., 2017).  Although this treatment may halt disease progression for 5 years 
in 46% of MS patients, there is a significant risk involved in using chemotherapy 





Basic cell types of the immune system 
There are multiple cell types involved in MS development and progression.  Among 
these are T and B cells, lymphocytes that are major components in the adaptive immune 
response (Sawcer et al., 2011).  Many of the key cells which play a role in MS can be seen 
in Figure 1, which shows the process of haematopoiesis and the resulting lineages of 
blood cells. 
 
Figure 1: Haematopoiesis diagram 
A diagram illustrating the various blood cell types produced during the process of 
haematopoiesis, beginning with haematopoietic stem cells (haemocytoblast) and ending in 
mature blood cell types. 
 
T cells play a key role in cell-mediated immunity, a part of the immune system which 
also involves the activation of phagocytes (cells that ingest foreign material or dying 
cells) and release of cytokines (Mosmann and Sad, 1996).  There are multiple types of T 
cells, including CD4+ T Cells (also known as T helper cells), CD8+ T cells (or cytotoxic T 
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cells) and regulatory T cells (Mosmann and Sad, 1996).  CD4+ T cells become activated 
when presented with peptide antigens; small molecules from a toxin, foreign substance 
or even part of the host that can produce an immune response (Mosmann and Sad, 
1996).  Peptide antigens are displayed from MHC class II molecules on antigen 
presenting cells such as dendritic cells or B cells (Mangalam, Rodriguez and David, 
1994).  Once the CD4+ T cells detect an antigen and become activated, they divide and 
secrete various cytokines (Mangalam, Rodriguez and David, 1994).  CD8+ T cells 
become activated when presented with antigens from MHC class I molecules, and 
proceed to destroy virus-infected cells, tumour cells or other damaged cells (Fletcher et 
al., 2010).  Regulatory T cells then secrete several molecules, including IL-10, to 
inactivate the CD8+ T cells (Fletcher et al., 2010).  Another important role of regulatory 
T cells is to suppress autoreactive T cells which have escaped the thymus; if left 
unsuppressed, autoreactive T cells can cause damage to other cell types, which is seen in 
MS (Fletcher et al., 2010). 
B cells, unlike T cells, are involved in humoral immunity, whereby they secrete 
antibodies and cytokines and present antigens (Høglund and Maghazachi, 2014).  
Similar to T cells, there are multiple types of B cells such as plasma B cells, which 
secrete antibodies such as immunoglobulin G1 (which is detected in the CSF of as many 
as 95% of diagnosed MS patients) (Høglund and Maghazachi, 2014). 
Monocytes, another leukocyte, are part of the innate immune system but also influence 
the adaptive immune system (Mallucci et al., 2015).  This type of cell travels from the 
bloodstream to tissues around the body where they differentiate into macrophages 
(large phagocytes) or dendritic cells (which present antigens to T cells) (Mallucci et al., 
2015). 
These cell types are involved in the two principal theories for the cellular processes 
underlying Multiple Sclerosis: the CNS-extrinsic model and the CNS-intrinsic model 
(Høglund and Maghazachi, 2014).  
CNS-extrinsic model 
Within the CNS-extrinsic model, also referred to as the peripheral model, MS is thought 
to be triggered in peripheral sites to the CNS rather than within the CNS itself.  A 
diagram of this model can be seen in Figure 2. 
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Figure 2: A diagram outline the CNS-extrinsic model for Multiple Sclerosis 
This diagram outlines the CNS-extrinsic model for Multiple Sclerosis, with key stages 




In the CNS-extrinsic model, autoreactive T cells escape from the thymus into the 
periphery (Vizier et al., 1999) and fail to be suppressed (likely due to a defect in Treg cell 
function or a resistance to suppression (Friese and Fugger, 2005)).  These autoreactive 
T cells then become activated, possibly through bystander signals from cytokines or 
molecular mimicry, where self-antigens are confused for foreign antigens (Friese and 
Fugger, 2005).  The activated autoreactive T cells, along with B cells and monocytes, 
then travel to the CNS.  At this stage, they cross the blood-brain barrier and mediate 
damage against the central neurons, principally to the myelin sheaths and axons.  The 
destruction of the myelin sheath involves both direct cell contact and the production of 
damaging antibodies, cytokines and chemokines (Dendrou, Fugger and Friese, 2015). 
CNS-intrinsic model 
Unlike the CNS-extrinsic model, in the intrinsic model the events that trigger MS take 
place within the CNS with resident CNS cells (Høglund and Maghazachi, 2014).  The 
events that would lead to the development of neurodegeneration in this model are not 
clear, although theories suggest that the inflammatory response may occur in response 
to a viral infection (Høglund and Maghazachi, 2014).  Autoreactive lymphocytes would 
then appear in the CNS as a secondary incident (Høglund and Maghazachi, 2014). 
It is more likely the pathology of Multiple Sclerosis follows that of the CNS-extrinsic 
model.  The CNS-extrinsic model is more consistent with the procedure of inducing 
experimental autoimmune encephalomyelitis (EAE) in animals, where pathogenic 
CD4+ T cells are artificially generated and proceed to cross the blood-brain barrier to 
cause an immune response against the CNS (Kipp et al., 2017). 
Remyelination 
Remyelination can often occur following the destruction of the myelin sheath as a repair 
tactic, which can help to prevent exposed axons from degeneration (Huebner and 
Strittmatter, 2009).  CNS axons do not spontaneously regenerate and so remyelination 
is an important process to slow MS progression through improving the functionality of 
the CNS neurons and potentially protecting axons (Huebner and Strittmatter, 2009).  
Remyelination in humans is a highly variable process, which can occur often in some 
individuals (20% of individuals in a study remyelinated 60% of their lesions) but not in 
others (Patrikios et al., 2006).  It can occur when oligodendrocyte precursor cells 
(OPCs), a type of non-neuronal cell within the CNS, undergo fast proliferation and 
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differentiation into oligodendrocytes (Patrikios et al., 2006).  Oligodendrocytes are able 
to form the myelin sheath surrounding the CNS neurons (Patrikios et al., 2006).  This 
process of differentiation of OPCs into oligodendrocytes is aided by the removal of 
myelin debris by macrophages, as this debris contains OPC differentiation inhibitors 
(Levine, Reynolds and Fawcett, 2001).  However, remyelination can fail due to 
differentiation failure or OPC recruitment failure (Levine, Reynolds and Fawcett, 2001), 
leaving CNS axons vulnerable to axon degeneration. 
 
1.1.4 Environmental factors in Multiple Sclerosis 
There is no one single factor that fully contributes to developing MS, however there is 
strong evidence that both environmental and genetic factors influence the disease 
(Ramagopalan, Giovannoni, et al., 2009), with MS arising most frequently in genetically 
susceptible individuals that may have been exposed to risk-associated environmental 
factors or stochastic events (Goodin, 2009). 
To investigate the influence of genetic factors versus environmental factors, twin studies 
can be used.  These are valuable studies which examine disease prevalence among 
monozygotic twins (identical, sharing 100% of genes) and dizygotic twins (fraternal, 
sharing 50% of genes) (Sadovnick et al., 2004).  For MS in monozygotic twins, there is a 
concordance rate (where both twins develop MS) of 20-40% (Sadovnick et al., 2004); 
therefore, monozygotic twins are more likely to be discordant for MS.  This indicates 
that environmental factors are influencing MS development, as a high genetic influence 
would result in a higher concordance rate between identical twins (Sadovnick et al., 
2004).  The concordance rate between dizygotic twins is much lower, estimated at 3-5% 
(Mumford et al., 1994).  The higher concordance rate between monozygotic than 
dizygotic twins indicates a significant genetic influence for MS, as if the disease were 
highly influenced by environmental factors, the concordance rate between dizygotic and 
monozygotic twins would be very similar (Mumford et al., 1994). 
The influence of environmental factors in MS development has been showed through 
migration studies of MS (Compston and Coles, 2008).  An individual who resides in a 
low-risk region but migrates to a high-risk region during adulthood will retain their low 
risk of developing MS (Gale and Martyn, 1995).  However, an individual who migrates 
 13 
from a low-risk region to a high-risk region during childhood (under 15 years of age) 
will acquire the high risk of their new host country (Gale and Martyn, 1995).  This has 
been seen across multiple studies in several population groups, for example, the United 
Kingdom and Australia (Barnett et al., 2016), France and the French West Indies 
(Cabre, 2007) and European and South Africa (Kurtzke, Dean and Botha, 1970; 
Kurtzke, Delasnerie-Lauprêtre and Wallin, 1998).  This indicates the importance of 
environmental effects on developing MS, particularly before the age of 15. 
The prevalence and incidence of MS varies by geographic region, in particular an 
individual’s latitude.  As mentioned in Section 1.1.1, the prevalence of MS is lowest 
around the equator, with prevalence rates increasing as you move further north or south 
away from the equator line (Simpson et al., 2011).  A meta-analysis of 321 peer-reviewed 
studies of MS prevalence confirmed this latitudinal gradient as statistically significant 
(p<0.001) (Simpson et al., 2011).  Furthermore, this gradient remained when adjusting 
for frequencies of the most strongly associated MS genetic variant, HLA-DRB1 
(Simpson et al., 2011).  This indicates that a prominent environmental factor that varies 
by geographic latitude affects the development of MS: likely candidates for this are 
ultraviolet radiation (UVR) and vitamin D (Acheson, Bachrach and Wright, 1960).  UVB 
is the type of UVR thought to be influential to MS risk.  Although UVB is not the only 
solar radiation emitted from the sun, it is considered biologically important for MS in 
particular, as UVB begins vitamin D synthesis within the skin (Lucas et al., 2015).  
Individuals further north and south of the equator will have lower exposures of UVB, 
and will therefore produce less vitamin D (Lucas et al., 2015).  However, it is 
challenging to disentangle the effect of sun exposure from vitamin D on MS, given the 
close connection between them (Lucas et al., 2015).  Many studies consider vitamin D 
and sun exposure as proxies for one another.  For example, past sun exposure was used 
as a proxy for past vitamin D status, and a low past sun exposure was shown to be 
associated with an increased risk of developing MS (Handel and Ramagopalan, 2012).  
Lower sun exposure has also been connected to more severe forms of MS, however this 
may be due to lower vitamin D status (Martinelli et al., 2014). 
There is evidence that vitamin D could affect MS independently.  A Mendelian 
randomisation (MR) study showed that genetically lowered levels of 25-hydroxyvitamin 
D has been shown to be strongly associated with an increased risk of MS (Mokry et al., 
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2015). In particular, increased vitamin D levels before the age of 20 were shown to 
decrease MS risk in later life (Soilu-Hänninen et al., 2005). Additionally, CYP27B1 
(which codes for an enzyme that converts 25-hydroxyvitamin D to the active form of 
vitamin D) and CYP24A1 (which breaks down vitamin D metabolites) are associated 
with MS risk (Sawcer et al., 2011).  A low frequency variant (carried at 5% frequency in 
the population) in CYP2R1 had a large effect on 25-hydroxyvitamin D levels, with 
heterozygote carriers having an increased risk of vitamin D insufficiency with an odds 
ratio (OR) of 2.2 (Manousaki et al., 2017).  Individuals with one copy of this variant had 
increased odds of developing MS (OR = 1.4) (Manousaki et al., 2017).  A vitamin D 
response element has also been found within the promoter region of HLA-DRB1*1501, 
the most strongly associated MS risk variant (Lucas et al., 2015).   
Although there has also been evidence to show that higher dietary intake of vitamin D is 
protective of MS (Mirzaei et al., 2011; Bäärnhielm, Olsson and Alfredsson, 2014), 
vitamin D supplementation trials have only shown improvements in some aspects of the 
patients’ immune system and MRI scans, with little clinical benefit observed (Jagannath 
et al., 2010; Hewer et al., 2013).  
Other environmental factors thought to influence MS susceptibility include viral 
exposure, particularly Epstein-Barr virus (although human herpes virus 6 and canine 
distemper virus have been investigated in the past (Holmøy and Hestvik, 2008)).  
Although there is not a particular risk for an individual to develop MS if they have at 
some point experienced an EBV infection (Holmøy and Hestvik, 2008), individuals who 
have been seronegative for EBV had almost no risk of developing MS when compared to 
seropositive individuals (Ascherio and Munger, 2007).  However, there appears to be a 
critical time period for EBV, with infection during adolescence and onwards being 
important for MS susceptibility (Makhani et al., 2016). 
Tobacco smoking has been shown to substantially increase the risk of MS, with smokers 
1.8 times more likely to develop MS than non-smokers (Riise, Nortvedt and Ascherio, 
2003).  The risk of developing secondary progression is also 3.6-fold higher in smokers 
than non-smokers (Hernán et al., 2005), emphasising the importance of individuals 
with MS to stop smoking as environmental factors affect disease progression as well as 
risk (Brey, 2003).  Smoking triggers lung inflammation and supports proinflammatory 
pathways (Shan et al., 2009).  It is possible that if CNS autoantigenic cells (cells that 
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target self-antigens) exist in the lung, they may become activated to attack the CNS 
(Odoardi et al., 2012). 
A higher body mass index (BMI) has been linked to an increased risk of MS, where a 
Mendelian Randomisation study found that 1 standard deviation increase in BMI was 
associated with an OR of 1.41 for MS risk (Mokry et al., 2016).  This may be because 
obesity is broadly a low-grade inflammation which causes proinflammatory mediators 
to be produced within fat tissues (which could potentially trigger neuroinflammatory 
activity) (Lumeng, Bodzin and Saltiel, 2007).  Alternatively, obesity leads to a decrease 
in the bioavailability of vitamin D due to its deposition in body fat compartments 
(Wortsman et al., 2000). 
Recent research has suggested a potential link between MS progression and gut 
microbiota.  A study in 2017 identified specific gut bacteria associated with MS that 
increased the proinflammatory T cell response, thereby increasing the proinflammatory 
environment within MS patients (Cekanaviciute et al., 2017).  Following transplantation 
of the gut bacteria from MS cases into germ-free mice, the mice experienced more 
severe symptoms of experimental autoimmune encephalomyelitis (an artificial mouse 
model of MS) than the mice with bacteria transplants from healthy control individuals 
(Cekanaviciute et al., 2017).  This was supported by another study that carried out faecal 
transplants to germ-free mice from monozygotic twins discordant for MS (Ridaura et 
al., 2013).  The mice that received the MS microbiota transfer again showed an 
exacerbation of EAE symptoms, along with a decrease in Interleukin 10 (IL-10) 
production (Ridaura et al., 2013).  IL-10 is an anti-inflammatory cytokine, a protein 
secreted by certain immune system cells that are important in cell signalling and is 
thought to have therapeutic effects in MS patients (Ersoy et al., 2005).  This research 
suggests that gut microbiota in MS patients may produce a sustained proinflammatory 
environment, giving potential for therapeutic targeting of the gut microbiota for MS 
treatment.  Although other chronic inflammatory diseases have been associated with a 
change in gut microbiota, there needs to be more exploration in determining if the 
relationship between disease status and gut microbiota is causal.  A causal relationship 
between gut microbiota and obesity has been previously identified (Ridaura et al., 
2013), and so a similar relationship with MS should not be readily ruled out.   
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1.2 Genetics of Multiple Sclerosis  
1.2.1 Introduction 
Multiple Sclerosis is a complex, relatively common disease, with a unique genetic 
architecture.  The evidence that has been accumulated over the years points to MS 
having one locus with moderate effect (HLA-DRB1*15:01) and multiple loci with small 
effects (O’Gorman et al., 2013).  Over the past 50 years, genetic studies have identified 
over 200 genetic associations with Multiple Sclerosis (Patsopoulos, 2018).  Particularly 
recently, large studies conducted by consortia such as the International Multiple 
Sclerosis Genetics Consortium (IMSGC) have involved upwards of 45,000 Multiple 
Sclerosis cases (International Multiple Sclerosis Genetics Consortium et al., 2017).  
These large-scale studies have created detailed genetic maps of MS, along with 
integrated functional annotations (International Multiple Sclerosis Genetics 
Consortium et al., 2017).  The majority of the associations identified in these genome 
wide association studies (GWAS) have implicated pathways within the innate and 
adaptive immune system, with the most strongly associated MS risk gene found in the 
HLA complex (International Multiple Sclerosis Genetics Consortium et al., 2017). 
The identification of genetic associations is not the final objective in studying the 
genetics of MS.  After identifying the causal gene, the specific mechanisms and 
pathways the gene influences need to be clarified to determine what role the gene has in 
MS susceptibility and development.  This is not always obvious, as the majority of MS-
associated variants lie in intronic or intragenic regions of the genome (International 
Multiple Sclerosis Genetics Consortium et al., 2017).  However, functional studies are 
improving with the advancement in high-throughput technologies to create MS-specific 
genomic maps to provide more information for the consequences of the genes 
implicated in MS (Patsopoulos, 2018). 
 
1.2.2 Heritability 
The initial suggestion that MS was partly hereditary came in 1896 from Eichhorst 
(Hermann Eichhorst in Ziirich, 1896), who discovered the disease clustered in families.  
Other observations suggested MS was caused at least somewhat by genetic factors, 
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including an excess occurrence of the disease in Northern Europeans in comparison to 
indigenous populations residing in the same latitude (Oksenberg and Barcellos, 2000).   
Multiple Sclerosis disease risk has been measured in a variety of familial relationships, 
including parents and children, monozygotic twins, dizygotic twins, siblings and half-
siblings (Sadovnick et al., 1996; Ebers et al., 2004; Hoppenbrouwers et al., 2008; 
Hawkes and Macgregor, 2009).  Within the family structure of an MS patient, it was 
found that the risk of developing MS in first-degree relatives is approximately 1-3%; 
siblings have a risk of 2.2% while parents have a risk of 1.4% (O’Gorman et al., 2013).  A 
risk of approximately 17.3% is expected for identical twins (O’Gorman et al., 2013).  In 
comparison, the general population risk of developing MS is 0.3% (O’Gorman et al., 
2013). 
Women have been shown to be more at risk for developing MS; the male to female risk 
ratio was 1:2 throughout the twentieth century, however Orton et al. (2006) reported an 
increase to 1:3 over the past 50 years across Canada (Orton et al., 2006).  There is no 
consensus on parent-of-origin effects, as there are many differences in family analysis 
although there appears to be a trend for maternal transmission (Ebers et al., 2004; 
Herrera et al., 2008; Hoppenbrouwers et al., 2008) as there are more mother-daughter 
pairs of MS than father-son pairs (Sadovnick, Bulman and Ebers, 1991).  In a study of 
half-siblings, maternal half-siblings (where two individuals share the same mother but 
not the same father) had an MS recurrence rate of 2.35%, whereas paternal half-siblings 
had a lower rate of 1.31% (Ebers et al., 2004).  A study with avuncular relationships 
(aunts/uncles-nieces/nephews) examined MS-affected avuncular pairs with an 
unaffected mother in comparison to MS-affected avuncular pairs with an unaffected 
father (paternal pair) (Herrera et al., 2008).  A significantly higher (p=0.038) number 
of maternal avuncular pairs were affected with MS (Herrera et al., 2008). 
The heritability, or the proportion of variance in MS liability that can be explained by 
genetic factors, has been estimated as 0.64 (with a 95% confidence interval of 0.36 - 
0.76), with twin, sibling and half-sibling data (Westerlind, Ramanujam, et al., 2014).  
This is a similar finding to other autoimmune diseases, where median values of 
autoimmune disease heritability is 0.60 (Selmi, Lu and Humble, 2012).  However, 
single nucleotide polymorphism (SNP) heritability estimates from the most recent 
IMSGC study are lower at 0.19 (95% CI 0.18, 0.20) (International Multiple Sclerosis 
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Genetics Consortium et al., 2017).  These heritability estimates, along with the concept 
of “missing heritability” will be discussed further in Chapter 3. 
 
1.2.3 HLA genes 
Among the genetic contributors to MS, the Human Leukocyte Antigen (HLA) genes 
associated with MS are considered to be the most influential (Chao et al., 2011).  The 
HLA complex, found on chromosome 6p21, contains a group of highly polymorphic 
genes involved in human immune function, including genes that encode the major 
histocompatibility complex (MHC) proteins (Lincoln et al., 2005).  These MHC proteins 
are necessary for the recognition of pathogens by the acquired immune system and are 
essential for mediating cell interactions with leukocytes (Lincoln et al., 2005).  There 
are three classes of MHC proteins, with MS risk associated with genes belonging to 
classes I and II (Lincoln et al., 2005).  MHC class I molecules (HLA-A,-B and -C) 
present non-self peptides from inside the cell (Martin, 2008).  For example, destroyed 
virus fragments are presented to instruct the immune system to destroy the cell.  This 
destruction is carried out by CD8+ T cells (Høglund and Maghazachi, 2014). Unlike 
MHC class I molecules, MHC class II molecules (HLA-DP,-DM,-DOA,-DOB,-DQ and -
DR) present non-self antigens that are found extracellularly, to stimulate CD4+ T cells 
(Moutsianas et al., 2015).  These CD4+ T cells then go on to stimulate B cells to produce 
antibodies for that specific antigen (Mallucci et al., 2015).  Any cells that have self-
antigens presented by MHC class II molecules are suppressed by regulatory T cells.  The 
connection of HLA class II genes with MS risk corresponds with the biology of the 
disease: after naive T cells have matured within the thymus, they enter the secondary 
lymphoid tissues following circulation in the blood, and it is within the lymphoid tissues 
that these cells interact with antigen-presenting cells (Dendrou, Fugger and Friese, 
2015).  HLA-II molecules present antigens to the T cell receptors, and it is the genes 
that code for these molecules which have been associated to an increased risk of 
developing MS (Moutsianas et al., 2015).   
A total of 32 independent effects have been identified within the MHC region 
(International Multiple Sclerosis Genetics Consortium et al., 2017).  Although MS-
associated genes have been found in both classes of MHC molecules, HLA class II genes 
are the main genetic contributors to MS, explaining up to 10.5% of the genetic variance 
 19 
underlying MS risk (Chao et al., 2011; Sawcer et al., 2011).  The first association 
between MS and the HLA region was found in 1972 (Jersild C, Svejgaard A, 1972), and 
this signal was refined in 2002 to the class II allele HLA-DRB1*15:01 (Barcellos et al., 
2002). The odds ratio for this allele was 3.08 (Barcellos et al., 2002); i.e., the odds of an 
individual with that specific allele having MS are 3.08 times the odds of an individual 
without that allele having MS.  Fine-mapping of the HLA region using HLA-specific 
reference panels confirmed this allele as having the strongest effect on MS risk within 
European ancestry populations (Patsopoulos et al., 2013).  Other independent HLA-
DRB1 associations include 03:01, 04:04, 04:01, 13:03 and 14:01 (Patsopoulos et al., 
2013).  The majority of the collective effect of these alleles can be explained by changes 
to four amino acids which exist in the peptide-binding groove of the HLA-DR molecule 
(Patsopoulos et al., 2013).  These changes would affect the recognition and binding of 
antigens to this molecule (Patsopoulos et al., 2013).  
In addition to HLA class II alleles, HLA class I alleles have been implicated in affecting 
MS risk (International Multiple Sclerosis Genetics Consortium et al., 2017).  A role for 
MS protection has been identified within the class I region: HLA-A*02:01 has been 
shown to protect independently from HLA-DRB1*15 activity (Fogdell-Hahn et al., 
2000; Patsopoulos et al., 2013), and has a reported odds ratio of 0.52 (Yeo et al., 2007).   
HLA-C*05 was also shown to have a protective effect against MS susceptibility, 
independent of HLA-DRB1 effects (Yeo et al., 2007).  HLA-B appears to contain 6 
independent effects for MS susceptibility (International Multiple Sclerosis Genetics 
Consortium et al., 2017). 
There has also been a suggestion that interactions between HLA alleles may further 
influence MS risk, with identified interactions between HLA-DQA1*01:01-HLA-
DRB1*15:01 and HLA-DQB1*03:01-HLA-DQB1*03:02 (Moutsianas et al., 2015).  
However, their role in MS risk has yet to be examined fully (Patsopoulos, 2018). 
 
1.2.4 Non-HLA genes 
Although genes within the HLA region exert the strongest effect on MS susceptibility, 
over 200 variants have been identified that lie outside of this region, including within 
the X chromosome (International Multiple Sclerosis Genetics Consortium et al., 2017).  
 20 
The largest and most recent study conducted by the IMSGC (with 47,351 MS cases and 
68,284 controls) identified novel genes with OR from 1.05 to 1.20 and described many 
of the molecular events that underpin MS susceptibility (International Multiple 
Sclerosis Genetics Consortium et al., 2017).  These variants explain approximately 20% 
of the genetics of MS.  All major immune cell types were shown to have a high 
enrichment of MS-associated variants, with MS-associated molecular events dispersed 
widely across the innate and adaptive immune system.   
Within the adaptive immune system, T cells and B cells are enriched with MS variants, 
and within the innate immune system both natural killer and dendritic cells are strongly 
enriched.  In specific tissues, the thymus has an enrichment of MS susceptibility genes, 
which indicates a possible role for the thymus in selecting autoreactive T cells in MS 
(Pugliese et al., 1997; International Multiple Sclerosis Genetics Consortium et al., 2017). 
Within the brain, there is an enrichment of MS genes within the microglia, but not 
within neurons or astrocytes.  This indicates that immune cells that are resident within 
the brain such as microglia, contribute to MS susceptibility.  Although there does not 
appear to be an enrichment of MS susceptibility loci within CNS tissues, this does not 
exclude the idea that some variants may directly affect neuronal tissues or their 
supporting cell types (Baranzini and Oksenberg, 2017).  The IMSGC study also 
predicted the functional consequences for non-HLA MS variants using gene expression 
levels within different tissue types.  For example, MS variant CLECL1 had an expression 
level that was 20-fold greater in cortical microglia when compared to bulk cortical 
tissue, suggesting a role for microglia in MS susceptibility.  Overall, the findings suggest 
that the origin of MS begins in the peripheral immune system, with functional failures 
across all parts of the immune system cumulating in the disease.   
However, determining the precise functional effects exerted from identified MS variants 
is often complex.  For instance, a pathway that has been implicated in MS susceptibility 
can elicit different responses depending on which cell type the pathway occurs in.  A 
good example of this is the response to type I IFNs: MS risk has been associated with 
response to type I IFNs, however it is unknown if the disease risk comes from the 
modified function of one specific cell type, or if all the cell types contribute to MS risk 
equally.  Innate immune cells respond to type I INFs by increasing the presentation of 
antigens and the production of cytokines and chemokines, while in the adaptive 
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immune system, B cells enhance antibody production and T cells amplify their effector 
function (Ivashkiv and Donlin, 2014).  This emphasises the importance of the context of 
each genetic variant.  
 
1.2.5 Rare variants 
A rare variant is a genetic variant that appears at a low frequency (<0.5%) in a 
population.  Rare variants have the potential to have a large effect on disease 
susceptibility and might be kept rare by the action of selection.  It is possible that there 
are some forms of MS that are caused by rare variants: although some evidence has 
been presented which supports this, replication of these findings has been limited.  For 
example, a rare variant in the CYP27B1 gene was found when 43 families with at least 
four cases were exome sequenced (Ramagopalan et al., 2011), but large-scale follow-ups 
did not replicate this finding.  Additionally, a NR1H3 mutation was suggested to cause a 
Mendelian form of MS after discovery in 7 patients across 2 families (Wang et al., 2016), 
however no evidence of this mutation was found in the 2016 IMSGC study (Antel et al., 
2016) and there have been individuals reported to carry this mutation who do not have 
MS or a similar disease (Minikel and MacArthur, 2016). 
Exome sequencing, where all protein-coding genes within a genome are sequenced, has 
provided some evidence for rare variants affecting MS susceptibility (such as a mutation 
in the NLRP1 gene (Maver et al., 2017) and TYK2 gene (Dyment et al., 2012)), however 
follow up replication studies, particularly using whole-genome sequencing, are needed 
to confirm these.   
 
1.2.6 Gene-gene interactions 
Epistasis is the interaction between alleles at different loci, and is another potential 
contributor to MS heritability (Cordell, 2002). Although common variants account for 
the bulk of MS heritability, they do not account for it entirely (International Multiple 
Sclerosis Genetics Consortium, 2018).  It is possible that some of these common 
variants interact with each other, and therefore contribute more to MS risk in 
combination than they do alone (International Multiple Sclerosis Genetics Consortium, 
2018).  Although limited, there has been some evidence that suggests that some 
heritability may come from these gene-gene interactions. 
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Evidence of interactions between HLA class II alleles has been found, with HLA-DRB1, 
HLA-DQA1 and HLA-DQB1 having novel epistatic interactions (Lincoln et al., 2009).  
Evidence for interactions between HLA class II alleles HLA-DQA1*01:01-HLA-
DRB1*15:01 and HLA-DQB1*03:01-HLA-DQB1*03:02 were later confirmed in a large-
scale study (17,465 cases and 30,385 controls) (Moutsianas et al., 2015).  Additionally, 
evidence has been presented for epistasis of HLA-DRB1*1501 with several alleles: the 
IL-2-330T allele (Shahbazi et al., 2010) and the TNF-α − 308 G/A polymorphism 
(Shahbazi et al., 2011) have both been shown to interact with HLA-DRB1*1501 to 
increase susceptibility to MS.  Another HLA gene, DDX39B, was shown to have epistatic 
interactions with alleles in IL7R exon 6, a non-HLA locus (Galarza-Muñoz et al., 2017).  
Thus, the extent of epistatic interactions for MS is not confined to the MHC region, 
although the role of these interactions is somewhat elusive (Patsopoulos, 2018).  While 
the current evidence shows that epistasis is involved in MS risk on some level, the 
limited amount of results discovered suggests that they are not major contributors 
towards the remaining proportion of heritability that is not accounted for by common 
variants.  This is consistent with other common complex diseases, where evidence of 
epistasis has not been abundant (Altshuler, Daly and Lander, 2008). 
 
1.2.7 Gene-environment interactions 
A genetic or environmental risk factor will have an absolute value for the effect it 
contributes to MS risk within an individual.  When an individual is exposed to both 
these causal genetic and environmental factors and the disease risk caused by those two 
factors is higher than the sum of their two absolute effect values, then gene-
environment interaction is present between these two factors.  In other words, 
individuals who have different genotypes respond to variation in the environment in 
different ways.  The interactions between environmental factors and genetic variants 
has the potential to explain a part of the heritability of MS (Baranzini and Oksenberg, 
2017). 
Smoking is a known risk factor for MS (Biran and Steiner, 2004; Handel and 
Ramagopalan, 2011).  It has also been shown to interact with HLA risk variants, 
including HLA-DRB1*15:01.  A combination of HLA-DRB1*15 presence, absence of 
protective allele HLA-A*02 and smoking gave an OR of 13.5 (compared to an OR of 4.9 
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in non-smokers).  This finding has been replicated in individuals exposed to passive 
smoke (Hedström et al., 2014).  A non-HLA MS gene, NAT1, which encodes an enzyme 
for smoke product metabolism, has also been shown to interact with smoking to 
influence MS susceptibility (Briggs et al., 2014). The effect of smoking on an 
individual’s risk of MS therefore depends on not only the HLA genotype but also other 
parts of an individual’s genome.  Smoking is known to post-translationally modify 
peptides in the lungs through inducing enzyme activity (Klareskog, Catrina and Paget, 
2009).  It is possible that these modified peptides may be recognised by T cells which 
have not been removed in the thymus, resulting in autoreactive T cells (Hedström et al., 
2011) (Odoardi et al., 2012). 
In addition to smoking, there is a possible interaction between Epstein–Barr virus 
(EBV) and MS (Sundqvist et al., 2012).  Epstein–Barr nuclear antigen 1 (EBNA1) is a 
protein associated with EBV; it is the only EBV protein observed in all EBV-related 
malignancies (Sundqvist et al., 2012).  An interaction between increased EBNA1 titres 
and HLA variants has been found to increase MS susceptibility (Sundqvist et al., 2012).  
This may suggest common pathogenetic pathways between EBV and HLA alleles, 
however it does not confirm a causative role for EBV with MS (Olsson, Barcellos and 
Alfredsson, 2017).  It is possible that increased antibody titres for EBNA1 may be due to 
poor virus elimination from insufficient cell-mediated immunity against EBV in people 
with MS (Olsson, Barcellos and Alfredsson, 2017).  Therefore, further research is 
needed to clarify the relationship between EBV and MS. 
Low plasma Vitamin D (1,25-dihydroxyvitamin D3) is a well-known risk factor for MS 
(Cantorna, 2006).  Strong evidence has been presented for the interaction between 
vitamin D and MS risk genes.  Vitamin D response element (VDRE), onto which the 
receptor for 1,25(OH)2D binds, is found in the promoter region for HLA-DRB1; thus it 
is very likely that the expression of HLA-DRB1 is controlled by vitamin D 
(Ramagopalan, Maugeri, et al., 2009).  Several other genes that are associated with MS 
susceptibility have been shown to be regulated by vitamin D, such as NADSYN1 and 
DHCR7 (Ahn et al., 2010).  This suggests that vitamin D has a role in modulating MS 
risk. 
In the future, it is possible that the relationship between environmental and genetic 
factors will be understood further by using epigenetic studies (Olsson, Barcellos and 
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Alfredsson, 2017).  Epigenetics is the study of changes made in an organism that are 
caused by the modification of gene expression (Petronis, 2010).  These changes can be 
caused by methods including DNA methylation, where methyl groups are attached to 
the DNA molecule, and post-translational histone modifications, which can alter the 
structure of chromatin (Petronis, 2010).  Many cell types within the immune system and 
CNS display different patterns of modification (Maltby et al., 2015).  Not only can these 
modifications change the activity of the genome in response to environmental factors 
(Gao et al., 2015), but they could also mediate the effect of exposure of environmental 
factors to genetic variation (Olsson, Barcellos and Alfredsson, 2017).  Studies are 
beginning to show differences in epigenetic modifications between MS cases and 
controls (Baranzini et al., 2010; Maltby et al., 2015), however more research will help 
improve the understanding of the interactions between environment and genes.  
Although it is difficult to quantify gene-environment interactions due to problems such 
as confounding and reverse causation (Patsopoulos, 2018), assessing the additive 
interactions between environmental exposures and susceptibility variants could offer 
further insight into the genetic architecture of MS.  Additionally, methods such as 
Mendelian Randomisation are able to help determine causative factors (Davey Smith 
and Ebrahim, 2005).  Regardless, the presence of gene-environment interactions allows 
lifestyle changes to positively impact MS susceptibility. 
 
1.2.8 Genetic link to other autoimmune diseases 
Comorbidities are defined as the presence of one (or more) diseases that are in addition 
to an initial disease, such as Multiple Sclerosis.  Many individuals who have developed 
MS often develop other immune-mediated inflammatory diseases, or have close family 
members that do (Nielsen et al., 2008).  The inflammatory diseases that are found to be 
in comorbidity with each other may share similar pathways and have an overlapping 
genetic structure (Barrett et al., 2008; Hunt et al., 2008; Stahl et al., 2010; Sawcer et 
al., 2011).  For example, many genes that are associated in autoimmune and 
inflammatory diseases are pleiotropic, or exhibit effects on multiple traits (Wagner and 
Zhang, 2011).  Many of the variants that have been associated with MS have been 
associated with diseases such as lupus, psoriasis, rheumatoid arthritis, ulcerative colitis, 
Crohn’s disease and type 1 and 2 diabetes (Sawcer et al., 2011).  For example, type 1 
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diabetes susceptibility genes CLEC16A and CD226 also affect susceptibility to MS 
(Booth et al., 2009).  However, being susceptible to one disease does not always result 
in a negative effect on another, as many autoimmune disease susceptibility loci can act 
protectively against other diseases (Sirota et al., 2009).  For example, key MS risk 
variant HLA-DRB1*1501 offers a protective effect for type 1 diabetes.   
A limited number of studies have examined the link between MS and neurological 
diseases (Patsopoulos, 2018).  One study that focused on 25 brain disorders (such as 
Alzheimer’s disease and MS) found no evidence that linked MS to any of the other 
neurological diseases (Anttila et al., 2017).  Additionally, no shared association has been 
found with MS and amyotrophic lateral sclerosis (Goris et al., 2014) or schizophrenia 
(Goris et al., 2014).  This suggests that the pathogenic processes for MS differs from 
those of neurological disorders and is more in line with that of inflammatory, 
autoimmune disorders. 
 
1.2.9 Population heterogeneity 
The majority of large-scale genetic MS studies have been carried out in European 
populations (International Multiple Sclerosis Genetics Consortium, 2010; Patsopoulos 
and (IMSGS), 2016).  However, studies from other subpopulations have suggested that 
different ethnic groups or subpopulations have different MS susceptibility variants. 
For example, the Italian island Sardinia has one of the highest risks of MS in the world, 
with a prevalence of 247.6 per 100,000 individuals (Pugliatti, Sotgiu and Rosati, 2002; 
Sotgiu et al., 2004).  Sardinians have been found to have different HLA variants 
associated with MS than those found on mainland Italy, with haplotypes DRB1*0301–
DQA1*0501–DQB1*0201 and DRB1*0405–DQA1*0501–DQB1*0301 having the 
strongest associations (Marrosu et al., 1997).  Ashkenazi Jews also have different HLA 
associations with MS, with HLA-A68:02 and HLA-B38:01-HLA-C12:03 implicated with 
MS risk (Khankhanian et al., 2015). 
Studies within African-American populations have been relatively small, and have 
therefore not revealed any novel variants associated with MS other than those found in 
European populations (Johnson et al., 2010; Isobe et al., 2013, 2015).  However, in 
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Afro-Brazilian populations, DQB1*0602 was found to have an association with MS 
(Caballero et al., 1999). 
These findings suggest that the broad immune pathways of MS are consistent among 
populations, however the variants implicated do vary.  This has the potential to be 
significant for treatment and prevention strategies for smaller subpopulations. 
 
 
1.3 Multiple Sclerosis in the Northern Isles 
1.3.1 Population isolates 
Population isolates are unique groups of individuals that are geographically, culturally 
or linguistically separated from nearby populations (Hatzikotoulas, Gilly and Zeggini, 
2014).  As a group, they have been of interest in of human genetics studies for a number 
of unique attributes (Jorde et al., 2000).  In general, they are less genetically diverse 
than larger, non-isolated populations as alleles are more likely to reach fixation or 
extinction than in larger populations (Kittles et al., 1998).  The founders, which are 
typically a small subset of individuals, may have particularly high or low frequencies of 
certain alleles by chance.  This is particularly useful when a rare allele associated with a 
disease in the parent population drifts to higher frequency in the isolate population, 
making it easier to identify (genetic drift refers to the random fluctuations of allele 
frequencies within a population) (Hatzikotoulas, Gilly and Zeggini, 2014).  Additionally, 
isolates tend to have a more uniform genetic, environmental and cultural background 
(Peltonen, Palotie and Lange, 2000), which makes them particularly useful for studying 
complex disease genetics.  In general, isolates have lesser differences in diet, exercise, 
climate and infectious disease exposure than that found in a large, non-isolated 
population.  Additionally, language and religious uniformity helps in fostering social 
unity.  This helps to reduce environmental noise which can be confounding in complex 
diseases studies.  However, population isolate growth is more susceptible to events 
which may cause bottlenecks, such as environmental change, infectious disease, war 
and famine (Jorde et al., 2000).  Recovery from a bottleneck is also influenced by 
higher rates of inbreeding and genetic drift.   
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There are several isolated populations which have higher frequencies of MS prevalence.  
Orkney, Sardinia and Iceland are excellent examples of geographically isolated 
populations with an MS prevalence higher than the surrounding populations, while the 
Finno-Ugric-speaking Saami population who are indigenous to northern Scandinavia 
and remain linguistically and culturally isolated, also have a high prevalence of MS 
(182.4 per 100,000) (Benjaminsen et al., 2014). 
Population isolates are likely to have unique factors, either genetic, environmental or 
both, that contribute to their high MS prevalence.  The Italian island of Sardinia has one 
of the highest risks of MS in the world, with the adjusted total prevalence rate at 247.6 
per 100,000 individuals (Pugliatti, Sotgiu and Rosati, 2002; Sotgiu et al., 2004).  
Within this population, the incidence rate of MS has increased substantially over the 
past forty years (Sotgiu et al., 2003).  One possible reason for this is the “hygiene 
hypothesis”.  Post-World War II, a distinct lifestyle change (which included a malaria 
eradication campaign) left a population which had evolved to combat a multitude of 
parasites and pathogens with no need for immunogenetic mutations, leaving the 
Sardinian population prone to autoimmune diseases (Sotgiu et al., 2003). 
Population isolates can also be a key resource when studying a complex disease such as 
MS.  A study of a high-risk population isolate within Finland revealed a novel STAT3 
gene variant that had a protective association with MS.  The study noted how using a 
GWAS on an isolated population aided discovery of the gene (Jakkula et al., 2010).  
Another study of Finland looked at the Seinäjoki-South region, which has a significantly 
high prevalence of MS (219 / 100,000 individuals).  Due to the settlement history of the 
region, along with molecular genetic evidence, the study suggested that the high 
proportion of MS was caused by a founder effect (Tienari et al., 2004).  When using 
population isolates to study a complex genetic trait, there is always potential to discover 
unique genetics or environmental causes that can give more information on the 
aetiology of the disease.   
 
1.3.2 Multiple Sclerosis in the Northern Isles of Scotland 
It has previously been discussed that Multiple Sclerosis varies with geographical 
distance from the equator, with a positive association seen between MS prevalence and 
global latitude (Simpson et al., 2011).  This gradient is seen at a regional level within the 
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United Kingdom; Wales has a prevalence of 138 per 100,000 individuals, England with 
164 per 100,000, Northern Ireland with 175 per 100,000 and Scotland with 209 per 
100,000.  However, the Northern Isles of Scotland have significantly higher rates: with 
295 per 100,000 found in Shetland and 402 per 100,000 in Orkney, the highest 
prevalence of MS in the world (Visser et al., 2012).  Based on global trends, the 
prevalence found in Orkney is significantly higher than what would normally be 
expected; Orkney therefore has an unexplained excess of MS prevalence.  A number of 
previous studies have investigated the potential cause of this excess of MS prevalence. 
Vitamin D deficiency was investigated by Weiss et al. in 2016, as at 10 to 60 miles north 
of mainland Scotland, vitamin D levels were expected to be lower than those on the 
mainland (Weiss et al., 2016).  Since strong associations between MS and vitamin D 
deficiency have been identified, it was speculated that this may be the cause of the high 
MS prevalence in the Northern Isles.  However, this cross-sectional study comparing 
MS control individuals in Orkney to those on mainland Scotland found this was not the 
case.  Mean plasma 25-hydroxyvitamin D was found to be significantly higher in those 
on Orkney (mean 35.3 nmol/L compared to 31.7 nmol/L).  Additionally, Orkney had a 
lower prevalence of severe plasma 25-hydroxyvitamin D deficiency (of 6.6% compared 
to 16.2% in mainland Scotland).  A combination of a high number of farming and 
outdoor occupations, along with older age and foreign holidays were significantly 
associated with the higher levels of plasma 25-hydroxyvitamin D on the islands. 
Another study investigated homozygosity on Orkney (McWhirter et al., 2012).  Many 
isolated communities often have higher degrees of parental relatedness, and it was 
thought this may contribute to the excess of MS prevalence (Roberts, Roberts and 
Poskanzer, 1983).  Three measures of homozygosity were generated for 88 MS patients 
and 178 controls and assessed for association with MS.  However, no association was 
detected, and so consanguinity and inbreeding are not thought to be the cause of excess 
MS prevalence. 
It is possible that this excess prevalence may be explained genetically through the 
Northern Isles having a higher proportion of common risk alleles.  If founders of the 
islands by chance had higher frequencies of these risk alleles, this may cause additional 
cases of MS.  Alternatively, one or more MS risk variants which are rare in mainland 
Scotland may be present at an elevated frequency in the Northern Isles.   
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It is possible that the Northern Isles may have unique rare variants.  If rare alleles were 
the cause of the excess of MS prevalence in Orkney, this has the potential to provide a 
new insight into new pathways or identify novel candidate genes for research.  This has 
been the case for other diseases, for example a rare non-polyposis colon cancer gene 
was discovered, resulting in a novel molecular mechanism identified for malignancy 
(Bronner et al., 1994). 
Other genetic reasons can include variations in copy number variants, but from other 
complex disease studies (Craddock et al., 2010) these are unlikely candidates for 
explaining MS heritability in the Northern Isles. 
Epigenetic variations, for example histone modifications, inherited expression of non-
coding RNA and DNA methylation may explain some of the excess of MS prevalence.  
Very few epigenetic studies have been performed for MS, and those that have been 
conducted do not provide strong evidence to support the occurrence of large 
transgenerational epigenetic risk factors (Petronis, 2010; Grossniklaus et al., 2013; 
Westerlind, Ramanujam, et al., 2014). 
Alternatively, MS in the Northern Isles may be influenced by gene-environment (GxE) 
and gene-gene (GxG) interactions (Zuk et al., 2012; Beecham et al., 2013).  However, to 
detect typical GxG interactions, a very large sample size is needed; as the population of 
Orkney is approximately 21,850 and Shetland is around 23,080, this would be a huge 
limiting factor for these studies (Zuk et al., 2012).  Very few reported GxE analyses have 
been conducted for MS, again due to a large required sample size with corresponding 
environmental data (Lill, 2014). 
Regardless, studying Multiple Sclerosis in the Northern Isles is nearly always going to 
be limited by sample size, given the small population of the islands and an even smaller 
number of MS cases.  However, a number of analysis methods can still be performed on 
subsets of each population.  Genetic and phenotypic data has been gathered for 
approximately 10% of each population (the ORCADES and VIKING cohorts, described 
in the next chapter).  The research in this thesis aims to use this data and perform a 
number of genetic analysis methods to elucidate why the prevalence of MS in these 
Northern Isles remains so high. 
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1.4 Aims of the study 
1.4.1 Complex disease research 
With the advent of modern genetic disease research, an initial focus was placed on 
Mendelian conditions.  Caused by one major genetic defect, Mendelian diseases such as 
Huntington’s disease result in a few cases within the population which are often 
characterised by a specific transmission pattern (for example, dominant or recessive 
inheritance) (Lander and Schork, 1994).  These studies were expensive, often requiring 
extensive family-based data collection, and commonly resulted in a low power for 
complex diseases (Altmüller et al., 2001; Pearson and Manolio, 2008).  As analysis 
methods progressed, thousands of individuals were able to be interrogated at a 
previously unreachable resolution and the focus shifted from Mendelian to complex 
diseases (Hirschhorn and Daly, 2005).   
The complexity of many common diseases develops from the presence of both 
influential genetic and environmental factors (Hirschhorn et al., 2002).  These factors 
contribute to an individual’s susceptibility to a particular complex disease in a 
probabilistic manner (as opposed to the deterministic risk alleles that are found in 
monogenic disorders), although no one single pattern of inheritance is followed for all 
complex disease.  The number, frequency, size and type of associated variants will differ 
between diseases (Pritchard, 2002).  However, in general selection acts to reduce the 
frequency of high-effect alleles to prevent individuals with extreme allelic effects from 
becoming commonplace in a population (Gibson and Wagner, 2000; Gibson, 2009).  
Therefore, it is more likely that common variants with low to moderate effect sizes 
contribute towards the genetics of complex diseases. 
Understanding the genetic architecture of a disease is essential to progressing in a 
clinical setting.  Complex disease research can lead to a greater understanding of the 
pathology and cellular mechanisms that contribute to disease risk and development.  
Disease diagnosis, patient treatment, disease management (for example, enabling a 
patient to make beneficial lifestyle choices), disease prediction and treatment response 
prediction (including the onset, severity and response to treatment) can all be improved 
from insight into the genetics of a complex disease (Manolio et al., 2009). 
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There are numerous genetic analysis methods which have the potential to reveal insight 
into complex disease mechanisms.  This thesis seeks to apply several of these methods 
in understanding Multiple Sclerosis and answer the question as to why the Northern 
Isles of Scotland have the highest rates of MS in the world.  
 
1.4.2 Research objectives 
Multiple Sclerosis is a multifactorial disease of autoimmune origin which is increasingly 
common at higher latitudes including Scotland.  It has previously been shown that the 
Northern Isles of Scotland have the highest prevalence of MS in the world. Various risk 
factors, both genetic and environmental, are implicated in MS, but the reasons for the 
peak in Orkney and Shetland are not well understood.  This thesis seeks to better 
understand these very high rates through a number of approaches using the data of the 
Northern Isles Multiple Sclerosis study, Orkney Complex Disease Study and the Viking 
Health Study - Shetland.  
The specific objectives of this research are as follows: 
• establish a heritability estimate for MS in Orkney and Shetland; 
• identify any novel SNPs which may contribute to MS in the Northern 
Isles, and; 
• determine the contribution of common risk variants to the excess risk in 
the Northern Isles. 
It is hoped that the findings of this thesis will contribute to a greater understanding of 







CHAPTER 2: STUDY DATA 
This chapter aims to explore the datasets used in this thesis by describing their content 
and structure and summarising the quality control procedures implemented prior to 
obtaining the data.  Further quality control checks that I performed on receiving the 
data will be described fully. 
 
2.1 Introduction 
2.1.1 Cohort populations 
This thesis focuses on the genetics of Multiple Sclerosis in the Northern Isles of 
Scotland, specifically Orkney and Shetland.  Orkney is an archipelago of 70 islands, 10 
miles north of Scotland, with a population of 21,850 (National Records of Scotland, 
2018).  Shetland lies 50 miles north of Orkney and has a population of 23,200 people 
that inhabit 15 islands (National Records of Scotland, 2018).  The ancestral history of 
the people of Orkney and Shetland differs from that of mainland Scotland: both have 
been inhabited for at least 6000 years but experienced an influx of Norse settlers during 
the 9th century (Wilson et al., 2001; Capelli et al., 2003; Goodacre et al., 2005).  It was 
not until the 15th century that both island groups became part of Scotland; thus, the 
ancestral genetics of the current population has a significant Scandinavian influence 
(Goodacre et al., 2005).  Scandinavian mtDNA and Y DNA lineages are found in 30% of 
individuals in Orkney, and 44% of individuals in Shetland, significantly high than the 
15% found in the North West coast of Scotland (Goodacre et al., 2005). 
In addition to a distinctive ancestral history, the Northern Isles also have remained 
largely isolated from the rest of the United Kingdom.  The geographical position of the 
islands combined with limited transport links (which are often reliant on weather 
conditions) means access to and from the islands is limited; this was particularly true in 
the past, before boat and air services were operational.  Therefore, both sets of islands 
remain considerably genetically isolated from mainland Scotland (Vitart et al., 2005; 
Weiss et al., 2016). 
The unique genetics and isolated nature of the islands have led the Northern Isles to 
become of focus to genetic health researchers.  Two cross-sectional, family-based 
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cohorts have been established in Orkney and Shetland and have become platform 
resources for the study of complex disease in Scotland.  For Multiple Sclerosis 
specifically, the Northern Isles Multiple Sclerosis Study (NIMS) was also created.  These 
three datasets, NIMS, The Orkney Complex Disease Study (ORCADES) and Viking 
Health Study - Shetland (VIKING) are the primary datasets that are used in this project.   
In addition to ORCADES and VIKING, Chapter 5 brings the introduction of the 
Generation Scotland dataset to allow a comparison of the Northern Isles populations to 
mainland Scotland (Smith et al., 2013).  Generation Scotland is a family-based genetic 
epidemiology cohort gathered for 23,960 individuals across Scotland.  For the research 
purposes in this study, only individuals from Glasgow and Dundee were included for 
analysis (n=8787).  Individuals from other regions within Generation Scotland were 
excluded (for example, Aberdeen); Northern Isles residents frequently travel to and 
reside in Aberdeen as this region holds the principal ferry route to and from the 
Northern Isles.  Therefore, to have a clear representation of mainland Scotland, only 
individuals from southern Scotland were included. 
 
2.1.2 Data collection 
Data collection consisted of gathering phenotypic and genotypic data from ORCADES, 
VIKING and NIMS.  This data collection was entirely carried out by other researchers 
and their teams prior to this thesis. 
ORCADES 
Ethical approval for data collection was granted in 2004, with the collection period 
running from 2005 to 2011.  Participation was voluntary and it was required that each 
participant had at least two grandparents born in Orkney, although the great majority 
had three or four grandparents from the archipelago.  High density genotype data was 
collected from 2080 participants, and up to 500 disease-related phenotypes were 
recorded, including data gathered from venepuncture and cardiovascular measurement 
clinics.  Most subjects gave measurements and participated in dual energy X-ray 
absorptiometry (DEXA) scans, eye clinics and cognitive function testing.  There is a high 
degree of kinship within ORCADES participants, which includes both nuclear families 
and further relations (McQuillan et al., 2008; McWhirter et al., 2012). 
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VIKING 
The Viking Health Study – Shetland (VIKING) is a family-based epidemiology cohort 
based in Shetland.  The recruitment period lasted from 2013 to 2015 and each 
participant required at least two grandparents from the island.  Genotypic and 
phenotypic information were collected from 2105 participants.  Like ORCADES, there is 
a high degree of kinship among participants. 
NIMS 
The Northern Isles Multiple Sclerosis (NIMS) study provided a useful resource to 
improve case numbers in the ORCADES dataset (McWhirter et al., 2012).  This study 
recruited MS patients and controls specifically from the Northern Isles: of the 266 
participants, 88 were cases.  These individuals were born between 1937 and 1939 and 
were selected on the basis that their risk of developing MS would be lower (as they are 
over 70).  All four grandparents were required to come from the same location.  
Generation Scotland 
Generation Scotland was established with the aim of creating a family-based cohort to 
represent the general population across Scotland for studying the genetics of health 
traits.  A key feature of this cohort is the ability to link both past and future health 
records to individual data.  Potential participants were invited at random based from 
collaborating medical practices, with the criteria that they were aged 18-65 and had 
one-first degree relative (> 18 years of age) who would also participate.  A total of 6665 
of individuals were recruited directly through invitation, along with 1288 individuals 
who volunteered without invitation, and 16 007 of their family members.  This gave a 
cohort total of 23 960. 
 
 
2.2 Cohort Data 
2.2.1 Data summary 
Data from ORCADES, VIKING and Generation Scotland was provided at the start of 
this thesis.   
Table 1 - Table 4 tabulate the cohort information ( 
Table 1), sample quality control measures (Table 2), SNP quality control measures 
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(Table 3) and imputation information (Table 4).  The quality control procedures 
described here were performed by other individuals prior to the beginning of this thesis.  
Following QC, 188 NIMS individuals were merged with 2027 ORCADES individuals.  
However, it is important to have a full understanding of the procedures to ensure that 
results produced in this thesis would not be inaccurate or biased.   



























Hap300v2 cluster files; 
Genome Studio using 
Illumina cluster files 
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Hap300v2 cluster files; 
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Table 1: Cohort information for ORCADES, NIMS, VIKING and Generation Scotland 
Cohort information for Orkney Complex Disease Study (ORCADES), Northern Isles Multiple 
Sclerosis Study (NIMS), Viking Health Study – Shetland (VIKING) and Generation Scotland 
cohorts.  This information was provided at the start of this thesis.  
 





Call rate < 97% < 97% < 97% 








Ethnic outliers; duplicates; 
gender mismatches; genomic 








Final number of 
subjects 
2215 2105 20,032 
 
Table 2: Sample Quality Control information for ORCADES, NIMS, VIKING and Generation Scotland 
Quality control information for Orkney Complex Disease Study (ORCADES), Northern Isles 
 36 
Multiple Sclerosis Study (NIMS), Viking Health Study – Shetland (VIKING) and Generation 
Scotland cohorts.  This QC work was carried out by other researchers prior to this thesis. 
 ORCADES NIMS VIKING Generation Scotland 
MAF                                                                   < 0.01 < 0.01 
< 0.01 for OMNI markers; 
< 0.0001 for Exome Chip 
markers 
< 0.01 for OMNI markers; 
< 0.0001 for Exome Chip 
markers 
HWE                                                                 < 10-6 < 10-6 < 10-6 < 10-6 
Call rate                                                                 < 98% < 98% < 98% < 98% 
 
Table 3: SNP Quality Control information for ORCADES, VIKING and Generation Scotland 
SNP quality control information for Orkney Complex Disease Study (ORCADES), Northern Isles 
Multiple Sclerosis Study (NIMS), Viking Health Study – Shetland (VIKING) and Generation 
Scotland cohorts.  This QC work was carried out by other researchers prior to this thesis. 
 
 ORCADES VIKING 
Generation 
Scotland 
Post-QC SNP N 287,208 611,836 519,798 
Phasing Software Shapeit v2-r644 
Shapeit v2-r837 and 
duohmm 
Shapeit v2-r837 and 
duohmm 
Imputation Panel 
1000 Genomes Phase 1 








Impute v2.2.2 PBWT Sanger server 
PBWT Sanger server 
Imputed SNPs ~ 37,000,000 39,131,578 24,111,857 
 
Table 4: Imputation information for ORCADES, VIKING and Generation Scotland 
Imputation information for Orkney Complex Disease Study (ORCADES), Viking Health Study – 
Shetland (VIKING) and Generation Scotland cohorts.  All imputation work was carried out by 
other researchers prior to this thesis.  Imputation quality control was carried out by removing 
monogenic and low imputation quality (INFO < 0.4) variants. 
 
2.2.2 Data description 
In total, 2215 ORCADES individuals, 2015 VIKING individuals and 20,032 Generation 
Scotland individuals were available for analysis (Table 5).  However, only 8787 
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individuals from Generation Scotland (from the Glasgow and Dundee regions) were 
taken forward for analysis; the data description here will apply only to these individuals. 
There were 97 MS cases in ORCADES, 15 cases in VIKING and 30 cases in Generation 
Scotland; of these, the majority (n=69, n=12 and n=25, respectively) were female.  The 
age distribution plots show generally normal distributions, with slightly uneven 
distributions with lesser sample sizes ( Figure 3).  There is some underlying population 
structure within the data (Figure 4), although there is no observed distribution bias of 
cases.  Population structure may be due to reported or cryptic relatedness within the 
island groups.  There are clear cluster differences between the Northern Isles groups 
and mainland Scotland.  There are a number of closely related individuals within both 
cohorts (   
Figure 5); these include first cousin relationships (relatedness coefficient @ 0.125), 
grandparent-grandchild and uncle/aunt-nephew/niece relationships (relatedness 
coefficient @ 0.25) and parent-offspring and sibling relationships (relatedness 
coefficient @ 0.50).  It is therefore necessary to account for relatedness in appropriate 
analyses (such as GWAS).  
   Count  Mean Age (standard deviation) 
Population Sex Case Control Total Case Control Total 



































































Table 5: Summary statistics for ORCADES, VIKING and Generation Scotland 
Count and mean age for the Orkney Complex Disease Study (ORCADES), Viking Health Study – 
Shetland (VIKING) and Generation Scotland cohorts, split by gender and (MS) status. 
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 Figure 3: Age distribution plots in Generation Scotland, ORCADES and VIKING 
Age distribution plots for Generation Scotland, ORCADES and VIKING, split by MS status; total 
number of individuals within each group can be found in Table 5.  Note that cases and controls 






Figure 4: Principal component plot for VIKING, ORCADES and Generation Scotland 
Principal component plot containing individuals from Orkney Complex Disease Study 
(ORCADES) (97 cases / 2118 controls), Viking Health Study – Shetland (VIKING) (15 cases / 
2090 controls) and Generation Scotland (30 cases / 8708 controls) cohorts, using PC1 and PC2.  




Figure 5: Relatedness in ORCADES, VIKING and Generation Scotland 
Relatedness coefficients for pairs in ORCADES, VIKING and Generation Scotland.  For clarity, 
this plot has been restricted to including individuals with relatedness coefficient > 0.10, as the 
majority of individuals below this point will be unrelated (Turner et al., 2011).  Therefore only 
5222 pairs are shown out of 2,449,791 in ORCADES, 4702 pairs out of 2,368,576 in VIKING and 
9998 out of 38,171,953 in Generation Scotland. 
 
 
B. VIKING A.  ORCADES 
     C.    Generation Scotland 
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2.3 Discussion 
Data for ORCADES, VIKING and Generation Scotland was presented to me at the 
beginning of this thesis, having undergone stringent quality control procedures at both 
a sample and SNP level for genotypes and phenotypes.  I carried out several sense 
checks on this data, which included counting the number of MS cases and controls and 
calculating their mean age, plotting principal component values and plotting 
relatedness between pairs of individuals.  The motivation to carry out these checks was 
to determine the quality of data, and to ensure that the quality procedures had produced 
a reliable and accurate data set for all three cohorts.  To this extent, my sense checks 
confirmed this; no unknown abnormalities were revealed in the data, and individuals in 
both case and control groups appear to be in similar age groups with a mostly normal 
distribution.  This is particularly important for diseases such as MS that have a mean 
age of onset that occurs later in life; in the case of MS this is 30 years old (Hauser and 
Oksenberg, 2006).  Although there was no distribution bias of cases in the principal 
component plots, there appears to be some underlying population structure within 
ORCADES and VIKING; both ORCADES and VIKING do not appear as one 
homogenous cluster.  ORCADES had a largely scattered appearance with one principal 
cluster, while VIKING had one main cluster and one secondary smaller cluster.  
Generation Scotland had an oblong cluster, which was separate from the Northern Isles 
groups (although a small number of individuals from the Northern Isles overlapped 
with this group).  The scattering and separate clusters within ORCADES and VIKING 
may be due to different island groups in each dataset.  This uneven data clustering, 
combined with the high number of related pairs within the data, suggests it is therefore 
important to correct for relatedness in downstream analyses that would be influenced 
by underlying population structure (such as genome wide association analyses).  Batch 
effect has previously been checked; relative pairs share exactly what is expected, 
therefore it is unlikely batch effect exists. 
In general, there are several advantages and disadvantages to using ORCADES and 
VIKING.  Both datasets are the largest collection of genetic information from each 
group of islands; therefore, they allow an insight into these populations that is not 
possible from phenotypic data alone.  However, as both islands have relatively small 
populations, the datasets will not yield a high number of MS cases, despite the 
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prevalence of MS within the islands being among the highest worldwide.  Although the 
small case numbers will be a major limitation when carrying out subsequent analyses in 
this study, both datasets have high quality genotypic and phenotypic information, and 
are most likely the best genomic dataset these regions will have in the foreseeable 
future.  Therefore, full advantage must be taken of the information available. 
 
2.4 Conclusion 
Quality control of genetic data is important for several reasons.  Primarily, it ensures 
that the data can be used to produce accurate information in subsequent analyses and 
allows researchers to successfully interpret results to a reliable conclusion.  Carrying out 
quality control procedures is a balance between retaining as much information as 
possible and retaining information that will be of high quality.  The methods discussed 
in this chapter have been designed to maintain this balance, and as such, they have 
processed both ORCADES and VIKING into useable and accurate datasets which can be 




















CHAPTER 3: HERITABILITY OF MULTIPLE SCLEROSIS 
IN THE NORTHERN ISLES OF SCOTLAND 
Heritability, or how much variation in a trait is influenced by genetics, is the 
cornerstone to genetic investigations of a trait.  Here, an estimate of heritability for 
Multiple Sclerosis is established for Orkney (case numbers for Shetland were too few to 
obtain an accurate estimate).  Although heritability estimates for MS have been widely 
reported in the literature, heritability is specific to a population and time period, and it 
is therefore useful to determine an estimate for the key populations of this project.  
 
3.1 Introduction 
3.1.1 What is heritability? 
Determining the genetic contribution to phenotypic variation is an important part of 
investigative disease studies, particularly for diseases such as Multiple Sclerosis that 
have a higher occurrence within families.  Within the general European population, the 
risk of developing MS is about 0.3% (O’Gorman et al., 2013).  However, this is much 
higher within families.  Second- and third-degree relatives of MS patients have a risk of 
~0.5%, first-degree relatives have a risk of ~1-3%, and identical twins have a ~17% risk 
(O’Gorman et al., 2013).  These findings suggest that a proportion of variation in MS 
risk is due to genetic factors, which have been quantified in numerous studies and will 
be discussed further in this chapter (Ristori et al., 2006; Patsopoulos et al., 2011; 
Westerlind, Ramanujam, et al., 2014; Patsopoulos and (IMSGS), 2016; Baranzini and 
Oksenberg, 2017).   
The proportion of variation in a trait that can be explained by genetic factors is known 
as heritability (Falconer and Mackay, 1996).  As heritability is a proportion, its value lies 
between 0 and 1.  If a trait has a heritability of 0, genetics do not explain any variation 
in the trait and all variation comes from the environment.  If a trait has a heritability of 
1, genetics explain all variation in the trait and the environment has no effect on trait 
variation.  However, these values of heritability are specific to a population at any given 
time period, as both genetic and environmental variance can change over time and 
population (Mayhew and Meyre, 2017).  For example, two populations may have 
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differing frequencies in effect alleles that influence the trait; if one of the populations 
has less variation in allele frequencies between its population members, it will have to 
less variation in the trait due to genetics and therefore have a lower heritability estimate 
than the other population.  In another example, two populations that have similar 
genetic variation but differ in the amount of environmental variance present will have 
different heritability estimates.  Heritability can therefore be described as measurement 
specific to a time period and population that gives an indication of what influences a 
trait more: genetics or environment. 
In simple terms, the relationship of genetics and environment in relation to a phenotype 
can be expressed as follows (Falconer and Mackay, 1996): 
' = 	* + , + *, 
     (1) 
 where   P is the phenotype, 
  * is the genotype, 
  , is the environment and 
*, is the genotype and environment interactions. 
 





          (2) 
 where   -'.  is the phenotypic variance,  
  -*.  is the genetic variance and 
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The values of these components can then be determined to obtain the heritability of the 
trait.  There are several distinct types of heritability, each corresponding to the genetic 
components that contribute to it.   
The most encompassing type of heritability is broad-sense heritability (H2), which is the 
variance in a trait explained by all genetic factors.  This is represented by the equation 







      (3) 
 where   H2 is the estimate of broad sense heritability, 
  -*.  is the variance in the trait explained by genetics (G) and 
  -'.  is the total variance in the trait within the population (P). 
 
This estimate of heritability makes no assumptions about the underlying genetic 
structure, i.e. the variance could come from hundreds of small effect variants or one 
large effect variant (de los Campos et al., 2015).  The genetic variation may come from 
additive genetic effects, dominant/recessive genetic effects and/or interactive genetic 
effects.  Additive genetic effects, where the sum of the effect of a group of alleles is equal 
to the sum of their individual effects, are typically the largest contributor to genetic 
variation within complex traits (Hill, Goddard and Visscher, 2008).  Hill, Goddard and 
Visscher examined empirical evidence for genetic variation from several species 
(including humans, using twin studies) and found that additive variation typically 
accounted for more than half of the total genetic variance.  Dominant/recessive effects 
(where the effect of an allele is masked by a second allele) and interactive effects (where 
the effect of an allele is dependent on the presence of one or several modifier alleles) 
also contribute to genetic variation between individuals, however they play a smaller 
role in heritability estimates than additive effects (Zhu et al., 2015).  Similar findings 
were found by Zhu et al, who examined the contribution of dominance effects to genetic 
variation.  They analysed 79 quantitative traits in 6715 European Americans and found 
that dominance genetic variance was around a fifth of that of additive genetic variance 
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for the majority of traits (Zhu et al., 2015).  The extent to which interaction effects like 
epistasis contribute to genetic variation is not fully understood but is thought to be 
small (Carlborg and Haley, 2004).   
As additive, dominant/recessive and epistatic effects all contribute towards the 
variation of a trait that can be explained by genetics, the variance in the trait explained 
by genetics can be broken down into its parts and written mathematically as the 






      (4) 
 where   -*.   is the variance in the trait explained by genetics (G), 
-0
.  is the variance in the trait explained by additive genetic effects (A), 
-1
.  is the variance in the trait explained by dominant/recessive genetic 
effects (D), and 
-2
. is the variance in the trait explained by interaction genetic effects. 
 
Of the three components of genetic heritability, additive variance is the most 
predictable form of variance, as it is passed from generation to generation.  The amount 
of variation due to additive variance is known as narrow sense heritability (h2).  This is 







      (5) 
 where   h2 is the narrow sense heritability, 
-0
.  is the variance in the trait explained by additive genetic effects (A) 
and  
-'
.  is the total variance in the trait within the population (P). 
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True narrow sense heritability is smaller than true broad sense heritability as narrow 
sense heritability does not include dominant/recessive or interactive effects, whereas 
broad sense heritability does include these effects, if present.   
Further types of heritability are SNP heritability (ℎ"#) and GWAS heritability (ℎ4567# ).  
SNP heritability measures the contribution of all common SNPs to variation in a trait 
(Yang et al., 2010), while GWAS heritability measures the contribution of those 
measured SNPs which are genome-wide significant in a specific study.  The SNP 
heritability estimate is calculated on unrelated samples and it is independent from 
sample size.  As GWAS heritability is dependent on variants crossing the prescribed 
significance threshold, it is therefore dependent on sample size.  Estimates of GWAS 
heritability can therefore in theory approach estimates of SNP heritability if a large 
enough sample size has been gathered.  As sample sizes increase, the power to detect 
small effect sizes also increases and thus novel common variants which may not have 
been detected with a small sample size may become significant and contribute to the 
GWAS heritability estimate. 
Estimates of SNP heritability have become more accurate over time given the recent 
advances in DNA technology.  Not only are SNP arrays psychically genotyping a huge 
number of common variants, but the effect of variants in LD with these is able to be 
captured.  The genetic contribution of these measured SNPs (S) can therefore be 







      (6) 
where   38.   is the SNP-heritability, 
-9:';<9
.  is the variance in the trait explained by the additive effects of 
common SNPs and  
-'
.  is the total variance in the trait within the population (P). 
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The previous measures of heritability described each capture different levels of genetic 
contributions to a trait.  The relationship between these heritability estimates can 
therefore be defined as follows (Manolio et al., 2009): 




where  H2 is broad-sense heritability (H2) which captures all variance in a trait 
due to genetics, 
h2 is narrow-sense heritability which captures variance in a trait due to 
additive genetic variants alone, 
38
.  is SNP heritability which captures variance in a trait due to SNPs and 
38>?;
.  is GWAS heritability which captures variance in a trait due to 
statistically significant SNPs. 
 
3.1.2 Missing heritability 
When calculating heritability for complex traits, it is important to be aware of the 
problem of “missing heritability”, i.e. not all heritability has been explained by 
measured variants alone (Manolio et al., 2009).  A classic example of this in complex 
traits is height.  Initial family-based studies measured the heritability of height as 
approximately 0.80 (Silventoinen et al., 2003; Macgregor et al., 2006; Visscher, Hill 
and Wray, 2008).  Narrow sense heritability for height was then calculated as slightly 
lower than broad sense heritability, with an estimate of 0.69 (0.67 – 0.71) from Zaitlen 
et al., 2013.  The authors of this study suggest that this estimate may be upwardly 
biased due to non-additive effects and common environmental effects.  However, when 
SNP-heritability estimates for height were calculated, only ~0.45 of variance was 
explained, with 50 significantly associated SNPs accounting for only ~0.05 (Yang et al., 
2010).  Thus, a proportion of heritability appeared to be “missing”.  A gap in heritability 
estimates is also seen in Multiple Sclerosis.  Broad sense heritability measured using 
twin studies was estimated at 0.64 (with a 95% confidence interval of 0.36-0.76) 
(Westerlind, Ramanujam, et al., 2014).  However, the most recent IMSGC (14,802 
cases, 26,703 controls) calculated SNP heritability to be 0.19 (95% CI 0.18, 0.20) 
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(International Multiple Sclerosis Genetics Consortium et al., 2017).  Although SNP 
heritability is a proportion of broad-sense heritability and so it is expected that it will be 
smaller, this leaves a large gap between the two estimates, even given the confidence 
intervals.  There are several reasons as to why gaps appear between heritability 
estimates, particularly when comparing pedigree studies to genotype studies.   
Firstly, broad sense heritability estimates calculated through familial studies using 
twins and siblings may be inflated.  These studies often disregarded gene/environment 
interactions and could underestimate common familial environment, which result in an 
overinflated heritability estimate.   
A gap may also exist between narrow sense heritability estimates and SNP heritability 
estimates as SNP heritability is dependent on array design and does not account for rare 
SNPs (Sandoval-Motta et al., 2017).  Only common SNPs are used to calculate the 
genetic relationship matrix, and so rare variants are automatically not accounted for.  
This can be understood through the difference in calculating the two estimates.  Narrow 
sense heritability estimates are calculated using a related population with a genetic 
relationship matrix (GRM) used to denote the relationship between each pair of 
individuals.  These matrices are constructed by identifying allele sharing in measured 
loci throughout the genome, to give an estimate of the actual proportion of the genome 
that is identical by descent across individuals (Stanton-Geddes et al., 2013). In contrast, 
SNP heritability estimates are calculated on unrelated populations.  The inclusion of 
related individuals for calculating narrow sense heritability allows information about 
allelic correlations across the whole genome to be inferred.  For example, if an 
individual has allelic correlations with a parent on chromosome 1, then it can be 
inferred that they will be correlated on their other chromosomes: that half their genome 
is shared.  Even if only common variants were assayed, it would be able to be inferred 
that you would also share half the rare variants.  In other words, the relatedness of the 
common SNPs would be predictive of the rare SNPs.  Therefore, by including a GRM 
and related individuals in calculating a heritability estimate, a full estimate of additive 
variation can be calculated. 
When an unrelated population is used as in the case with calculating SNP heritability, 
the GRM is only measuring local allelic sharing (i.e. sharing of that particular SNP and 
the SNPs in LD with that SNP).  Therefore, SNP heritability is far more dependent on 
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array design and rare SNPs are not measured, resulting in smaller SNP heritability 
estimates. 
Another gap exists between SNP heritability and GWAS heritability.  This is due to a 
combination of small effect size and sample size.  GWAS are dependent on sample size, 
as small effect variants require a larger sample size to be detected and cross a 
significance threshold.  Therefore, small-effect variants often remain hidden, although 
GWAS heritability has, in theory, the potential to approach SNP heritability given a 
large enough sample size.  
 
3.1.3 Measuring heritability in binary traits 
Many of the assumptions when calculating heritability rely on the trait being 
continuous.  For binary traits, where individuals are either affected or not affected by a 
trait with no intermediate state, the variance calculation becomes more challenging.   
To calculate heritability estimates for this type of phenotype, a threshold model was 
developed.  This uses an underlying measurement of liability to determine if an 
individual will obtain disease status or not (Gottesman and Shields, 1967).  Liability 
collectively describes all genetic and environmental factors that contribute to 
developing a binary trait and can be estimated using a group of individuals to plot a 
standard distribution curve (Figure 6).  At some point individuals will cross a certain 
liability threshold and they will be affected by the trait.  All individuals will have the 
same liability threshold level; however individuals will be more likely to exceed the 
threshold level depending on their exposure to environmental risk factors and their 
genetics (Lee et al., 2011).   
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Figure 6: Liability threshold model 
The liability threshold model, which describes the distribution of individuals with a. binary trait; 
the red area indicates individuals affected by the binary trait, with the dashed line indicating the 
threshold which needs to be crossed to obtain affected status. 
 
In calculating the heritability estimate for a binary trait, the observed heritability is first 
calculated and is used alongside the population prevalence and sample prevalence to 
estimate the heritability of the liability distribution.  Observed heritability (or 
heritability on the observed scale) is the ratio of phenotypic variance due to additive 
effects (as described in Equation 5).  Converting heritability on the observed scale to 









   (8) 
 where   3@A?BA@ACD.  is the heritability on the liability scale, 
  3EB;FGHFI.  is the heritability on the observed scale, 
J is the frequency of the binary trait within the population, 
  ' is the frequency of the binary trait in the observed data, and 
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OTUQL[J]V is the probability density function, evaluated at the K 
quantile of the inverse cumulative density function of the standard 
normal distribution. 
 
The heritability estimate is calculated as quantitative on an observed scale, and then 
subsequently converted into the liability scale.  As the liability scale calculation 
considers sample and population prevalence, it allows for comparisons across 
populations to be made. 
 
3.1.4 Research aims 
Establishing estimates of heritability provides a quantification of the burden of disease 
variance attributable to genetic factors.  Estimates of broad sense heritability of MS 
have been estimated using twin studies as 0.64 (with a 95% confidence interval of 0.36 -
0.76) (Baranzini and Oksenberg, 2017), and SNP heritability estimates using over 200 
MS risk genes have been estimated at 0.19 (International Multiple Sclerosis Genetics 
Consortium et al., 2017).  An estimate of heritability in the Northern Isles has not yet 
been published, and so this chapter seeks to investigate if the heritability estimates for 
MS in Orkney and Shetland are of a similar value to those published in the literature.   
 
3.2 Methodology 
SNP heritability estimates were calculated separately for ORCADES and VIKING using 
the software package Genome-wide Complex Trait Analysis (GCTA), v1.91.7 beta (Yang 
et al., 2011).  The datasets were those described in Chapter 2. 
GCTA was first used to estimate genetic relationships between individuals and construct 
a GRM.  Individuals with a relationship coefficient greater than 0.05 were removed 
from the analysis.  GCTA was then used to conduct a mixed linear model analysis of 
variance explained by SNPs.  GCTA works by fitting the effects of all SNPs (with a MAF 
greater than 0.05) in the analysis as random effects using a mixed linear model.  The 
model can be written as follows: 
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D = WX + 8 + 	Y 
     (9) 
where  D is an n x 1 vector of phenotypes (in this case MS status) and n is the 
sample size, 
W is an incidence matrix for fixed effects, 
X is a vector of fixed effects (for ORCADES: sex, age and array; for 
VIKING: sex and age), 
8 is an n x 1 vector of the total genetic effects of the individuals and 
Y is a vector of residual effects. 
 




    (10) 
where   Z is var (y), 
0 is the genetic relationship matrix, 
-8
.  is the variance explained by all included SNPs, 
2 is an n x n identity matrix and 
-Y
. is the variance explained by residual effects. 
 
Using the above equation, SNP heritability was estimated using a genome-based 
restricted maximum likelihood (GREML) approach; a type of maximum likelihood 
estimation where the parameters of a statistical model are estimated given a set of 
observations (Patterson and Thompson, 1971).  GCTA uses an AI-GREML approach, 
which uses less computational power than standard GREML calculations (Gilmour, 
Thompson and Cullis, 1995).  The GREML approach is useful as it is not biased by 
sample size or individually significant associations. 
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The estimate of variance that was produced was on the observed scale, however GCTA 
used prevalence information to convert this to a liability scale using the linear 
transformation described in the chapter introduction.  Prevalence information is 
necessary to account for ascertainment bias that is typically found in case-control 
studies.  For the ORCADES calculation, prevalence information of 0.00402 was used, 
and for VIKING the prevalence 0.00295 was used (Visser et al., 2012). 
 
3.3 Results 
SNP heritability estimates were calculated for both Orkney and Shetland.  Orkney had 
an estimate of 0.307 (95% CI 0.129, 0.485), while the very small number of cases in 
Shetland resulted in an estimate of 0, with confidence intervals spanning the full gamut 
from not at all heritable to completely heritable (95% CI 0, 1).  Heritability estimates 
from key sources in the literature were gathered as a comparison (Table 6).  These 
sources include estimates of broad-sense heritability (H2) from a twin study and sibling 
study (Ristori et al., 2006; Westerlind, Ramanujam, et al., 2014), and estimates of SNP 
heritability (ℎ"#) from the most recent and largest IMSGC study (International Multiple 
Sclerosis Genetics Consortium et al., 2017; Zheng et al., 2017).  These were compared to 
the estimates produced in this thesis ( 
Figure 7 and Figure 8). 
Estimates of broad heritability ( 
Figure 7) are higher than those of SNP heritability (Figure 8) which would be expected, 
with the twin study estimate at 0.48 and the sibling study estimate at 0.64.  However, 
the confidence intervals for these are wide, particularly the twin study estimate (95% CI 
0.06, 0.86).  The SNP heritability estimate had much smaller confidence intervals; the 
largest IMSGC study gives an estimate of 0.19 (95% CI 0.18, 0.20). 
The heritability analysis conducted in this study for Shetland was underpowered, and as 
such the SNP heritability estimate produced in this study for Shetland is not 
meaningful.  The SNP heritability for Orkney is higher than that of the consortium 
estimate, however the confidence intervals for the Orkney estimate overlaps that of the 






(95% CI) Study size 




216 twin pairs 
Sibling study** (Westerlind, 




74,757 twin pairs 
(containing 315 MS cases) 




Consortium et al., 2017) *** 
38
.  0.19 
(0.18, 0.20) 
14802 cases and 
26703 controls 
 
ORCADES (current study) 38
.  0.31 
(0.13, 0.49) 
97 cases and 
2118 controls 
 
* The environmental contribution for this estimate was 0.29 (95% CI 0, 0.60) for shared environmental 
factors and 0.23 (95% CI 0.12, 0.39) for individual environmental factors 
** The environmental contribution for this estimate was 0.01 (95% CI 0, 0.18) for shared environmental 
factors and 0.35 (95% CI 0.24, 0.51) for individual environmental factors  
*** The super-extended MHC (chromosome 6, ~24M-35M) explained 21.4% of the overall ℎ"
# estimate 
 
Table 6: Heritability estimates from published and current study 
Heritability results published from the major sources of MS research, including sibling and twin 














Figure 7: Comparison of broad sense heritability estimates (H2)  
Published broad sense heritability results, using a twin study (216 twin pairs; Ristori 2006) and a 
sibling study (74757 twin pairs (containing 315 MS cases) and 2.5 million sibling pairs; 
Westerlind, Ramanujam, et al., 2014a). 
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Figure 8: Comparison of SNP heritability estimates 
Published SNP heritability results from IMSGC (14802 cases and 26703 controls; (International 
Multiple Sclerosis Genetics Consortium et al., 2017)) compared with the ORCADES heritability 
estimate. 
3.4 Discussion 
Summary of Findings 
SNP heritability was calculated for Orkney and Shetland using the ORCADES and 
VIKING cohorts, with the aim of quantifying the burden of Multiple Sclerosis variance 
that was attributable to genetic factors.  As Multiple Sclerosis has a particularly high 
prevalence in Orkney (and to a lesser extent, Shetland), it is possible that excessive 
environmental or genetic burdens may be influencing disease prevalence in this 
population.  Thus, it was important to determine if the heritability of MS in the 
Northern Isles was significantly higher or lower than the estimates published in current 
literature.  It was found here that the SNP heritability in Orkney was 0.307 (95% CI 
0.129, 0.485), while an accurate estimation of SNP heritability for Shetland was unable 
to be obtained due to small case numbers.  The Orcadian SNP heritability estimate is 
higher than that predicted by the IMSGC consortium, however as confidence intervals 
overlap for the IMSGC estimate, it is not significantly different.  Based on the limited 
evidence in this study, we give no evidence to indicate that our findings differ from 
those previously published.  However, this study was somewhat underpowered so the 
possibility that Orkney has a higher heritability than other populations cannot be 
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excluded.  Any difference seen in the heritability of MS in Orkney compared to the 
heritability of MS in other populations could be accounted for by chance, given the 
confidence intervals. 
Although the findings here were not significant, a broader discussion can still be had 
regarding the variability of heritability estimates for MS.  Four key studies of MS 
heritability were highlighted in this chapter: these estimates of heritability include two 
broad-sense heritability estimates (H2) and two SNP heritability estimates (ℎ"#). 
Broad-heritability estimates 
Two of the key twin and sibling study findings which give broad-sense heritability 
estimates are those by Ristori et al (2006) and Westerlind et al (2014).  Ristori et al 
estimated H2 using twin pairs within an Italian population while Westerlind estimated 
H2 using twin pairs and siblings within a Swedish population.  Both these studies have 
obtained estimates of broad heritability which at first glance, appear to show 
heterogeneity between the two populations: the Italian study (Ristori et al., 2006) 
estimates MS H2 as 0.48, while the Swedish study estimated MS H2 as 0.64.  However, 
if the confidence intervals are included, there is no significant difference between the 
estimates (Westerlind, Kuja-Halkola, et al., 2014).  In general, the low prevalence of MS 
has resulted in the twin study lacking power and causing large confidence intervals in 
comparison to the Swedish study which additionally included siblings.  A key advantage 
of this type of study design is that it can capture the total genetic (additive, dominance 
and epistasis) and environmental (shared and non-shared) effects that contribute to 
variation in a phenotype (Røysamb and Tambs, 2016): these studies provide a 
“maximum” estimate of heritability of which SNP heritability makes up a proportion.  
Thus, the SNP heritability estimates produced in the key published studies and the 
estimate produced in this study, are in line with the H2 estimates. 
However, there are several limitations with twin and sibling studies.  Most obviously, 
these estimates of heritability fail to identify any specific genes or environments that 
influence the estimate.  Studies estimating SNP heritability and narrow heritability may 
have smaller estimates of heritability than twin and sibling studies, leading to the 
“missing heritability” gap.  It is unlikely that twin studies are invalid, but rather that a 
combination of factors result in the heritability gap: extremely large sample sizes are 
needed to provide sufficient power to identify small effects (resulting in smaller 
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estimates of narrow-sense and SNP heritability), large confidence intervals in the twin 
and sibling studies and the presence of non-additive genetic effects contributing a small 
amount to heritability (Goldman, 2014).  Additionally, twin studies cannot tell shared 
environmental variance from genetic variance, and this can result in an overestimation 
of heritability.  The confidence intervals for the broad-sense and SNP heritability 
studies overlap, so it is difficult to quantify and estimate of missing heritability for MS. 
SNP heritability estimates 
A key SNP heritability estimate was included as comparison to the SNP heritability 
estimate produced in this study: the IMSGC estimated SNP heritability of 0.19 (95% CI 
0.18, 0.20).  The estimate provided from the consortium is comparable for the Orkney 
estimate, as they were both produced using the same program (GCTA).  When 
compared to the Orkney SNP heritability estimate, the IMSGC estimate is lower and 
more accurate (lower CI) estimate, due to its larger sample size with 14802 MS cases.  
Although the Orkney estimate of SNP heritability is higher, overlapping confidence 
intervals suggest that the results in this study for Orkney are in line with these 
results. 
Finding Implications 
There are currently no published studies indicating the heritability of MS in Orkney.  
The findings here indicate that Orkney does not appear to have an excessively high or 
low heritability and the heritability estimates of the Orcadian population is in line with 
those in other European populations.  However, region-specific heterogeneity in MS 
heritability cannot be ruled out due to the limited sample size of this study. 
The findings here suggest that variation in genetics and environment in Orkney are both 
important in determining disease status.  Although this is not new knowledge, it is 
important confirmation to the people of Orkney that both play an important role in 
disease variation. 
Study Limitations 
There has been some discussion regarding the accuracy of GCTA (Krishna Kumar et al., 
2016), however the consensus appears that GCTA is a well-used and well-proven 
software tool that provides accurate estimates of heritability, given model assumptions 
are met (Speed et al., 2012; Gusev, 2015). 
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The largest caveat in this study is the small number of cases when performing 
heritability analysis, particularly for Shetland where an accurate estimate of heritability 
was unable to be obtained.  It would be interesting to repeat this study in future 
providing more genetic data from individuals suffering from MS within the island 
populations has been gathered. 
 
3.5 Conclusion 
This chapter estimated the SNP heritability of Orkney to be 0.307 (95% CI 0.129, 
0.485).  An accurate SNP heritability estimate for Shetland was not able to be obtained 
due to a small number of cases.   
The SNP heritability estimate for Orkney was based on a limited sample size and did not 
indicate a statistically significant difference from previously published results.  
Although this appears to indicate that there are not any excessive environmental or 
genetic burdens causing the high prevalence on the islands, the possibility of this cannot 
be excluded at this stage until a larger study is conducted. 
Several types of heritability estimates exist, including broad-sense, narrow-sense, SNP 
heritability and GWAS heritability.  For MS, an accurate estimation of SNP heritability 
has been obtained in the largest MS study to date, however the estimates for broad-
sense heritability appear less precise in comparison.  It is more possible that twin and 
sibling studies are likely to yield biased results due to the nature of these studies 
(inflation through unaccounted gene/environment interactions and underestimation of 
common familial environment).  However, they provide a rough estimate as to the total 
genetic contribution to trait variation.  Both types of heritability estimate provide useful 
insight regarding what influences a trait, genes or environment, and at what proportion.   
However, a gap between the heritability estimates for broad sense and SNP heritability 
clearly indicate that missing heritability is an issue in Multiple Sclerosis.  SNP 
heritability does not include some genetic factors that may contribute to MS, including 
rare variants and dominant/recessive effects.  Additionally, Multiple Sclerosis is a 
multifactorial disease involving both genetic and environmental factors, and so the 
contribution of interactive effects may also contribute to the missing heritability. 
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As genetic studies become larger and more studies are carried out on the other genetic 
factors that contribute to MS, heritability estimates will move further to the true 




















CHAPTER 4: GENOME WIDE ASSOCIATION STUDY 
OF MULTIPLE SCLEROSIS IN THE NORTHERN ISLES 
OF SCOTLAND 
Within this chapter, genome wide association studies are performed using the 
ORCADES and VIKING datasets to determine if any novel common MS risk variants 
exist in the Northern Isles of Scotland.  It is possible that this region has experienced 
the jackpot effect, where large effect MS risk variants rarer elsewhere, exist in the 
Northern Isles at a higher frequency through the effect of drift and low effective 
population size.  If this is the case, it is possible that these variants contribute to the 
excess of MS risk in the region.   
 
4.1 Introduction 
4.1.1 What is a GWAS? 
A genome-wide association study (GWAS) aims to identify common genetic variants 
that contribute to a specific trait (for example, disease risk) within population samples.  
It is a collection of simple regressions carried out on millions of SNPs across the 
genome to test for an association with a trait of intent.  The overarching goal when 
conducting GWAS is to increase understanding of the biology of specific traits.  When 
that trait is a human disease, it is the goal that this increased understanding will lead to 
improved prediction, prevention and treatment of the disease.   
GWAS is a particularly useful method of analysis as detailed prior knowledge of 
physiology is unnecessary.  When a GWAS is carried out, the genome is scanned using 
genome-wide SNP arrays; by considering all common variants equally, no hypothesis is 
required.  If a variant in the genome is found to be significantly more frequent in people 
with the trait than without, it is said to be associated with that trait.  This variant points 
to a region of linkage disequilibrium which influences the trait. 
In the pre-GWAS era, genotyping was vastly more expensive and small-scale methods 
such as candidate gene and linkage studies were the primary method of genetic analysis.   
In comparison to GWAS, these studies typically had small sample sizes and included 
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limited numbers of variants (Long and Langley, 1999).   These early studies in genetic 
disease research commonly focused on monogenic or oligogenic diseases, and required 
multiple individuals in each family tested at great expense (Pearson and Manolio, 
2008).  The results from these studies were frequently large effect variants which were 
often private to a family, and so the findings were not able to be extrapolated to a larger 
population where the variant would not be found.  Often in candidate gene studies, 
multiple independent tests were carried out until a significant result was found.  This 
multiple testing was not taken into account when determining the appropriate 
threshold of statistical significance; this often led to a failure to replicate results as the 
original finding was a false-positive obtained by chance (Hirschhorn et al., 2002; 
Morgan et al., 2007).  There was an explicit need for analysis methods that focussed on 
multifactorial traits, that produced results at a higher genetic resolution (better 
pinpointing of the region of the genome that influenced the trait) and that did not 
require extensive family pedigrees.  This came to focus following the completion of the 
human genome project and the HapMap Project in the early 2000s (International 
Human Genome Sequencing Consortium, 2001; Human Genome Sequencing 
Consortium, 2004; The International HapMap Consortium, Altshuler and Donnelly, 
2005), which led to a vastly increased public database of SNPs.  Coupled with rapid 
advances in technology that allowed the price of genotyping to drop, genetic analysis 
methods swiftly progressed to take advantage of the cheaper genotyping and thousands 
of individuals were able to be interrogated at a previously unreachable resolution 
covering every gene in the genome (Hirschhorn and Daly, 2005).  Genetic analysis 
moved from hypothesis-driven testing at specific loci to hypothesis free, genome-wide 
testing, and the focus moved to variants of moderate effect sizes within complex, 
multifactorial traits.  
 
4.1.2 Strengths, weaknesses, findings and prospects in GWAS 
Strengths 
GWAS have shown great success in aiding complex trait genetic research and improving 
our understanding of disease biology.  However, with every genetic method there are 
advantages and disadvantages to its use.   
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In general, GWAS is a powerful method for detecting common variants associated with 
multifactorial diseases.  They have proven that they are robust in identifying risk alleles, 
and subsequently novel genes and pathways.  An identified gene or pathway can then go 
on to inform drug development trials, which have a higher chance of reaching a phase 
III trial (or above) with supportive genetic evidence: this could lead to large savings in 
an already vastly expensive industry (Nelson et al., 2015).  Identified associations have 
also proven to be very replicable, within populations and between populations (with an 
adequate sample size) (Marigorta and Navarro, 2013). 
Practically, GWAS are good value for money, due to the low cost of genotyping arrays 
and standard analysis pipelines.  If it is feasible to gather large enough sample sizes for 
common diseases or traits, then significant discoveries usually follow.  Additionally, as 
population samples can be unrelated, GWAS avoids the difficulty and expense of 
recruiting family groups. 
In recent years, GWAS have also proved fruitful in the production and public 
availability of summary statistics.  Following publication of a GWAS, the summary 
association statistics (in the form of SNP effect sizes and their standard error or p-
values) are often released into the public domain (Welter et al., 2014).  These summary 
statistics can be used for a number of subsequent analyses, including detecting new 
associations (Zhu et al., 2016), estimates of SNP heritability (B. K. Bulik-Sullivan et al., 
2015) and refining disease prediction scores (Krapohl et al., 2018).   
Key Findings 
There are several key findings which have arisen following over a decade of GWAS 
results that are important to highlight.  Firstly, GWAS has shown that high polygenicity 
is found for most common diseases and complex traits (Gibson, 2018).  For many traits, 
GWAS conducted on hundreds of thousands of unrelated individuals have discovered 
hundreds of loci (with thousands more suggestive associations), each contributing a 
fraction towards the genetic variance of that trait.  Up to 5% of all common variants, and 
a greater percentage of genes, may associate with any one trait (Boyle, Li and Pritchard, 
2017).  A consequence of having multiple variants contributing towards a trait is that 
the proportion of variance explained by each variant is small.  At an individual level, 
high trait polygenicity will mean a person will have a most likely unique combination of 
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alleles that both increase and decrease risk for that trait, given the high number of 
possible combinations that can occur. 
GWAS has also proven less fruitful than originally expected for accounting for genetic 
variation, resulting in much discussion surrounding the missing heritability.  However, 
the realisation that most genetic effects have very small effect sizes resulted in the 
conclusion that this heritability is hidden rather than missing; this highlights a key 
problem with many GWAS, that they are largely underpowered to detect these small 
effect variants (Gibson, 2010).  In recent years, sample sizes have been growing with 
ever larger consortia and meta-analyses used to make new discoveries.  For example, in 
2009, a GWAS of schizophrenia with 3000 cases discovered the first locus associated 
with the disease (Purcell et al., 2009).  Five years later, cases numbers of 35,000 
increased this number to 108 (Ripke et al., 2014). 
GWAS have also revealed the extent to which pleiotropy exists amongst traits: it is 
thought that the majority of functional variants influence more than one trait (Pickrell 
et al., 2016).  This finding was known from previous research (for example, Mendelian 
mutations are often associated with multiple phenotypes in affected individuals 
(Visscher et al., 2017)).   However, GWAS have shown the extent to which pleiotropy 
occurs across traits, with the same variants associated with multiple traits in different 
groups of individuals (Sivakumaran et al., 2011).  For example, several causal variants 
have been found across multiple autoimmune diseases (Ellinghaus et al., 2016) AND 
genetic correlations have been found between a number of different traits using GWAS 
data (for example, anorexia nervosa and schizophrenia) (B. Bulik-Sullivan et al., 2015).  
These findings suggest that traits and diseases should not be studied in isolation from 
one another, as pleiotropy may cause variants to impact different tissues or act at 
different times in an individual’s life. 
Within Multiple Sclerosis specifically, GWAS have progressed understanding of the 
disease.  The first Multiple Sclerosis GWAS was published in 2007 by the International 
Multiple Sclerosis Genetics Consortium; with 931 cases, this study identified the first 
genome-wide association outside the MHC region (Hafler et al., 2007).  The variant 
identified lay in the first intron of IL2RA (OR: 1.25, p=2.96 x 10-8), a gene which 
encodes the interleukin-2 receptor α chain.  Important for multiple immune-related 
pathways (Liao, Lin and Leonard, 2011), IL2RA is the target of the MS drug daclizumab 
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(Bielekova et al., 2004).  The current largest MS GWAS has now analysed 47,351 cases 
(with 68,284 controls) and identified 233 genome-wide loci that explain around 20% of 
MS genetic variation; each locus ranges in OR from 1.02 to 1.2 (Patsopoulos and 
(IMSGS), 2016).  
In general, the findings that have arisen from the use of GWAS have influenced the way 
researchers think about the genetic architecture of traits and diseases, with the future 
looking to embrace huge sample sizes and holistic approaches when considering disease 
biology. 
Weaknesses 
Although the benefits of GWAS have been tremendous in progressing the 
understanding of disease biology, it is not a panacea for genetic research. 
When examining a successful GWAS association, there is often not a straightforward or 
clear link between the identified SNP and causal gene or pathway.  If a GWAS is 
successful, multiple common variants can be identified that are associated with a 
specific trait.  However, these variants are not directly informative of the trait-
influencing gene or mechanism, as the associated SNP is usually in LD with the causal 
variant, which may be some distance away in a different gene.  Additionally, that gene’s 
function may be unknown, particularly in the role it plays in disease development.  In 
order to find the direct causal gene or pathway, follow up studies are required.  Current 
methods applied to select variants include fine mapping to define GWAS hits (where 
probabilities of causality are assigned to candidate variants and these are connected to 
likely genes (Spain and Barrett, 2015)), and investigating putative functional SNPs 
through in vitro and in vivo experimentation to determine molecular mechanisms to 
identify target genes (Edwards et al., 2013).  Although laboratory methods have been 
developed to progress with GWAS findings, these are costly and time consuming 
(Claussnitzer et al., 2015).  GWAS is only the first step in a long and often expensive 
process of determining the biological underpinnings of a locus. 
GWAS require large sample sizes to detect low frequency variants.  In one association 
study, a signal is deemed significant if the p-value is less than a threshold of 0.05.  
When testing multiple SNPS (assumed to be more than 1 million), a correction on this 
threshold is applied (5 x 10-8) to reduce the false positive rate.  This strict threshold 
 67 
means that adequate statistical power is critical to detect association, and so sample 
sizes need to be very large to allow for low frequency variants to be detected (Visscher et 
al., 2017).  The requirement for large sample sizes makes GWAS unsuitable for rare 
diseases, due to the difficulty of gathering a large enough population sample. 
Another weakness of current GWAS publications is most published data are from 
populations of European descent.  This is in part due to circumstance (a large 
percentage of research institutes and funders lie within Europe and North America, and 
so research populations in these regions), however recent attention to this issue is 
encouraging the future of GWAS to expand to populations in other regions (Huffman, 
2018). 
Prospects 
The future years of GWAS will hopefully address several of the weaknesses discussed 
here.  Firstly, it is hoped that studies will expand to focus on populations of non-
European descent.  By including more diverse populations in genetic studies, 
understanding of variation in complex disease will be improved, along with better 
knowledge for personalised medicine.  For example, populations have different allele 
frequencies and LD structures; this can be used to help fine-map causal variants 
(Morris, 2011). 
The future of GWAS is dependent on larger sample sizes: bigger samples sizes will lead 
to the identification of more associated variants of smaller effect.  This will in turn 
account for more genetic variation of a trait and improve the accuracy of genetic 
predictors.  Larger sample sizes are coming to the forefront in recent years with the 
advent of mega-biobanks that have over 100,000 individuals (such as UK Biobank 
(Sudlow et al., 2015)). However, larger sample sizes (of 100,000+ individuals) bring 
new problems to focus.  Firstly, there are problems with replication (Huffman, 2018).  
In a study of such large magnitude, replication can come from meta-analysis of other 
smaller studies, or from splitting the main sample into a discovery and replication set.  
However, it is argued that when splitting a sample, the two datasets are not entirely 
independent due to the combined data collection and processing (Huffman, 2018).   
Currently, GWAS is based on common SNP arrays (relying on LD); in the future it is 
likely that GWAS will be based on whole genome sequencing, however the cost of WGS 
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is still prohibitive at very large scales and does not warrant switching from using arrays, 
particularly as imputation can recover genotypes at millions of ungenotyped markers 
when using the most up to date imputation reference panels (see below). Focus in 
upcoming years will also move to post-GWAS work; improving overall biological 
understanding and using that knowledge to improve medicine. 
 
4.1.3 GWAS protocol 
Quality Control 
Genome wide association studies use high-throughput genotyping technologies to assay 
hundreds of thousands single nucleotide polymorphisms (SNPs) to determine if any 
association exists between variants and a phenotypic trait (Pearson and Manolio, 
2008).  These large genotyping arrays of 500,000+ SNPs are estimated to capture a 
significant proportion of variation in populations (67-89% in European and Asian 
populations and 46-66% in African populations (Frazer et al., 2007).  However, genome 
wide association studies by their design are prone to small effects of assay and 
selection bias if proper quality control measures are not undertaken.  QC procedures 
have been designed to address both SNP-specific and individual-specific problems 
found in raw data, which generally arise from either mis-identified or unidentified 
data.  Some QC procedures can also highlight any larger problems with the data; for 
example, discordant sex information in individual samples may suggest a sample mix-
up (Turner et al., 2011).  Left unchecked, errors in data can result in both false 
positives (false associations that cloud real associations) or false negatives (real 
associations which are not detected). 
Population substructure within the dataset is also checked. It is important that the 
individuals sampled are from an ancestrally homogeneous population.  If there are 
several groups of individuals who differ in genetic ancestry, this has the potential to 
cause false associations: for example, if the groups also differed systematically in their 
phenotype, any detected association could be due to differences in ancestry rather than 
a true association of an allele causing the phenotype (Cardon and Palmer, 2003).  The 
substructure is assessed through the calculation of principal components.  The 
calculation of principal components reduces the dimensionality of the data: rather than 
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an individual being represented by values from thousands of variables (e.g. genetic 
markers), it can be represented by relatively few variables (the principal components) 
(Ringnér, 2008).  The first principal component calculated shows the largest variation 
between samples, and the second principal component shows the largest variation that 
is uncorrelated to the first (Ringnér, 2008).  Typically, 10 principal components are 
calculated (Turner et al., 2011).  The principal components can be plotted against one 
another to visually assess the differences between samples.  Individuals with similar 
ancestry tend to cluster together, allowing the identification of ethnic outliers for 
removal (Ringnér, 2008). Principal components are also used as covariates to account 
for the minor differences in ancestry still present after removing frank outliers. 
Imputation 
Although genotyping chips are rapidly improving in regard to the number of SNPs that 
can be genotyped, it is often not financially possible to obtain maximum genetic 
coverage for every individual in a cohort (Herzig et al., 2018).  To overcome this, it is 
possible to take advantage of linkage disequilibrium patterns and sequence data from 
many individuals to create imputation reference panels; large panels of SNPs that 
include markers on all arrays used and many others, and which thus can be used to 
predict SNPs not present on the genotyping chips.  By using imputed SNPs in an 
analysis, a causal locus can be identified even if the causal SNP is not genotyped, via an 
indirect association between the imputed SNP and phenotype (Hirschhorn and Daly, 
2005).   
Imputation uses known reference panels that have been genotyped with a much higher 
number of genetic variants to infer an individual’s haplotypes, based on their observed 
SNPs (McCarthy et al., 2016).  There are several panels which can be used to impute 
genetic data, however the Haplotype Reference Consortium (HRC) panel currently has 
the largest coverage for European populations (McCarthy et al., 2016).  The HRC panel 
uses 64,976 haplotypes at 39,235,157 SNPs, constructed from 20 European genetic 
studies and allows minor allele frequencies as low as 0.001 to be imputed accurately 
(McCarthy et al., 2016).  The reference panel contains dense genetic information for the 
markers surrounding the haplotype, however, as the study sample haplotype may have 
several matches in the reference panel, the surrounding genetic information is given a 
match score rather than assigned a specific allele.  For example, instead of assigning a 
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SNP as allele C, it would be reported as 0.88 C, 0.11 A, 0.01 T.  This probability 
information is considered in analyses and allows an estimate of uncertainty to be 
accounted for. 
Tests of association 
Following data quality control and imputation, tests for association are carried out to 
estimate the desired fixed effects (and in mixed models, random effects).  Genotypes 
can be grouped under several different types of models, including additive, dominant 
and recessive, although the additive model is most frequently used in complex trait 
GWAS (Visscher et al., 2017).  In this model, it is assumed that each additional copy of 
the minor allele will increase the trait or risk of disease by the same value. 
A test of association is carried out on each individual SNP.  The type of test used can 
include linear regression, logistic regression and mixed modeling, where both fixed and 
random effects are included in the model. 
Linear regression is used as a statistical tool used to model the relationship between the 
genotype and phenotype of continuous traits, under the assumption that the 
relationship is linear.  Each SNP is tested using the following equation: 
[ = \ + XWA + FA	
     (11) 
where  Y is a n x 1 vector of phenotype data, 
i is the ith individual, 
  a is the baseline phenotype (the intercept), 
b is the fixed effect size, 
X is an n x 1 vector of the nonreference allele count at the SNP and 
e is the random error term of individual i. 
 
The distributional properties of the random error term e must be independent and 
identically distributed with a normal distribution.  However, with related populations, 
the independence of e is violated. 
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Binary traits use logistic regression instead of linear regression, which constrains 
predicted probabilities to a range of 0 to 1.  The basic logistic regression model for each 




` = \A + XWA	
   (12) 
where  q is is a n x 1 vector of phenotype data, 
i is the ith individual, 
  a is the baseline phenotype (the intercept), 
b is the fixed effect size and 
X is an n x 1 vector of the nonreference allele count at the SNP. 
 
These methods can be applied successfully with the condition that there is no 
population structure causing stratification within the data.  Although QC procedures try 
to detect and remove population structure (if possible), some structure may still exist 
within the data.  Population stratification may be present in seemingly homogeneous 
populations, for example a population that has experienced several isolated migratory 
events from various source populations may exhibit stratification, or populations that 
contain family groups (Hirschhorn et al., 2002).  A solution for population stratification 
in a population that has substructure is by using linear polygenic mixed effects models, 
which consider the relationship between individuals within the population sample.  
These models combine both fixed effects and random effects, in this situation using a 
relationship matrix, to control for kinship structure.  A relationship matrix is estimated 
from the genome-wide SNP data.  By using a kinship matrix to account for random 
effects, samples which have similar kinship-values have stronger random effects 
correlations.  The model can be written using the equation (Meyer and Tier, 2012): 
[ = aX+ *b + 8 + F	
     (13) 
where  Y is the n x 1 vector of phenotype data, 
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  W is a matrix of covariates, 
b is a matrix of covariate effects, 
G is an n x 1 vector of genotype data, 
b is a matrix of genotype effect size, 
g is length n random vector of polygenic effects akin to heritability, 
where g ∼ N(0, s8.Y) and s8.  represents additive genetic variance and Y  
is the genetic relatedness matrix and 
e is the random error term (residuals). 
 
However, applying LMM to binary traits is more complex than when using fixed-effects 
models, as in LMM the normally distributed vector is unobserved and as such it is more 
difficult to apply a logit transformation.  Additionally, cases are generally oversampled: 
this can lead to several issues when using LMM, for example the genetic effect and error 
vector stop being independent.  
This problem applies to the analysis in this chapter, as GWAS are conducted on a binary 
trait in two population samples with family substructure.  To overcome this, a linear 
fixed effects model is fitted to the data, using MS status as the phenotype and including 
covariates (discussed further in the methodology section).  The residuals from this 
model are then used, along with a kinship matrix, to fit a linear mixed model.  The 
resulting residuals from this model are then used as a phenotype for a GWAS, where a 
linear regression is performed on each SNP to produce estimates of effect. 
As this regression is run for every SNP in the imputed panel, the significance level 
threshold of GWA studies needs to be very rigorous to ensure significant associations 
that appear by chance due to multiple testing are not classed as meaningful.  For 
example in a study of 1 million SNPs the conventional level of P < 0.05 would lead to 50 
000 SNPs being classed as associated with the trait of interest (although the SNPs are 
not independent so the 50K, while true, is misleading) (Pearson and Manolio, 2008).  
To avoid this, a Bonferroni correction is applied (Pearson and Manolio, 2008).  Under 
the same conditions as given previously, the significance level would decrease from 
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p=0.05 to p= 5 x 10-8, with SNPs having to cross this threshold to be deemed significant.  
Although this commonly used method does remove the risk that the association is 
present by chance, studies with small sample size will struggle to detect significant 
variants due to a lack of power to allow small effect disease-associated SNPs to reach the 
significance threshold (Pearson and Manolio, 2008). 
Why might GWAS results fail to replicate? 
If findings from an initial study cannot be replicated, this is usually due to one or more 
factors, including chance, population stratification (although if a similar population is 
used this is likely to wrongly replicate), study bias, genotyping error, winner’s curse or 
jackpot effect in the initial study (Khoury et al., 2006; Chanock et al., 2007). 
The winner’s curse results in overestimation of genetic effect sizes in initial studies.  
This was first described in 1983 from an auction theory context: within an auction, the 
winning bid on an item is likely to overestimate the true value of that item as it was the 
highest of all the bids (Bazerman and Samuelson, 1983).  This can be applied to genetic 
association studies, where the initial positive association is the winning bid.  The genetic 
effect size at this locus are determined from that “winning bid”, and thus tend to be 
upwardly biased (Palmer and Pe’er, 2017).  It is commonly found among GWA studies 
as these studies can easily be underpowered to detect small genetic effects.  As the 
initial effect size is upwardly biased, this leads to an underestimation for the subsequent 
sample size required to replicate the result (Hirschhorn et al., 2002).   
The jackpot effect arises within family studies and population isolates; these groups 
may have higher frequencies of rare, moderate effect variants by chance, and so novel 
associations can be discovered (Feng et al., 2015).  However, the allelic architecture of 
these populations is often unique to that isolate, and so results are unlikely to be 
replicated in subsequent studies (Feng et al., 2015). 
Although the winner’s curse and jackpot effect produce association results which often 
fail to replicate in subsequent studies, the results are true associations (despite 
statistical inflation).  However, association results may also fail to replicate as they are 




4.1.4 Research aims 
The aim of the research in this chapter is to carry out a GWAS on the ORCADES and 
VIKING cohorts to assess if any novel common variants exist in these populations that 
contribute to the excess prevalence of MS in these regions.  Both Orkney and Shetland 
are small and relatively isolated populations.  It may have been possible that rare MS 
risk variants, by chance, drifted to higher frequencies in these regions, and thus the 
allelic enrichment of these variants is causing the high rates of MS found in the islands. 
 
4.2 Methodology 
4.2.1 Creating a merged dataset 
When conducting a GWAS, it is important to maximise the sample size as much as 
possible (in particular, case numbers) to increase the power to detect associations and 
improve estimates of effect size.  For more than one population, this is typically done via 
meta-analysis.  With ORCADES and VIKING, it is especially important to maximise the 
number of cases given the limited population size.  However, performing a meta-
analysis on the data is more challenging given the nature of the two populations: there 
is some migration between the populations of Orkney and Shetland, and as such many 
Orcadian individuals have relatives on Shetland and vice versa.  While this does not 
cause issues for independent analyses on both datasets, it can cause a problem if there 
are related individuals between datasets when meta analysing results.  Therefore, to 
account for relatedness between populations, a merged dataset was created.  This 
merged dataset contained several additional ORCADES individuals who were not 
genotyped within the first group. 
Merging Genotypes and Imputed Files 
In the genotyped data, the intersecting SNPs in the ORCADES and VIKING PLINK 
array files were determined (the ORCADES PLINK files contained the NIMS 
individuals).  A new set of PLINK files containing all individuals from ORCADES and 
VIKING with the intersectional SNP subset was then created using PLINK (v1.90b3.29).  
The ORCADES and VIKING array datafiles used to create these were those that 
underwent the quality control procedures discussed in Chapter 2. 
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HRC-imputed files were merged on a per chromosome basis using the program QC Tool 
(v2). 
Merging Phenotypes 
The ORCADES and VIKING phenotype files were merged in R (v3.4.4).  Phenotypes 
were quality controlled to ensure units were consistent between phenotypes. 
Calculating principal components and GRM 
Principal components were created using the genotype files and PLINK.  PLINK 
generates a variance-standardised genetic relationship matrix and extracts the top PCs 
from that matrix. 
 
4.2.2 GWAS 
A GWAS was carried out on the merged HRC-imputed ORCADES/VIKING dataset.  The 
phenotype used for the GWAS were GRAMMAR+ residuals; several stages were 
performed to take the raw MS phenotype to the GRAMMAR+ residuals to allow them to 
be analysed as a quantitative trait.   
Stage 1: Fitting a linear fixed effects model 
Here, the phenotype MS status and covariates (not including kinship) were fit in a 
linear fixed effect model.  Age and sex were included as covariates due to their 
association with MS: MS has an age of onset of around 30 years of age and is twice as 
common in women than men.   Principal components 1 through 10 were included to 
adjust for population structure.  The following model was fit using the program 
GenABEL v1.8-0 (Aulchenko et al., 2007): 
Model 1:   MS status (1,0) ~ Age + Sex + PC1..PC10    
Fitting this model produced covariate-adjusted residuals, which were then passed on to 
the next stage of analysis.  No genotype data is used at this stage. 
Stage 2: Fitting a random effects model 
Residuals produced from Stage 1 along with a GRM (see 4.2.1) were fit in a random 
effects model:  
Model 2:   Residuals (Model 1) ~ GRM      
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As previously discussed in Chapter 2, both cohorts have a high degree of relatedness, 
and so accounting for kinship as a random effect is necessary to prevent population 
stratification within this data.  GenABEL’s polygenic function was used to fit the mixed 
model.  This model generated GRAMMAR+ residuals. 
Stage 3: Genome-wide association analysis 
The GRAMMAR+ residuals produced in Stage 2 were passed on to REGSCAN (v0.5) for 
GWA analysis.   
Model 3:   Residuals (Model 2) ~ SNP    
REGSCAN performs a linear regression for each SNP using the GRAMMAR+ residuals 
as a phenotype to produce estimates of effect sizes and their standard errors. 
 
4.3 Results 
4.3.1 Merged dataset (ORCADES/VIKING) summary 
Both the genotyped and imputed data files for ORCADES and VIKING were merged 
successfully.  A subset of 156,040 SNPS, found in both ORCADES and VIKING, were 
kept for the merged genotype files (Figure 9).  It should be noted that the number of 
ORCADES SNPs is much lower than that of VIKINGs due to the merger of two SNP 
arrays when creating ORCADES (resulting in a smaller subset of SNPs), as described in 
Chapter 2.  The genotype data was used to generate principal components for the data: 
the first two PC are plotted in Figure 10.  A clear divide can be seen between the two 
island population groups, indicating that population structure exists in the dataset. At 
least one pure Shetlander exists within ORCADES.  There also appears to be a small 
cluster of individuals between both populations which may be admixed between Orkney 
and Shetland. 
Table 7 provides a summary of the new dataset, which has 112 cases and 4223 controls, 
with the majority of cases (81) being female.  The mean age in this dataset is 52 years 
(standard deviation of 15.4 years). Both men and women have a similar age distribution 
amongst cases and controls (Figure 11). 
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Relatedness is an important feature of both ORCADES and VIKING, each of which 
include many extended families.  The possible relatedness of individuals across both 
datasets was a point of concern for analysis, and the key motivation for creating a 
merged dataset (to allow relationships between populations to be assessed and 
accounted for).  9,620,692 relationship pairings were assessed – of these, 9,610,161 
pairs had a relationship coefficient below 0.10 and were deemed unrelated. Pairs with a 
relationship coefficient above 0.1 can be seen in Figure 12.  There are 2588 pairs who 
have a relatedness coefficient between 0.20-0.30 (approximately the equivalent of a 
grandparent / grandchild or uncle-niece relationship) and 2736 pairs who have 
relationship coefficient between 0.38-0.62 (equivalent of parent/child or siblings). 
 
 
Figure 9: A summary of genotyped SNPs in ORCADES (blue) and VIKING (pink) 
ORCADES had a total of 161,663 SNPs while VIKING had a total of 668,762 SNPs.  Of these 
SNPs, 156,040 were the same between both genotyped groups, and were subsequently used as 
the genotyped SNPs in the merged ORCADES/VIKING dataset.  It should be noted that the 
number of ORCADES SNPs are much lower than that of VIKINGs due to the merger of two SNP 
arrays when creating ORCADES (resulting in a smaller subset of SNPs), as described in Chapter 













Figure 10: Principal component plots for the merged ORCADES/VIKING dataset 
Principal component (PC) plots for the merged ORCADES/VIKING dataset (n=4335), using PC1 
and PC2.  Individuals from ORCADES are plotted in red and individuals from VIKING are 
plotted in turquoise. 
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Table 7: Summary statistics for merged ORCADES/VIKING dataset 
Count and mean age for the merged ORCADES/VIKING dataset, split by gender and Multiple 







Figure 11: Age distribution plots in merged ORCADES/VIKING dataset 
Age distribution plots in the merged ORCADES/VIKING dataset, split by MS status; total 











Figure 12: Relatedness in the merged ORCADES/VIKING dataset 
Relatedness coefficients for 10,531 pairs in merged ORCADES/VIKING dataset.  For clarity, this 
plot has been restricted to having a relatedness coefficient >0.10, as the majority of the 9,610,161 
pairs below this point will be unrelated (Turner et al., 2011).   
A. Cases      B. Controls 
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4.3.2 ORCADES/VIKING GWAS results 
A GWAS was conducted on the merged ORCADES/VIKING dataset to determine if 
there were any novel common MS risk variants that existed in the Northern Isles of 
Scotland.  The ORCADES/VIKING dataset contained 112 MS cases and 4223 control 
individuals from the Northern Isles of Orkney and Shetland in the United Kingdom.  In 
this results section, only SNPs with a MAF above 0.05 were considered, as SNPs with a 
MAF below 0.05 are more likely to be genotyping errors (Turner et al., 2011), as well as 
being poorly powered, given our limited sample size.   
There is little evidence of genomic inflation within the ORCADES/VIKING dataset 
(Figure 13).  The quantile-quantile plot of the observed versus expected p-values found 
that the majority of the p-values followed the expected distribution.  The lack of 
inflation (λ = 1) indicates that the analysis methods used have successfully corrected for 
any population structure within the dataset. 
In this GWAS, one SNP (SNPID chr1_145044288) crossed the genome-wide 
significance threshold of 5 x 10-8, however this looks unlikely to be a true signal as it is 
the only SNP within 1000 kb to have a p-value below 1 x 10-4.  In total, 89 SNPs had a p-
value below the suggestive significance threshold of 1 x 10-5 (the threshold as defined in 
Björkegren et al., 2015).  A shortened list of these SNPs, with only the lead SNPs within 
1000 kb, can be found in  
Table 8 (lead SNP defined as the SNP with the lowest p-value), and a full list of these 
SNPs can be found in Supplementary Table 1.  Although beta values and SE are listed, 
these should be read with caution as these SNPs (apart from chr1_145044288) were not 
genome-wide significant.  Therefore, the results are not very informative with regards to 
effect size but are suggestive of possible MS susceptibility loci in the Northern Isles.  
Also included in this table are the p-values and associated allele frequencies from the 
most recent 2018 IMSGC study for comparison of results (International Multiple 
Sclerosis Genetics Consortium et al., 2018).  This study used 32,367 MS cases and 
36,012 controls from Europe, Australia and the USA. 
There were six regions that had two or more SNPs that had p-values below the 
suggestive significance threshold that were within 1000 kb of each other.  These regions 
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can be viewed in the Manhattan plot (Figure 13) and are found on chromosomes 2, 6, 12 
and three regions on chromosome 18. 
Chromosome 2 had 14 SNPs within a 1000 kb region that passed the suggestive 
significance threshold.  Lead SNP rs1398972 had a p-value of 1.49 x 10-7 in the GWAS 
results (Figure 14).  13 SNPs nearby were in strong LD with this SNP (r2 > 0.9), along 
with multiple weakly correlated SNPS (0.2 < r2 < 0.6) that did not pass the suggestive 
significance threshold.  The cluster of these SNPs appears between two recombination 
peaks of around 20cM/Mb.  rs1398972 was not significant in the 2018 IMSGC study (p-
value=0.06), however the frequency of the allele in the ORCADES/VIKING dataset 
(0.32) is greater than that of the IMSGC dataset (0.13).  This SNP is not reported to 
have any clinical significance and has no listed associations on the PhenoScanner 
website, which is a curated list of large-scale GWAS results (Staley et al., 2016).  The 
closest gene to this SNP is LINC01117, Long Intergenic Non-Protein Coding RNA 1117 
(Bethesda (MD): National Center for Biotechnology Information, 2005). 
Chromosome 6 had 27 SNPs within a 1000 kb region that passed the suggestive 
significance threshold, however 25 of these did not have an assigned RSID.  The SNP 
with the lowest p-value and an assigned RSID number was rs9268154, which had a p-
value of 9.7 x 10-6 (Figure 15).  The SNP with the lowest p-value without an assigned 
RSID number was SNPID chr6_32411726 which had a p-value of 3.9 x 10-6.  As LDplot 
(the tool used to assess linkage disequilibrium between SNPs and plot them on the locus 
zoom plots) uses RSID to index SNPs, the majority of these SNPs could not be assessed 
for LD with the lead SNP or plotted on the locus zoom plot.  However, the 2 SNPs with 
RSIDs that passed the suggestive significance threshold were in LD with each other 
(r2=1).  These two SNPs were moderately correlated with HLA-DRB1*1501 tag SNP 
rs3135388 (r2=0.65).  There are also several correlations between 0.4 < r2 < 0.6 in the 
HLA-DRB region, which lies approximately 200 kb from rs9268154.  This group of 27 
SNPs was the only region to show significance in the IMSGC paper; rs9268154 had a 
reported p-value of 0 in the IMSGC results.  The associated frequency was also higher in 
the IMSGC results at 0.85 (compared to the 0.78 frequency in the ORCADES/VIKING 
dataset).  The most significant association for the SNP rs9268154 on PhenoScanner was 
self-reported Multiple Sclerosis, which listed a p-value of 8.9 x 10-89 from a UK BioBank 
study (n=337159). 
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Chromosome 12 had 12 SNPs within a 1000 kb region that passed the suggestive 
significance threshold.  Lead SNP rs11055646 had a p-value of 5.6 x 10-7 in the GWAS 
results (Figure 16).  4 SNPs nearby were in strong LD with this SNP (r2 > 0.9), and 7 
SNPs had an r2 between 0.6 and 0.7.  rs11055646 was not significant in the IMSGC 
study (p-value = 0.14), and the SNP was at a higher frequency (0.22) in the IMSGC 
study than in ORCADES/VIKING (0.13).  There are no listed associations for the 
rs11055646 SNP on PhenoScanner.  The region that contained these SNPs is part of the 
GRIN2B gene, and this gene has no reported clinical significance (Bethesda (MD): 
National Center for Biotechnology Information, 2005).   
Three regions on chromosome 18 had multiple SNPs that passed the suggestive 
significance threshold, at around 20 Mb, 36 Mb and 56 Mb along chromosome 18. 
The first region, at around 20 Mb, had 7 SNPs within a 1000 kb region that passed the 
suggestive significance threshold.  Lead SNP rs1893251 had a p-value of 2.9 x 10-7 in the 
GWAS results (Figure 17), and the other 6 SNPs which passed the suggestive threshold 
were in strong LD with this SNP (r2 > 0.8).  Within the IMSGC study, rs1893251 was not 
significant (p-value = 0.68) and had a higher frequency (0.12) than ORCADES/VIKING 
(0.05).  This SNP has no reported associations on PhenoScanner.  The gene in nearest 
proximity to this SNP is CTAGE1 (within 2000 kb; Cutaneous T Cell Lymphoma-
Associated Antigen 1). 
The second region on chromosome 18 at around 36 Mb had 4 SNPs within a 1000 kb 
region that passed the suggestive significance threshold.  Lead SNP rs17602961 had a p-
value of 5.3 x 10-6 in the GWAS results (Figure 18) and the other 3 SNPs which passed 
the suggestive threshold were in very strong LD with this SNP (r2 > 0.96).  There are a 
number of other SNPs stretching across approximately 0.2 Mb which are in strong LD 
with rs17602961 that did not pass the suggestive threshold; three of these are found on 
nearest gene, MIR924HG (also known as Long intergenic non-protein coding RNA 
669).  This SNP was not significant in the IMSGC study (p-value=0.61) but had a similar 
frequency (0.02) to that of ORCADES/VIKING (0.05).  It has no listed associations on 
PhenoScanner.   
The third region, at around 56 Mb, had 5 SNPs within a 1000 kb region that passed the 
suggestive significance threshold.  Lead SNP rs62096323 had a p-value of 4.2 x 10-6 in 
the GWAS results (Figure 19), and the other 4 SNPs which passed the suggestive 
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threshold were in strong LD with this SNP (r2 > 0.8).  rs62096323 was not significant in 
the IMSGC study (p=value 0.48) and had a lower frequency (0.04) than in 
ORCADES/VIKING (0.10).  It has no known associations on PhenoScanner; however, it 
is within 0.1 Mb of a known MS SNP rs7238078, found in MALT1 (which encodes 
mucosa-associated lymphoid tissue lymphoma translocation protein 1).   rs7238078 has 
a p-value of 3 x 10-9, from the 2011 IMSGC study with 9772 MS cases and 26621 controls 
(Sawcer et al., 2011).  The MS associated SNP rs7238078 is not in LD with rs62096323 
(r2=0.002). 
 
Figure 13: Manhattan and QQ plot from GWAS of Multiple Sclerosis in Shetland 
and Orkney 
Results from a GWAS of MS using the ORCADES/VIKING dataset (cases: 112, controls: 4223).  
The top graph is a Manhattan plot, with chromosomes along the x-axis and -log10 p-values along 
the y-axis. The genome-wide significant threshold of 5 x 10-8 is shown in red, with the suggestive 
threshold of 1 x 10-5 is shown in blue.  The bottom graph is a quantile-quantile plot of observed 
and expected p-values, -log10 transformed.  The genetic inflation factor (λ) was 1. Only SNPs with 
a MAF above 0.05 are included in both plots. 
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1 145044288 C T 0.09 0.15 0.03 4.4 x 10-8 0.50 NA NA 
rs34584371 2 153037808 A G 0.12 0.08 0.02 4 x 10-6 0.99 0.76 0.1 
rs1398972 2 177569251 C G 0.32 0.06 0.01 1.5 x 10-7 0.99 0.06 0.13 
rs7635898 3 55408967 C A 0.09 0.09 0.02 3.9 x 10-6 0.84 NA NA 
rs816545 3 156092170 T C 0.05 0.11 0.02 5.4 x 10-6 0.93 0.06 0.03 
rs73221623 3 196370840 T C 0.10 0.08 0.02 4.4 x 10-6 0.97 0.76 0.04 
rs9268154 6 32266021 A T 0.78 -0.06 0.01 9.7 x 10-6 1.00 0.00 0.85 
chr6: 
32411726 
6 32411726 A G 0.75 -0.06 0.01 3.9 x 10-6 1.00 0.00 0.87 
rs12209200 6 57217336 T C 0.08 0.10 0.02 1 x 10-6 0.84 NA NA 
rs4720446 7 4982335 C G 0.88 -0.07 0.02 7.6 x 10-6 0.98 0.60 0.96 
rs10965046 9 21518275 G A 0.14 0.07 0.02 7.9 x 10-6 0.98 0.50 0.16 
rs76585251 9 24750193 T G 0.07 0.10 0.02 2.2 x 10-6 0.95 0.76 0.02 
rs78870428 10 25662804 G A 0.10 0.09 0.02 6.6 x 10-6 0.86 0.03 0.03 
rs117374511 10 134496477 T C 0.06 0.10 0.02 7 x 10-6 0.91 0.63 0.02 
rs11055646 12 14005719 C T 0.13 0.08 0.02 5.6 x 10-7 1.00 0.14 0.22 
rs73162646 12 130464398 C T 0.13 0.08 0.02 1.5 x 10-6 0.99 0.66 0.13 
rs8008067 14 72941207 A G 0.07 0.10 0.02 2.4 x 10-6 0.88 NA NA 
rs8041424 15 97359414 T C 0.06 0.11 0.02 1.9 x 10-6 0.95 0.89 0.02 
rs7199663 16 86608899 C A 0.16 0.07 0.01 1.9 x 10-6 0.95 NA NA 
rs62048038 16 88727961 A T 0.08 0.09 0.02 4.8 x 10-6 0.92 0.71 0.03 
rs2567473 17 70738077 A G 0.75 -0.06 0.01 6.4 x 10-6 0.99 0.17 0.56 
rs1893251 18 19991432 T C 0.05 0.12 0.02 2.9 x 10-7 0.98 0.68 0.12 
rs17602961 18 36627629 A C 0.05 0.11 0.02 5.3 x 10-6 0.99 0.61 0.02 
rs62096323 18 56304224 G C 0.10 0.08 0.02 4.2 x 10-6 0.97 0.48 0.04 
rs75479243 19 2739091 T C 0.08 0.10 0.02 9.2 x 10-6 0.85 0.37 0.02 
 
Table 8: Key results from MS GWAS in ORCADES/VIKING dataset  
Key results from a GWAS of MS on the ORCADES/VIKING dataset (cases: 112, controls: 4223).  
SNPs with a MAF below 0.05 were not considered.  The SNPs listed here have passed the 
suggestive significance threshold of 1 x 10-5 and have the lowest p-value within a 1000 kb region.  
Two SNPs are included for the chromosome 6, 32-33 Mb region to allow the top hit without an 
assigned RSID and a top hit with an assigned RSID to be shown.  Within this results table, it 
should be noted that only one of these SNPs passed the genome-wide significance threshold 
(SNPID chr1_145044288), and so beta values should be read with caution.  The RSID is the 
Reference SNP cluster ID; if no RSID number has been assigned, the SNPID is listed.  Chr is the 
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chromosome the SNP is located on.  Position is the base pair position the SNP can be found at 
GRCh37.  A1 is the reference allele, and A0 is the non-reference allele.  Freq is the frequency of 
the A1 allele within the dataset.  Beta is the effect size estimated in the analysis.  SE is the 
standard error of the effect size.  The p-value is the calculated probability or level of significance 
of the effect.  The IMSGC p-value is the p-value from the SNP from the 2018 IMSGC summary 
statistics (International Multiple Sclerosis Genetics Consortium et al., 2018).  The IMSGC is the 
associated (Europe-wide) frequency for the IMSGC summary statistics (International Multiple 
Sclerosis Genetics Consortium et al., 2018).  Info is a measure of quality for imputation. 
 
Figure 14: Locus zoom plot for chromosome 2 SNP rs1398972 
This locus zoom plot is showing the results from a GWAS on MS in ORCADES/VIKING (cases: 
112, controls: 4223) for the SNP rs1398972 (p-value = 1.5 x 10-7).  This SNP passed the suggestive 
significance threshold of 1 x 10-5 and is the SNP with the lowest p-value within 1000 kb in this 
locus.  On the x-axis is the position on chromosome 2 in Mb.  The y-axis on the left-hand side 
shows the -log10 p-value, while the axis on the right in blue shows the recombination rate in 
cM/Mb.  SNPs are coloured based on the degree of LD (r2) to rs1398972 (indicated by a purple 
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diamond).  Previous significantly associated traits from the GWAS catalogue are shown 
underneath the locus zoom plot, along with gene locations within the plotted region. 
 
 
Figure 15: Locus zoom plot for chromosome 6 SNP rs9268154 
This locus zoom plot is showing the results from a GWAS on MS in ORCADES/VIKING (cases: 
112, controls: 4223) for the SNP rs9268154 (p-value = 9.7 x 10-6).  This SNP passed the 
suggestive significance threshold of 1 x 10-5 and is the SNP with the lowest p-value within 1000 
kb in this locus.  On the x-axis is the position on chromosome 6 in Mb.  The y-axis on the left-
hand side shows the -log10 p-value, while the axis on the right in blue shows the recombination 
rate in cM/Mb.  SNPs are coloured based on the degree of LD (r2) to rs9268154 (indicated by a 
purple diamond).  Previous significantly associated traits from the GWAS catalogue are shown 
underneath the locus zoom plot, along with gene locations within the plotted region.  A large 
proportion of this graph is not plotting SNPs; however, this is not due to genetics.  Rather, a 
large number of SNPs in this region do not have assigned RSIDs.  When LDPlot is used to index 
SNPs for plotting, it uses RSIDs; if a SNP does not have an assigned RSID, it is not plotted.  
Therefore, although there are SNPs present, they are not shown on the plot. 
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Figure 16: Locus zoom plot for chromosome 12 SNP rs11055646 
This locus zoom plot is showing the results from a GWAS on MS in ORCADES/VIKING (cases: 
112, controls: 4223) for the SNP rs11055646 (p-value = 5.2 x 10-7).  This SNP passed the 
suggestive significance threshold of 1 x 10-5 and is the SNP with the lowest p-value within 1000 
kb in this locus.  On the x-axis is the position on chromosome 12 in Mb.  The y-axis on the left-
hand side shows the -log10 p-value, while the axis on the right in blue shows the recombination 
rate in cM/Mb.  SNPs are coloured based on the degree of LD (r2) to rs11055646 (indicated by a 
purple diamond).  Previous significantly associated traits from the GWAS catalogue are shown 





Figure 17: Locus zoom plot for chromosome 18 SNP rs1893251 
This locus zoom plot is showing the results from a GWAS on MS in ORCADES/VIKING (cases: 
112, controls: 4223) for the SNP rs1893251 (p-value = 2.9 x 10-7).  This SNP passed the suggestive 
significance threshold of 1 x 10-5 and is the SNP with the lowest p-value within 1000 kb in this 
locus.  On the x-axis is the position on chromosome 18 in Mb.  The y-axis on the left-hand side 
shows the -log10 p-value, while the axis on the right in blue shows the recombination rate in 
cM/Mb.  SNPs are coloured based on the degree of LD (r2) to rs1893251 (indicated by a purple 
diamond).  Previous significantly associated traits from the GWAS catalogue are shown 






Figure 18: Locus zoom plot for chromosome 18 SNP rs17602961  
This locus zoom plot is showing the results from a GWAS on MS in ORCADES/VIKING (cases: 
112, controls: 4223) for the SNP rs17602961 (p-value = 5.3 x 10-6).  This SNP passed the 
suggestive significance threshold of 1 x 10-5 and is the SNP with the lowest p-value within 1000 
kb in this locus.  On the x-axis is the position on chromosome 18 in Mb.  The y-axis on the left-
hand side shows the -log10 p-value, while the axis on the right in blue shows the recombination 
rate in cM/Mb.  SNPs are coloured based on the degree of LD (r2) to rs17602961 (indicated by a 
purple diamond).  Previous significantly associated traits from the GWAS catalogue are shown 




Figure 19: Locus zoom plot for chromosome 18 SNP rs62096323 
This locus zoom plot is showing the results from a GWAS on MS in ORCADES/VIKING (cases: 
112, controls: 4223) for the SNP rs62096323 (p-value = 4.2 x 10-6).  This SNP passed the 
suggestive significance threshold of 1 x 10-5 and is the SNP with the lowest p-value within 1000 
kb in this locus.  On the x-axis is the position on chromosome 18 in Mb.  The y-axis on the left-
hand side shows the -log10 p-value, while the axis on the right in blue shows the recombination 
rate in cM/Mb.  SNPs are coloured based on the degree of LD (r2) to rs62096323 (indicated by a 
purple diamond).  Previous significantly associated traits from the GWAS catalogue are shown 
underneath the locus zoom plot, along with gene locations within the plotted region. 
 
4.4 Discussion 
Summary of Findings 
In this chapter, a genome-wide association study was performed on a dataset containing 
112 Multiple Sclerosis cases and 4223 controls from Orkney and Shetland.  A common 
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MS risk variant, unique in frequency to the Northern Isles of Scotland, may exist; this 
study was undertaken to detect if such a variant existed. 
In this study, six separate regions (separate defined as 1000 kb apart) were detected 
with suggestive significance.  One of these regions was previously associated with MS, 
therefore we were powered to detect a real MS variant at suggestive significance.  
However, there was no evidence from larger population studies that other suggestive 
variants detected were associated with MS.  These variants are therefore false positives 
or are in LD with an unusual variant in Orkney. 
A chromosome 6 region in this study (lead SNP rs9268154, p-value of 9.7 x 10-6) was 
previously associated with MS in the IMSGC study (International Multiple Sclerosis 
Genetics Consortium et al., 2018).  This SNP was in LD (0.4 < r2 < 0.65) multiple SNPs 
in the HLA region, including HLA-DRB1*1501 SNP rs3135388 (r2 = 0.65).  Significant 
variants within the HLA region are well known to associate with increased MS 
susceptibility, for example MS cases carry HLA-DRB1*1501 twice as frequently as 
healthy controls (Sawcer et al., 2011). 
The detection of a previously identified MS risk variant shows that the methodology in 
this study works to detect a variant at the suggestive significance level.  However, as this 
is one of the strongest known MS associations and it is one of the most significant 
variants in this study, it suggests that there isn’t a Northern-Isles-specific common 
variant that is dominating the phenomenon of excess MS cases in the region.  If a 
common variant of stronger effect size were present in the Northern Isles population, it 
would have been detected with a better significance in this study. 
However, the other variants that are detected at suggestive significance may be MS-
associated variants unique to the Northern Isles.  Although they may be due to chance, 
it is possible that with greater power these regions could be genome-wide significant.  It 
is important to note that the SNP results from this study are discussed tentatively, with 
the knowledge that none of the association results considered below achieved genome-
wide significance.  Discussion is speculative based on suggestive (5 x 10-8 < p < 1 x 10-5) 
findings, and these variants did not reach significance in the larger IMSGC study 
(International Multiple Sclerosis Genetics Consortium et al., 2018). 
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Discussion of suggestive variants 
One of the six suggestive hits, chromosome 2 SNP rs1398972 (p-value 1.49 x 10-7), was 
found to have a frequency of 0.32 in the Northern Isles dataset, which is higher than 
that of the IMSGC study (frequency 0.13). There would thus be about three times more 
power in the Northern Isles for a given sample size, however the IMSGC study is much 
more than three times the size of the present study and so is the more powerful study 
even for this variant.  The SNP itself did not have any reported clinical significance, 
however it was within 100 kb of a locus associated with Alzheimer disease, another 
neurodegenerative disease.   The nearest gene to rs1398972 was LINC01117, Long 
Intergenic Non-Protein Coding RNA 1117.  Long non-coding RNAs (lncRNA) have been 
extensively studied in recent years, and have associations with many complex diseases, 
including Multiple Sclerosis (Cipolla et al., 2018).  For example, lncRNA GAS5 was 
found to be differentially expressed in individuals with MS, indicating it has a role in the 
function and regulation of the immune system (Mayama, Marr and Kino, 2016).  
LncRNAs themselves do not translate into proteins, and are involved in the regulation 
of transcription processes, post-transcription processes (such as splicing and 
translation) and epigenetic processes.  It is possible that this locus may have a causative 
role in Multiple Sclerosis, or that LINC01117 may be have a role which influence 
immune system function. 
Another suggestive hit, rs11055646 on chromosome 12, had a p-value of 5.6 x 10-7.  
There were several SNPs around this 14Mb region on chromosome 12 with a strong 
correlation to rs11055646 (r2 > 0.6), all within the GRIN2B gene.  This gene codes for 
GluN2B, a protein found in brain neurons primarily in development before birth.  This 
protein makes up part of the NMDA (N-methyl-D-aspartate) receptors on the neuron, 
which works as a channel to allow the flow of cations: the flow of cations excites the 
neurons to allow them to pass on cell signals and helps in the process of neuron 
maturation (Zarate et al., 2006).  This gene has previously been associated with 
immune response to smallpox (Kennedy et al., 2012) and several neurodevelopmental 
disorders including attention deficit hyperactivity disorder and schizophrenia (Kim et 
al., 2018).  De-novo mutations in this gene are known to cause GRIN2B-related 
neurodevelopmental disorders, characterised by developmental delay and intellectual 
disability in known cases (Platzer and Lemke, 1993).  As this gene is strongly tied to 
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brain development and neuron function, it is possible that an allele may be associated 
with Multiple Sclerosis development.  
The final suggestive hits were found on chromosome 18.  Chromosome 18 SNP 
rs1893251 had a p-value of 2.9 x 10-7.  The most closely located gene to this SNP was 
CTAGE1 (within 2000 kb).  CTAGE1 produces the tumour antigen Cutaneous T Cell 
Lymphoma-Associated Antigen 1 (Koch et al., 2003).  Cutaneous T cell lymphomas are 
a group of non-Hodgkin’s lymphomas that are derived from T cells.  The development 
of this type of cancer has been noted as a side effect in treatment of the MS drug 
Fingolimod (Kappos et al., 2015; Papathemeli et al., 2016).  Fingolimod is an 
immunomodulator and prevents the migration of T and B cells from the lymph nodes to 
circulate in the bloodstream.  Although the association in this study is only suggestive, it 
may indicate a potential link between MS, Fingolimod and cutaneous T cell lymphoma.  
Chromosome 18 SNP rs17602961 (p-value 5.3 x 10-6) was in strong LD with several 
SNPs in nearby gene MIR924HG (also known as Long intergenic non-protein coding 
RNA 669), the only gene within the region.  This gene has no known association with 
any disease in Northern Europeans, and so it is likely this result is due to chance.  
The final chromosome 18 SNP, rs62096323, had a p-value of 4.2 x 10-6.  This SNP is 
within 0.1 Mb of (but not in LD with) known MS SNP rs7238078, on MALT1, which is 
essential for regulating the NF-κB pathway and known to have a role in Multiple 
Sclerosis development (Juilland and Thome, 2018).  Mice which are deficient in Malt1 
have impaired B and T cell responses and problems in the development of lymphocyte 
subsets, and are resistant to the induction of experimental autoimmune encephalitis, a 
mouse model of MS (Brüstle et al., 2012; Mc Guire et al., 2013).  The dysregulation of 
MALT1 can result in immunodeficiencies and autoimmunity, as well as psoriasis and 
cancer.  As it has enzymatic activity, it has the potential to be targeted by drugs; a 
MALT1 inhibitor has been used to relieve paralysis symptoms of MS (Jaworski et al., 
2014; Bornancin et al., 2015).  This study provides further evidence, although 
suggestive, of the involvement of MALT1 in MS. 
However, the discussion of these suggestive associations in this study remains 
speculative.  In investigating a specific, small population such as Orkney and Shetland, 
identifying genome-wide significant associations will be challenging.  In GWAS, one of 
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the most common ways to increase power is by enlarging the sample size (Sawcer et al., 
2011): Orkney and Shetland have small populations (~ 21,000 and 23,000 respectively), 
of which a small fraction have Multiple Sclerosis.  As many of these cases are already 
present within the study, it is impossible to increase the sample size without waiting 
decades for more cases to arise. 
Originally, this study set to identify if there were any SNPs which may have experienced 
a jackpot effect within the Northern Isles, where a large effect MS risk variant rarer 
elsewhere exists in the Northern Isles at a higher frequency, due to the effect of drift and 
low effective population size.  These results suggest that because a real MS variant was 
detected at suggestive significance, there isn’t a Northern-Isles specific common variant 
that is dominating the phenomenon of excess MS cases in the region.  However, the lack 
of evidence produced here does not discount the idea that the jackpot effect may have 
increased the frequency of a rare MS risk allele or alleles to greater frequency.  It may be 
the case that rare MS risk SNPs exist in this population at an increased frequency but 
were not detected due to small case numbers in this study. In general, the results were 
underpowered due to the limited number of MS cases.   
Finding Implications 
The GWAS did produce several suggestive results which may, given more cases, have 
been significantly associated with MS: at the least, this study has highlighted some 
potential regions of the genome for further investigation which have the potential to be 
validated in future studies.  The loci identified have potential functions within the 
immune system; previous enrichment methods in MS have strongly implicated immune 
system cells, and it is thought that a large percentage of MS variants alter the regulation 
of immune-related genes (Patsopoulos, 2018).  However, the clarification of these will 
need to utilise methods that go beyond GWAS.  A principal goal of GWAS is to identify 
risk variants, and subsequently genes and causal pathways in disease risk and 
development.  This has been achieved with relative success over the past 14 years with 
the use of moderate to large population samples, particularly with Multiple Sclerosis 
(International Multiple Sclerosis Genetics Consortium et al., 2017).  However, the 
future of GWAS lies in using the genetics of hundreds of thousands of individuals with 
mega-biobanks.  This will lead to the discovery of more variants (particularly those of 
smaller effect size and rare variants), account for more genetic variation and will give a 
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more complete picture of genetic architecture and understanding of biological 
pathways.  In turn, genetic predictors will have improved accuracy and the ability to 
assess disease and develop diagnosis methods based on genetic testing will improve.  
Although this progression of GWAS is good for many aspects of understanding disease, 
small populations with unique or rare variants at a higher frequency will not benefit 
from this. As such, analysis methods for these populations should apply other methods 
which are more suited to a limited sample size.  For example, whole genome sequencing 
is an expensive method of analysis, but could be applied to small populations to identify 
unique rare variants.  Additionally, a regional heritability approach could be used by 
treating known susceptibility loci as the genomic region.  This would capture more of 
the genetic variance and identify additional loci in comparison to a traditional GWAS. 
The discovery of genetic associations is not the end goal with MS research; it is to 
identify causal genes and their functional consequences.  Unfortunately, with small 
populations in which unique, rare variants may play an important role, GWAS is not 
always the most effective method to achieve this end goal. 
Study Limitations 
This GWAS was principally limited by sample size.  In order to maximise sample size, 
there were two options: i) conduct a GWAS separately on each population and meta-
analyse the results or ii) create a merged dataset and conduct one large GWAS.  Both 
options had positive and negative aspects.  The first option would avoid any errors that 
may arise in merging both datasets, however the second option would allow the GRM to 
give an overarching view of relatedness between ORCADES and VIKING.  There is some 
migration between the two population groups, and it is possible that individuals have 
relatives within the other island group.  The overlapping PCA plots from Chapter 2 give 
further evidence to support the second method.  Therefore, it was decided that a merged 
dataset would be created, to account for this relatedness and reduce any potential bias 
in meta-analysing results from two non-independent populations.  However, there is 
some issues surrounding this method.  Primarily, ORCADES and VIKING were 
genotyped on different arrays.  By pooling imputed results from the two cohorts, any 
heterogeneity between studies is amplified; even small individual effects due to 
platform specific errors such as genotyping batch effects may result in false positive 
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results.  However, to counteract this, stringent QC methods (both before and after 
imputation) were carried out to remove any potential sources of bias. 
 
4.5 Conclusion 
This study carried out a genome-wide association study on 112 Multiple Sclerosis cases 
and 4223 controls from the Northern Isles of Scotland.  This study is not able to provide 
substantial evidence towards the understanding of the high prevalence of MS in the 
Northern Isles, due to the low case numbers used in this study.  However, it is unlikely 
that there is a dominating common variant beyond those that are already known in the 
literature (primarily those within the HLA region).  There are several suggestive loci 
which do not have a previous association with MS.  These may have arisen by chance or 
may be in LD with an unusual variant in Orkney.  These suggestive loci are: i) a 
chromosome 2 SNP (rs1398972), found near lncRNA gene LINC01117 (some lncRNAs 
have previously been linked to Multiple Sclerosis); ii) a chromosome 12 SNP 
(rs11055646) found within the GRIN2B gene, an important contributor to 
neurodevelopment; iii) a chromosome 18 SNP (rs1893251) found near CTAGE1, 
suggesting a possible link between CTAGE1, cutaneous T cell lymphoma and MS 
(cutaneous T cell lymphoma has been reported as a side effect of taking MS drug 
fingolimod) and iv) a chromosome 18 SNP rs62096323 which was found near MALT1, a 
known MS-associated gene.  A further group of SNPs was found on chromosome 18 
(lead SNP rs17602961), however there was no evidence of involvement in any related 
disease.  Although these results remain speculative, they may be of interest for further 
research using alternative methods to GWAS. 
Orkney and Shetland have some of the highest rates of Multiple Sclerosis in the world, 
and to date, a GWAS has not been conducted on this region as a whole.  Although it was 
unlikely that any significant findings would be discovered in the dataset, given the 
number of cases, it was necessary to carry out this GWAS to rule out this possibility. To 
date, GWAS have been successful in reporting results for thousands of complex traits, 
including common diseases, quantitative traits, behavioural traits (such as educational 
attainment) and genomic measures (such as gene expression).  However, this method of 
analysis favours large sample sizes in order to detect small effect and rare variants.  The 
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results here do not rule out the possibility of unique, rare or jackpot variants 
contributing towards the high prevalence of MS in the islands; it merely highlights the 
limitations of the method applied.  As such, the future for MS research in Orkney and 




















CHAPTER 5: CONTRIBUTION OF COMMON RISK 
VARIANTS TO MULTIPLE SCLEROSIS IN THE 
NORTHERN ISLES OF SCOTLAND 
This chapter looks at the contribution of common risk variants to the prevalence of 
Multiple Sclerosis in Orkney, Shetland and mainland Scotland.  The Northern Isles, 
particularly Orkney, have an excess of MS prevalence and this chapter seeks to 
determine the role common risk variants play in that excess risk.  The hypothesis is that 
Orkney, and to a lesser extent Shetland, will have an increased burden of common risk 
variants for Multiple Sclerosis when compared to mainland Scotland. 
 
5.1. Introduction 
5.1.1 What are common risk variants? 
Common risk variants are found in all human populations and can individually 
influence the risk of developing a complex disease by conferring a relatively small 
additive or multiplicative effect on a disease phenotype (Gibson, 2012).  They remain 
prevalent in the population due to their small effect size, as it is typically only large 
effect alleles that are purged from the population due to selection (Reich and Lander, 
2001). 
The odds ratios of common risk variants typically lie between 1.1 and 2 (Bodmer and 
Bonilla, 2008), and can go down to 1.02 or less.  When examined as a group, a collective 
assessment of their effect on disease risk can be determined.  This combined effect can 
significantly impact disease risk; therefore, it is important to determine the genetic 
effects and cumulative risk of these variants when examining the genetic components of 
a complex disease.  
The cumulative risk of common risk variants on developing a disease phenotype can be 
assessed using a polygenic risk score (PGRS) (Tesli et al., 2014).  Polygenic risk scores 
provide a method to summarise disease risk by using the estimated effect size to weigh 
the genetic dosage of each allele and produce an aggregate risk score including many 
susceptibility loci (Coleman et al., 2016).  This condensation of genome-wide SNP data 
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into a singular summary measure means that the detection of a genetic signal can be 
achieved using a lower sample size than would be required in a GWAS (Peyrot et al., 
2014): this is particularly useful when using a smaller dataset such as in this research. 
To calculate a PGRS, an initial GWAS is carried out on a discovery sample and the odds 
ratios produced are then used to construct a score for every individual in an 
independent sample.  The initial discovery sample GWAS determines the likelihood that 
each marker is associated with a specific disease phenotype (Dudbridge, 2013).  It is 
conventional to use a previously conducted GWAS or GWAMA provided that there is no 
overlap of individuals between the GWAS and the population that the risk score is 
calculated for, as this may inflate PGRS results.  Continental ancestry must also remain 
the same between the discovery sample and the independent sample to avoid 
population stratification, as discussed in Chapter 2.  A large discovery sample size is 
favourable, as this will yield more accurate effect sizes for the markers and it is more 
likely that a PGRS calculated using these values will explain more disease variance 
(Dudbridge, 2013). 
After choosing a set of results from an appropriate discovery GWAS, the SNPs are 
clumped to remove linkage disequilibrium.  When a SNP is in linkage disequilibrium 
with another SNP in a sample, one locus is, in effect, represented more than once.  This 
can bias results and lead to artificially inflated PGRS scores.  Clumping can remove 
SNPs in linkage disequilibrium with another SNP by assessing blocks of SNPs within a 
specified window, identifying those which are in linkage disequilibrium with one 
another, then removing the least significant SNPs until only one SNP in the clump 
remains.  Linkage disequilibrium is assessed using the r2 value: the square of the 
correlation coefficient between two variables which denote the absence or presence of 
an allele at two loci (So and Sham, 2017).  Typically, an r2 value between 0.2 and 0.5 is 
the minimum value used to classify a pair of SNPs as in LD with one another (Ware et 
al., no date; Mak et al., 2017; So and Sham, 2017).  More stringent thresholds are 
typically applied to larger (>1000) sets of SNPs where there is a higher chance of having 
SNPs in LD with one another. 
Following the finalisation of a list of markers and their corresponding odds ratios, risk 
scores are calculated by multiplying the effect size by the number of risk alleles at a 
locus (none, one or two).  The values at all loci are then summed for each individual, 
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  (14) 
where   PGRS is the polygenic risk score, 
i is the susceptibility locus, 
  j is the individual, 
  n is the total number of SNPs, 
OR is the OR of the risk allele and 
AD is the allelic dosage of the risk allele. 
 
Polygenic risk scores can be calculated over multiple p-value thresholds; for example, 
PGRS have the potential to include several SNPs which have previously reached a 
genome wide significance level, or hundreds and thousands to millions of SNPs across 
the genome which have not previously reached statistical significance, but nevertheless 
associate with the phenotype to some degree (Tesli et al., 2014). 
Risk scores can traditionally be used in two separate ways - to assess an association 
between the disease of interest and score in an independent sample, or to predict an 
individual's disease risk (Dudbridge, 2013).  The former is carried out to determine if 
the markers used to construct the score are truly associated with the disease, and the 
latter is used to provide a more accurate, discriminatory predictor for disease by 
considering small effect markers as a whole (Wray, Goddard and Visscher, 2007), and 
to add to traditional, clinical risk factors.  To assess disease prediction in binary traits 
such as Multiple Sclerosis, the area under the receiver-operator characteristic curve is 
calculated, as binary traits are assumed to come from a liability threshold model where 
a threshold exists that divides the group of individuals into the two separate trait 
categories; cases and controls (Neale, Neale and Ben, 2014).  The ROC curve plots the 
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true positive fraction (also known as the sensitivity or probability of detection) against 
the false positive fraction (or 1-specificity or the probability of false alarm) (Hajian-
Tilaki, 2013).  The greater the value of the area under the curve, the more accurately the 
diagnostic test (in this case, PGRS) can discriminate between cases and controls 
(Hajian-Tilaki, 2013).   
Each application for the PGRS has variable considerations to take into account: the 
power of association testing between PGRS and a disease phenotype depends on the 
sample size of the replication analysis, whereas determining predictions for individuals 
disease risk depends on the discovery sample size (Dudbridge, 2013).   
 
5.1.2 The contribution of common risk variants to disease 
The idea that common risk variants could explain the high levels of MS found in Orkney 
and Shetland was first suggested in 1981 by Compston, who implied that Orcadians in 
general may have a higher frequencies of common risk variants (Compston, 1981).  
Citing HLA-B7, Dw2 and DR2 specifically, he stated that controls in Orkney had a 
higher frequency of these variants than controls in the UK, Northern Europe and United 
States (Compston, 1981).  This hypothesis had not previously been studied in Orkney, 
however common risk variants have previously been looked at in other populations for 
MS, with the principal study carried out by The International Multiple Sclerosis 
Genetics Consortium in 2010 (International Multiple Sclerosis Genetics Consortium, 
2010).  This study used two previously published datasets in their analysis: the IMSGC 
GWAS from 2007 (a study which revealed novel susceptibility locus IL2RA and 
confirmed IL7R) (Hafler et al., 2007) and the Partners MS Centre GWAS data (De 
Jager, Jia, et al., 2009).  These datasets were chosen for their sample sizes (931/2431 
and 806/2077 cases/controls, respectively), high quality control procedures and 
standardised MS diagnosis criteria (McDonald et al., 2001; Hafler et al., 2007; De 
Jager, Jia, et al., 2009).  The IMSGC GWAS was used as the discovery dataset, and the 
aggregate PGRS generated were used to conduct a logistic regression analysis to assess 
the disease status / score relationship (International Multiple Sclerosis Genetics 
Consortium, 2010).  Varying SNP sets (determined by p-value threshold) significantly 
associated with disease status, suggesting that common risk variants within the genome 
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contribute to the polygenic inheritance of MS.  Specifically, around 3% of the total 
variance for MS risk (as estimated by Nagelkerke’s pseudo R2) was explained by the 
combined effect of 12, 627 SNPs where all SNPs had p < 0.2 from the discovery sample.  
The Nagelkerke’s pseudo R2 value had a significant fit, where p= 9.9 x 10-19.  This 
reaffirmed the idea that MS is partly caused by modest effect variants spread across the 
genome (International Multiple Sclerosis Genetics Consortium, 2010).  
Polygenic risk scores have also been used to study other complex diseases, such as 
schizophrenia (Purcell et al., 2014); case-control status for schizophrenia has been 
successfully predicted to a high level of statistical significance using PGRS (Purcell et 
al., 2014).  Previously, the common variants for this disease remained largely unknown 
with only a small number of significant markers identified (Purcell et al., 2009).  
However, an initial GWAS identified many common variants, and an independent 
follow-up PGRS study was able determine an association between almost half the 
markers from an initial GWAS and the disease (Purcell et al., 2009).  These markers 
also associated with bipolar disorder, establishing a common polygenic basis for both 
diseases (Purcell et al., 2009).   
Polygenic risk scores are useful to highlight the potential burden that carrying multiple 
risk alleles can have on your disease susceptibility. For example, in prostate cancer, 36 
validated genetic variants have been associated with disease risk, with the odds ratios 
varying from 1.1 to 1.6 (with the majority residing closer to an OR of 1) (Aly et al., 2011).  
Many researchers have speculated against the clinical use of identifying these genetic 
markers, however it has been shown that carrying an increasing number of these 
markers can lead to an increased risk of developing a disease (Zheng et al., 2008).  
PGRS allow genetic risk profiles to be calculated for individuals, which has the potential 
to lead to an improved accuracy of disease prediction.  This was shown with prostate 
cancer: a PGRS was constructed using the most significant 35 SNPs associated with the 
disease (Aly et al., 2011).  When the PGRS was used to predict prostate cancer risk, 480 
biopsies (22.7%) carried out could have been avoided than if the model had been used, 
with a cost of 3% of patients with an aggressive form of the disease being missed in 
diagnosis.  By using the PGRS in risk prediction, unnecessary invasive biopsies could be 
avoided (Aly et al., 2011).  Using SNPs to inform a genetic risk profile in this manner 
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has a number of benefits; they are an affordable method of testing, easy to analyse, and 
they only need be measured once (Aly et al., 2011). 
Polygenic risk scores have multiple important uses, both within research and in a 
clinical setting.  Most importantly for this study, they can be used to quantify and 
compare the genetic burden of common risk variants within and between populations.   
 
5.1.3 Research aims 
Extensive studies have proven that Multiple Sclerosis risk is heavily influenced by 
genetic variation, from the initially identified HLA-DRB1*1501 to now over 200 loci 
associated with MS susceptibility.  However, many aspects of Multiple Sclerosis, 
including the excess risk of MS in the Northern Isles of Scotland, are not well 
understood, despite Orkney having the highest confirmed prevalence of MS globally.   
Populations such as Orkney and Shetland can remain relatively genetically independent 
from other populations through geographic isolation (Hatzikotoulas, Gilly and Zeggini, 
2014).  This can be compounded by many factors, including having multiple founding 
events (for example in Finland, which had 500- and 2000-year-old isolates in one 
region) (Peltonen, Palotie and Lange, 2000), variation in founder numbers, the 
occurrence of genetic bottlenecks, age of isolation events and endogamy levels 
(Hatzikotoulas, Gilly and Zeggini, 2014).  These events uniquely shape the genetics of 
population isolates and can alter disease prevalence.  This typically results in unique 
rare disease alleles; however, it is also possible for isolated populations to have different 
frequencies of common genetic variants.  If the founders of Orkney, by chance, had 
higher frequencies of common risk variants for Multiple Sclerosis, this may explain the 
excess MS prevalence seen in the islands. 
If the effect size of a discovered variant is small, the effect of this variant alone is often 
not significant to an individual.  However, the cumulative effect of many variants can 
often be more meaningful to a person in the context of their own individual risk.  This 
can bring understanding the genetic architecture of Multiple Sclerosis within Orkney 
and Shetland has the potential to influence and improve healthcare on the islands, and 
the progression of MS research and therapy.  By identifying the structure of the 
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underlying genetic architecture of complex traits, both short and long-term research 
and healthcare benefits can be gained, both locally within the Northern Isles and for 
global disease understanding.  If common risk variants are not the cause of the excess 
prevalence of MS in the Northern Isles, research can be focused on other genetic causes 
such as identifying unknown rare variants.  Identification of rare variants can direct the 
search for novel therapeutic targets in drug development or diagnostic testing.  
Conversely, confirmation that common risk variants are a large contributor to excess 
Multiple Sclerosis prevalence in Orkney has the potential to improve disease risk and 
susceptibility prediction, leading to attention on prevention and early detection tactics.  
Generally, increased knowledge in the underlying causes of the genetics of Multiple 
Sclerosis can influence the design of future studies to further understand and implicate 
causal genes.  This is particularly evident in drug development pipelines, where the 
majority of failures (less than 5% of potential drugs come to fruition) are due to 
insufficient disease models and improper knowledge of biology (Plenge, Scolnick and 
Altshuler, 2013).   
The first chapter of this thesis discussed the various methods that have been used to 
understand the genetic architecture of MS in Orkney and Shetland.  Both island groups 
have an excess of MS prevalence that has yet to be explained.  This research in this 
chapter aims to uncover the impact of common risk variants for MS to elucidate if this is 
the reason why the prevalence of MS is significantly higher in the two island groups.  
Broadly, this chapter aims to answer the following question: how do common risk 
variants for MS in the Northern Isles compare to those in mainland Scotland? 
Common risk variants will first be selected to compile the PGRS.  These will be assessed 
individually between populations by calculating the allele frequencies of each individual 
variant and determining if there is a significant difference in any one variant between 
populations.  The hypothesis is that Orkney, and to a lesser extent Shetland, should 
have a higher overall frequency of common risk variants than mainland Scotland.  
These variants as a collective will then be used to construct a PGRS.  It is expected that 
the tag SNP for the HLA-DRB1 locus, which has the most significant association with 
MS, will have the largest impact on the PGRS.  Therefore, PGRS will be constructed 
with and without this allele to assess its effect in contributing to the collective effect of 
common risk variants.   
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As a control measure, PGRS will be compared between cases and controls, with the 
hypothesis that cases will have a higher score than controls. 
The contribution of common risk variants to explaining variance in MS risk will then be 
assessed, along with the ability of common risk variants to predicting MS status.  This 
will determine the importance of common risk variants collectively in explaining MS 
risk and will indicate how useful these variants can be in a clinical setting, as well as 
providing an indicator of quality for the constructed PGRS.  
Finally, the common risk variants will be compared at a population level between 
Orkney, Shetland and mainland Scotland. If the Northern Isles by chance have higher 
frequencies overall of the common MS risk variants, due to the population founders 
carrying more of these variants, it would be expected that they would have a 
significantly higher PGRS than the PGRS of mainland Scotland.  The collective effect of 
the common risk variants may then help in explaining the increased prevalence seen in 
the Northern Isles.  If the Northern Isles do not have a significantly higher burden from 
common risk variants when compared to mainland Scotland, then it may suggest 
specific (rare) genetic variants or environmental conditions, or some interaction of 
these, may be the cause.   
 
5.1 Methods 
5.2.1 Study population quality control 
In addition to the standard quality control methods carried out on the study 
populations (see Chapter 2), several specific quality control measures for this analysis 
were implemented.  Along with ORCADES and VIKING, the Generation Scotland (GS) 
cohort is used as a sample of individuals from mainland Scotland.  This cohort contains 
over 24,000 individuals from regions including Glasgow, Ayrshire, Tayside and the 
North-East of Scotland (Smith et al., 2013).  There is potential for overlap between 
ORCADES and GS, as many individuals from Orkney live in the North-East of Scotland 
and could possibly be included in the Generation Scotland dataset.  To ensure the GS 
dataset was representative of mainland Scotland only, in terms of latitude as well as 
 106 
genetics, only individuals from Glasgow and Dundee were kept for this study, with the 
other individuals excluded. 
 
5.2.2 Selecting common risk variants for MS risk 
To assess the contribution of common risk variants to Multiple Sclerosis risk and 
compare this burden across populations (mainland Scotland, Orkney and Shetland), a 
comprehensive list of variants was compiled along with previously reported odds ratios.  
Within this list, it was important that the probability of linkage disequilibrium between 
variants was minimised, as LD allows the preferential retention of variants with more 
significant p-values, leading to biased and inaccurate results (Pasaniuc and Price, 2017).  
Therefore, strict quality control thresholds were applied to the list of variants. 
Sourcing Common Risk Variants 
To compile a list of common risk variants for Multiple Sclerosis, two key sources were 
used: the GWAS Catalogue (Welter et al., 2014) and the 2011 International Multiple 
Sclerosis Genetics Consortium Nature GWAS (International Multiple Sclerosis Genetics 
Consortium, 2011).  The GWAS Catalogue is a curated collection of all published GWAS 
results, and was the primary resource used to compile the list of SNPs.  However, the 
GWAS Catalogue only curates SNPs with a minimum p-value threshold <1 × 10−5; 
therefore, the results from the largest MS GWAS were also examined to add any 
additional SNPs whose p-values did not pass this threshold.  The 2011 IMSGC GWAS 
was chosen as this was the most recent and largest IMSGC GWAS that did not contain 
ORCADES individuals (ORCADES individuals were used in the 2013 IMSGC GWAS 
(Beecham et al., 2013) and so using these results to generate a PGRS in ORCADES 
would have led to inflated results). 
The raw GWAS Catalogue was downloaded (v1.0_e88_r2017-03-30) and SNPs were 
kept if the disease trait was listed as “Multiple Sclerosis” and the study that the data 
originated from only included European individuals (n SNPS = 175).  Summary 
statistics for the 2011 IMSGC were obtained online at ImmunoBase (ImmunoBase, 
2019); of the 102 SNPs listed, 82 were already listed in the GWAS Catalogue.  The 20 
remaining SNPs from the 2011 IMSGC paper which were not already present in the 
GWAS Catalogue were added to the discovery SNP set (n SNPs = 195).   
 107 
Quality Control of the Common Risk Variant List 
A total of 195 SNPs were compiled from both the GWAS Catalogue and the 2011 IMSGC 
GWAS results.  However, several strict quality control procedures were applied to 
ensure that PGRS results produced from this list were not biased or inaccurate. 
SNPs that did not have reported odds ratios and / or risk alleles were removed (leaving 
n SNPs =166).  There were 12 pairs and 1 trio of duplicated SNPs, either due to being 
listed more than one time in the GWAS Catalogue or listed both in the GWAS Catalogue 
and in the IMSGC results.  Inverse variance meta-analysis was performed within each 
duplicated group of SNPs, resulting in one SNP with a meta-analysed odds ratio and p-
value to replace each group of duplicate SNPs (leaving n SNPs = 152).  The inverse 
variance meta-analysis was calculated by first finding the log of the odds ratio for all 
SNPs within the duplicate group (the β).  The inverse of the normal cumulative 








                                                      (15)  
where   f is the inverse of the normal cumulative distribution, 
µ is the mean of the distribution (in this case, 0), 
  σ is the standard deviation (in this case, 1) and 
x is the independent variable for evaluation (the p-value determined 
from the source study). 
 
The absolute value of this result was used to divide β for each SNP to find the standard 
error, which was in turn used to divide β to determine the z-score.  The p-value for this 
z-score was obtained by applying the normal probability density function, with x 
defined as the absolute value of the z-score, and µ=0, σ=1, with the value multiplied by 2 
to get the p-value.  The precision estimate for each SNP was calculated by squaring the 
inverse of the standard error. These calculations were carried out for every SNP within 
each duplicate group.  Finally, to obtain the meta-analytical values, the beta for each 
SNP was multiplied by the precision estimate.  These were then summed within each 
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duplicated group then divided by the summed total of the precision estimate.  Meta 
analysed standard errors were taken from the inverse of the square root of the precision 
estimate.  Meta analysed z-scores were taken by dividing the meta analysed β by the 
meta analysed standard error.  Finally, the meta analysed p-value was calculated as 
described above, with x equal to the meta-analysed z-score.  The meta analysed odds 
ratios were taken by finding the exponent of the meta analysed β. 
Of the 152 SNPs remaining, 15 SNPs were not present in the HRC-imputed data for 
ORCADES, VIKING and Generation Scotland.  LDLink v3.3 (Machiela and Chanock, 
2015), a tool designed to assess linkage disequilibrium using genotypic data from Phase 
3 of the 1000 Genomes Project, was used to search for proxies for these SNPs.  Each 
missing SNP was queried using its associated RSID and a specified 1000 Genomes 
population group, in this case Europe (which included the 1000 Genomes Project 
populations CEU; Northern Europeans from Utah, TSI; Tuscans from Italy, FIN; 
Finnish in Finland, GBR; British in England and Scotland and IBS; Iberian Population 
in Spain) (Clarke et al., 2012).  This returned a list of proxy variants for each SNP, 
ranked by r2.  If a proxy variant was present in the HRC-imputed datasets and had both 
an r2 and D’ above 0.90, the proxy variant was used in replacement of the missing SNP: 
11 out of the 15 missing SNPs were replaced in this manner (n SNPs =148).  Four SNPs 
were not replaced as they did not have a proxy SNP that matched the threshold 
requirements. 
Finally, the remaining compiled SNPs were clumped for linkage disequilibrium, with a 
cut-off threshold of r2=0.25 within a 200-kb window or clump, removing a further 21 
SNPs (n SNPs =127).  The LD values were calculated by determining the deviation of the 
observed haplotype frequency from the allele frequencies that were expected under 
equilibrium.  Different r2 thresholds were trialled in clumping (r2=0.25, r2=0.40, 
r2=0.50) based on r2 values used as cut-offs in previously published polygenic risk score 
studies; the effect of increasing the r2 threshold from 0.25 to 0.50 allowed an additional 
6 SNPs to be included in the risk score calculation, however the effect of this was not 
significant in the results, and so a stricter r2 threshold was applied for the results. 
This quality control procedure narrowed the compiled list of common risk variants from 
195 to 127 and ensured that bias was kept to a minimum while retaining as many SNPs 
as possible. 
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5.2.3 Assessing the effect of the HLA-DRB1 locus 
In assessing the effect of an aggregate collection of common risk variants, it was 
important to determine the contribution from the HLA-DRB1 locus, the most strongly 
associated MS risk variant with by far the largest effect size (OR: 2.77, p-value: 3.2 x 10-
199).   
To investigate the effect of HLA-DRB1, PGRS were calculated both with and without 
rs9271069 (an HLA-DRB1 tag SNP; R2 = 1, D’ = 1), and risk scores were calculated for 
rs9271069 alone. 
 
5.2.4 Calculating common risk variant frequencies 
To provide more information when assessing the difference in PGRS between 
populations, the frequencies of the common risk variants in each population were 
calculated.  At a population level, the mean PGRS ultimately depends on the frequency 
of each allele within the population.  For example; if the PGRS of two hypothetical 
populations were compared and population A was found to have a mean PGRS that is 
significantly higher than population B, this could potentially indicate that there is a 
small number of high effect alleles that have a significantly higher frequency in 
population A (with the other alleles in a lower frequency), or that all alleles have a 
slightly higher frequency in population A: not enough to be significantly different, but 
enough to increase the PGRS overall.  Calculating the frequencies of the common risk 
variants therefore gives more information as to the construction of the PGRS. 
The frequency of all common risk variants were calculated in individuals without MS, 
allowing the general population frequency to be assessed without bias.  Allelic count 
data was calculated for Generation Scotland, ORCADES and VIKING genotypic data 
using qctool v1.4 (Band and Marchini, 2018).  The allelic counts were used to determine 
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where   RAF is the risk allele frequency, 
AA is the count of individuals homozygous for allele A, 
  AB is the count of heterozygous individuals and 
BB is the count of individuals homozygous for allele B. 
 
A comparison of RAF was made between Generation Scotland and both ORCADES and 








where   m. is the chi-squared statistic, 
Oi are the observed count of allele i and 
  Ei are the expected counts of allele i. 
 
A Bonferroni-corrected threshold of 0.0004 (0.05 / 126) was used to determine 
significance following multiple testing at 126 loci.  
 
5.2.5 Calculating polygenic risk scores 
Polygenic risk scores were calculated using the R package PRSice (v1.25), which used 
the HRC-imputed dosage data for ORCADES, VIKING and GS as the target SNP set 
along with the effect sizes from the discovery SNP set to calculate risk scores for all 
individuals.  Risk scores were calculated using Equation 14: an individual’s dosage of a 
risk allele is weighted using the previously calculated log odds ratio to weight the 
dosage, and this is summed for every SNP for the individual. 
Different groups of SNPs can give more accurate risk scores than others, and so PGRS 
were calculated for several groups of SNPs based on different thresholds for the 
reported p-value that accompanied the reported OR.  Polygenic risk scores were 
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calculated at the following p-value thresholds (pT): pT 5 x 10-8 (n SNPs=61), pT 5 x 10-6 
(n SNPs =101), pT 0.0005 (n SNPs =126) and pT 0.05 (n SNPs =127).  Two main 
criteria for selection of a p-value threshold were in place: i) success in distinguishing 
between MS cases and controls (as determined by p-value significance) and ii) the value 
of Nagelkerke’s pseudo R2 when PGRS were used to predict MS status along with 
appropriate covariates (age, sex, principal components 1 and 2; full model description 
outlined in section 5.2.6).  A better separation of cases and controls would indicate a 
more effective risk score, while a higher Nagelkerke’s pseudo R2 (a measure of explained 
variance) would indicate that the PGRS explains more variance in MS risk.  All 
procedures listed in section 5.2.6 were carried out at each pT threshold group to 
determine which group would be the most accurate in estimating the role of common 
variants on Multiple Sclerosis status: descriptive statistics for each pT group can be 
found in Supplementary Table 2.  All groups were successful in statistically 
differentiating between cases and controls at each population level, however pT 0.0005 
had the lowest p-value score in Generation Scotland, ORCADES and VIKING for 
distinguishing between cases and controls (although this was a very minor difference).  
Additionally, when used to model PGRS as a predictor of MS status, all groups had a 
Nagelkerke’s pseudo R2 value within 0.004% of each other (both with and without 
covariates included).  p-value threshold 0.0005 was consequently chosen as it had the 
lowest p-value in distinguishing cases and controls, however all thresholds were largely 
the same and the results produced by this p-value threshold group would likely be 
comparable to the results produced by any of the other three threshold groups.  
Therefore, the results in the subsequent sections will refer to the results produced from 
the SNPs included in this p-value threshold (n=126).  As described in 5.2.3, PGRS were 
also produced for pT 0.0005 without HLA-DRB1 tag SNP rs9271069 and for rs9271069 
alone. 
 
5.2.6 Determining the contribution of common risk variants to MS risk 
From stage 5.2.5, PGRS were produced for Generation Scotland, ORCADES and 
VIKING for the p-value threshold group (pT) 0.0005 (n SNPs = 126), pT 0.0005 
without rs9271069 (n SNPs = 125) and rs9271069 alone (n SNPs = 1).  Several statistical 
analysis methods were carried out to assess the validity and quality of these scores and 
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to quantify the effect of common risk variants on MS risk in the Northern Isles when 
compared to mainland Scotland. 
Differentiating MS cases and controls with common risk variants 
As a quality control measure to determine if cases and controls could be distinguished 
using polygenic risk scores, a case-control comparison was conducted within each 
dataset (Generation Scotland, ORCADES and VIKING) for each SNP group (pT 0.0005, 
pT 0.0005 without rs9271069 and rs9271069 alone).  It was expected that MS cases 
would have significantly higher PGRS than MS controls. 
Within each SNP group, the three datasets were first standardised by z-scoring the 
PGRS to allow comparison between populations.  To z-score each individual’s risk score, 





  (18) 
where   z is the z-score statistic, 
x is an individual’s risk score, 
µ is the mean PGRS for Generation Scotland, ORCADES and VIKING 
and 
σ is the standard deviation for Generation Scotland, ORCADES and 
VIKING. 
 
The mean z-scored PGRS value was calculated separately for each dataset, along with 
95% confidence intervals, which were calculated using the formula: 




  (19) 
where   CI is the confidence interval, 
ms is the PGRS mean, 
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σ is the standard deviation of the PGRS 
z is the critical value (here: 1.96) and 
n is the sample size. 
 
The mean z-scored PGRS values for cases and controls were then compared within each 
dataset using two-sample t-tests. 
Cases and controls were compared between populations (and within SNP set groups) 
using two-sample t-test formula: 
C = 	










  (20)  
 
where   t is the t statistic, 
1 refers to the first sample (here: cases), 
2 refers to the second sample (here: controls), 
ms are the sample means, 
Δ is the hypothesized difference between the case / control means (here, 
0; to determine if cases and control means were equal) 
s are the sample standard deviations and 
n are the sample sizes. 
Finally, a meta-analysis for cases and controls was performed to determine an estimate 











where   T is the effect size (here: the mean PGRS), 
i is the dataset (here: Generation Scotland, ORCADES or VIKING), 
k is the total number of datasets (here: 3) and 
w is the weight (here: the sample size). 
 
The corresponding meta-analysed 95% confidence intervals would be calculated as 
stated in Equation 19, with n equal to the sum of wi. 
Developing a PGRS MS risk model 
Following on from confirmation of the validity of the PGRS in discriminating between 
cases and controls, a logistic regression model was developed to analyse the quality of 
the PGRS by assessing how much of MS risk variance could be explained by common 
risk variants and if common risk variants could be used to predict MS. 
To investigate the association between PGRS and MS status, a logistic regression model 
was developed.  However, logistic regression models do not account for genetic 
relatedness within the dataset, which can bias standard error values of the beta by 
incorrectly adjusting for type I error.  To resolve this, related individuals were removed 
before fitting the data to a logistic regression model. 
To remove related individuals from the dataset, the program KING v2.1 (Manichaikul et 
al., 2010) was used to estimate kinship coefficients from pairwise relationships.  The 
kinship coefficient is defined as 2φij = π1ij/2+π2ij for two individuals i and j, where π1ij 
and π2ij respectively represent the probability that the two individuals share one and two 
alleles identical by descent (IBD).  KING provides a robust algorithm to calculate the 
kinship coefficient by inferring pair-wise relationships by using allele frequencies to 
model the genetic distance between a pair of individuals (Manichaikul et al., 2010).  A 
kinship coefficient between 0.088-0.177 indicates a second degree relative, while a 
kinship coefficient between 0.044 and 0.088 indicates a third degree relative.  A kinship 
coefficient cut off threshold of 0.05 was chosen for this study to maintain a balance 
between retaining information and removing related individuals, with any relationship 
which had a coefficient above 0.05 had an individual removed; cases were retained 
where possible to limit the loss of power.   
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The dataset containing polygenic risk scores was then merged with relevant covariate 
data and any individuals with missing data entries were removed. Following removal of 
related individuals and individuals with missing data, cases and controls in each dataset 
were as follows: 29/ 8341 Generation Scotland individuals, 14/642 VIKING individuals 
and 80/645 ORCADES individuals.   
The following logistic regression model was fitted separately to each dataset for each 
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 (22) 
where   log |(m)
LQ|(m)
  is the logit,  
  β0 is the Y intercept, 
  β1..5 are the regression coefficients, 
X1 is the first predictor variable; the polygenic risk score, 
X2 is the first covariate; age, 
X3 is the second covariate; sex, 
X4 is the third covariate; principal component 1 and 
X5 is the fourth covariate; principal component 2. 
 
Age, sex and the first two principal components were included as covariates.  Age can be 
predictive of MS as the disease onset typically occurs between the ages of 30 and 40.  
Sex was included as the sex ratio of women to men with MS is 2:1.  Inclusion of the first 
two principal components adjusted for population structure, as discussed in Chapter 2 
(Wu et al., 2011).  The same model but without covariates was fitted to the data to serve 
as a comparison measure in later analyses, described below. 
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Determining how much variance in MS risk is explained by common risk variants 
After fitting the logistic regression model to the data, the model results were used to 
assess how much variance in MS risk common risk variants could explain.   
Nagelkerke’s pseudo R2 value was calculated for each dataset and SNP group using the 
model results to determine the proportion of variance explained by the common risk 
variants.  This calculation is based on the Cox-Snell’s R2 calculation (Nagelkerke, 1991), 
which compares the log likelihood of the current model to the null model.  The log 
likelihood is the natural logarithm of the likelihood function, which is the joint density 
of the variables but viewed as a function of the parameters of the statistical model.  
Nagelkerke’s pseudo R2 calculation follows the same formula, however it divides the 
Cox-Snell formulae by the upper bound to adjust the scale of the results to span from 0 






                                                (23) 
where   L0 is the value of the likelihood function from the null model, 
  LM is the value of the likelihood function from the full model, 
p is the marginal proportion of cases with events and 
n is the sample size. 
 
Using common risk variants to predict MS 
To determine if common risk variants could be a predictor of an individual’s MS status, 
the model results were used to calculate a receiver-operator curve (ROC) and the area 
under this curve (AUC).  Using common risk variants as a predictor for MS status not 
only suggests a potential use of common risk variants in a clinical setting, but it also 
gives an indication of quality for the PGRS by evaluating the model results from a 
different facet. 
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Receiver-operator curves were plotted for each dataset and SNP group, for the model 
with covariates and the model without covariates, to assess how well both the PGRS 
alone and the PGRS with covariates predicted MS diseases status.   
The predictive capacity of each corresponding model was used to plot the fraction of 
true positive results against the fraction of false positive results (sensitivity versus l-
specificity).  This allowed a visual evaluation of the performance of the predictor in 
distinguishing between cases and controls, with a curve arching further from the centre 
line being more favourable. 
In conjunction with the ROC curve, the area under the curve (AUC, or AUROC) was 












where   AUC is the area under the curve, 
i iterates over every m data point with true class label 1 (MS case), 
j iterates over every n data point with true class label 0 (MS control) and 
pi and pj represent the probability score that was assigned by the model 
to data point i and j, respectively. 
 
The AUC values for each dataset were meta-analysed (following Equation 21) to give an 
overall predictive indicator for each SNP set. 
Comparing common risk variants between mainland Scotland and the Northern Isles 
Finally, the common risk variants were compared at a population level between 
Generation Scotland, ORCADES and VIKING, with the aim of determining i) if there 
was a significant difference at a general population level between the collective effect of 
common risk variants and ii) if there was a difference, how this compared to observed 
prevalence differences in the populations. 
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To assess the difference in common risk variants between each population, mean PGRS 
between individuals without MS were compared between Generation Scotland, 
ORCADES and VIKING.  Cases were not used so as not to bias the results due to 
inflated numbers of cases included in each study.  A comparison between populations 
was carried out visually via probability density plots of the mean PGRS and statistically 
through two-sample t-tests, with the calculation as described above (mean PGRS 
comparison between Generation Scotland and ORCADES, Generation Scotland and 
VIKING and ORCADES and VIKING, with Bonferroni corrected p-values of 0.016 
applied and 95% confidence intervals calculated). 
Finally, a comparison was made between the expected calculated difference in common 
risk variants between datasets and the observed prevalence differences seen in 
mainland Scotland, Orkney and Shetland.  This comparison was carried out in several 
stages. 
In the first stage, the mean PGRS for each dataset was calculated.  For ease of 
comparison, the Generation Scotland PGRS mean was then set to 0, and the difference 
in means between Generation Scotland and VIKING, then Generation Scotland and 
ORCADES was calculated. 
Secondly, the beta value from each of the dataset’s model with covariates was meta-
analysed and 95% confidence intervals were calculated, using the formula described in 
Equation 19.  The beta produced from these models is the ratio between the effect from 
the initial GWAS and the actual effect on the population; as it is a polygenic risk score, if 
the initial beta values were correct it would be expected that the same effects in the 
population would be observed, and thus the beta would be 1.  However, since the model 
provides an estimation of beta, this value can appear to fluctuate slightly.  Therefore, a 
one-sample t-test was used on the meta-analysed beta values to verify that there was no 






where   t is the t statistic, 
ms is the meta-analysed beta value, 
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  s is the standard deviation, 
n is the sample size and 
µ is the specified mean (here: 1).   
 
As there was no significant deviation from 1 in all the meta-analysed beta values, the 
beta value was set to 1 (Supplementary Figure 1). 
The third stage was to work out the expected risk of MS from the common risk variants.  
This could be calculated from the confirmed beta value (the log of odds) and the mean 
difference in PGRS between both ORCADES and VIKING with Generation Scotland.  If 
the beta value was 1, that would indicate that the log of odds of developing MS increased 
by 1 for every additional increase in 1 in the PGRS above the Y-intercept baseline value 
(this translates to an odds ratio of 2.7 (exp(β) = OR; exp(1) = 2.7)).  To determine the 
expected risk of developing MS from common risk variants, this beta value was 
multiplied by the difference in mean PGRS values between ORCADES and VIKING with 
Generation Scotland; the proportion of risk that can be attributed to the difference in 
means.  Thus, given the frequencies of the common risk variants that have been looked 
at in the PGRS, these values would be the expected increase in MS risk for the Northern 
Isles populations, using Generation Scotland (Glasgow/Dundee) as the baseline.  This 
would reflect the genetic difference due to common risk variants. 
The fourth stage was to determine how this expected difference in MS risk explained by 
common risk variants compared to the observed MS risk between populations.  
Observed MS prevalence data was obtained from Visser et al (Visser et al., 2012).  The 
Visser prevalence data is as follows: 145 per 100,000 for individuals in Glasgow, 295 per 
100,000 in Shetland and 405 per 100,000 in Orkney. This data was used to create 
contingency tables to compare i) Glasgow and Shetland ( 
Table 9) and ii) Glasgow and Orkney ( 
Table 10). 
 
 MS Case MS Control 
Shetland 295 99 705 
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Glasgow 145 99 855 
 
Table 9: Contingency table for odds ratio calculations in Shetland and Glasgow 
The contingency table for odds ratio calculations of Multiple Sclerosis in Shetland compared to 
Glasgow.  The table uses prevalence data directly taken from Visser et al (Visser et al., 2012). 
 
 MS Case MS Control 
Orkney 402 99 598 
Glasgow 145 99 855 
 
Table 10: Contingency table for odds ratio calculations in Orkney and Glasgow 
The contingency table for odds ratio calculations of Multiple Sclerosis in Orkney compared to 
Glasgow.  The table uses prevalence data directly taken from Visser et al (Visser et al., 2012). 
 





                                                       (26) 
where OR is the odds ratio and 
a, b, c and d are based on the standard contingency table format ( 
Table 11). 
 
 Case Control 
Population 1 a b 
Population 2 c d 
 
Table 11: Standard contingency table format for odds ratio calculations 
The standard contingency table format for odds ratio calculations of a disease (case / control) 
between the treatment group (population 1) and control group (population 2).  Odds ratio 
calculations (see Equation 26) are taken directly from this table. 
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The odds ratio values were then directly converted into log of odds ratios by taking the 
natural logarithm of each value.  Standard error values (Equation 27), and then 95% 















 (27)           
where 9,{@](hd)} is the standard error of the log of odds ratio (beta) and 
a, b, c and d are based on the standard contingency table format ( 
Table 11).                  
 
ç%	r2 = @](hd) ± L. çê × 9,{@](hd)} 
 (28) 
where ç%	r2 is the 95% confidence interval, 
ln(OR) is the natural log of odds ratio (beta value) and 
 íì{îï(ñó)} is the standard error values of the beta value, as calculated in 
Equation 27. 
 
To convert the expected log of odds risk due to each PGRS SNP set into prevalence data, 
the log of odds was converted into an odds ratio and substituted into Equation 26, 
setting c equal to 145 and d equal to 99,855 (the observed prevalence data for mainland 







5.3.1 How do individual common risk variants differ between 
populations? 
The frequencies of all common risk variants were calculated in individuals without MS, 
with the aim of providing more information as to the composition of the PGRS 
calculation.  A Pearson’s chi-square test was then performed on risk allele frequencies 
between populations to determine if SNPs had a significantly higher frequency in any of 
the three population groups (with the null hypothesis that allele frequencies are the 
same, and the alternate hypothesis that allele frequencies are different). 
The SNP with the highest associated MS risk, HLA-DRB1 tag SNP rs9271069 
(OR=2.77), had a significantly higher frequency in Orkney (RAF=0.23) and Shetland 
(RAF 0.21) than mainland Scotland (RAF 0.17: respective p-values of 8 x 10-13 and 2.3 x 
10-6,  
Table 12). 
From the 126 common risk variants included in the study, Shetland and Orkney had 18 
and 21 SNPs respectively that had a significantly higher frequency than mainland 
Scotland.  Mainland Scotland had 20 and 12 SNPs higher than Shetland and Orkney, 
respectively ( 
Table 12).  A full list of results (including non-significant results) can be found in 
Supplementary Table 3. 
 
    RAF Chi-Squared p-value 
RSID CHR RA OR GS ORC VIK GS / ORC GS / VIK 
rs4648356 1 C 1.16 0.67 0.68 0.70 0.16 4.89 x 10-5 
rs11810217 1 A 1.15 0.27 0.26 0.24 0.17 8.86 x 10-5 
rs1323292 1 A 1.12 0.82 0.81 0.79 0.04 1.23 x 10-8 
rs7522462 1 G 1.11 0.70 0.68 0.66 3.66 x 10-3 4.61 x 10-7 
rs6718520 2 A 1.17 0.46 0.40 0.47 7.72 x 10-14 0.13 
rs7592560 2 A 1.1 0.54 0.58 0.57 6.79 x 10-5 0.01 
rs17174870 2 G 1.1 0.74 0.74 0.71 0.98 9.00 x 10-7 
rs882300 2 C 1.19 0.53 0.51 0.50 0.03 2.97 x 10-5 
rs10201872 2 A 1.13 0.17 0.16 0.14 0.06 3.08 x 10-6 
rs9821630 3 G 1.09 0.28 0.30 0.25 1.79 x 10-3 1.55 x 10-4 
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rs11129295 3 T 1.11 0.35 0.42 0.37 2.33 x 10-20 0.02 
rs669607 3 C 1.13 0.47 0.43 0.43 4.86 x 10-8 7.04 x 10-7 
rs1500710 3 A 1.09 0.58 0.53 0.58 1.64 x 10-11 0.92 
rs9657904 3 T 1.4 0.79 0.75 0.75 2.28 x 10-8 5.95 x 10-9 
rs228614 4 G 1.09 0.54 0.59 0.54 6.71 x 10-8 0.65 
rs6821894 4 T 1.08 0.62 0.59 0.60 3.09 x 10-5 0.01 
rs6879677 5 A 1.08 0.40 0.36 0.37 5.11 x 10-6 3.64 x 10-3 
rs1062158 5 A 1.09 0.62 0.59 0.65 2.48 x 10-4 1.16 x 10-4 
rs10866713 5 A 1.17 0.21 0.20 0.18 0.02 2.59 x 10-6 
rs9260119 6 A 1.21 0.45 0.42 0.43 1.97 x 10-4 0.01 
rs9271069 6 A 2.77 0.17 0.23 0.21 3.36 x 10-5 2.05 x 10-11 
rs12212193 6 G 1.09 0.45 0.53 0.47 5.53 x 10-23 0.05 
rs11962089 6 G 0.69 0.11 0.11 0.08 0.44 4.65 x 10-10 
rs802734 6 A 1.1 0.67 0.65 0.63 4.19 x 10-3 7.24 x 10-8 
rs17066096 6 G 1.14 0.24 0.28 0.28 7.58 x 10-10 8.07 x 10-8 
rs2066992 7 C 1.18 0.95 0.97 0.95 2.05 x 10-8 0.89 
rs354033 7 G 1.1 0.74 0.78 0.79 9.43 x 10-10 4.33 x 10-14 
rs2019960 8 C 1.1 0.23 0.23 0.20 0.65 1.77 x 10-4 
rs2150702 9 G 1.16 0.49 0.54 0.53 4.18 x 10-8 4.92 x 10-6 
rs3780792 9 G 1.6 0.33 0.34 0.36 0.15 7.43 x 10-5 
rs12722489 10 C 1.24 0.84 0.82 0.80 0.06 1.24 x 10-10 
rs793108 10 A 1.09 0.49 0.54 0.45 2.00 x 10-11 1.09 x 10-4 
rs7912269 10 A 1.16 0.94 0.94 0.96 0.08 9.53 x 10-11 
rs7923837 10 G 1.1 0.62 0.66 0.64 2.80 x 10-7 0.01 
rs650258 11 C 1.12 0.64 0.66 0.61 0.02 3.35 x 10-5 
rs694739 11 A 1.08 0.62 0.62 0.56 0.75 7.96 x 10-13 
rs4409785 11 G 1.11 0.19 0.22 0.14 4.72 x 10-8 1.20 x 10-13 
rs10466829 12 A 1.09 0.50 0.46 0.51 1.40 x 10-7 0.26 
rs17594362 13 T 1.12 0.12 0.12 0.09 0.39 5.23 x 10-7 
rs9596270 13 T 1.35 0.93 0.90 0.92 8.14 x 10-16 1.81 x 10-3 
rs2300603 14 T 1.11 0.76 0.73 0.71 4.75 x 10-6 3.11 x 10-12 
rs11864333 16 A 1.09 0.50 0.54 0.53 6.11 x 10-7 1.31 x 10-4 
rs386965 16 G 1.09 0.21 0.21 0.27 0.70 5.93 x 10-18 
rs17445836 16 G 1.25 0.77 0.76 0.79 0.29 7.88 x 10-5 
rs9891119 17 C 1.1 0.35 0.33 0.39 0.01 2.65 x 10-7 
rs1373089 17 A 1.08 0.49 0.54 0.52 3.84 x 10-10 9.49 x 10-5 
rs8081176 17 C 1.09 0.31 0.33 0.34 0.01 7.22 x 10-5 
rs12456021 18 A 1.1 0.19 0.23 0.18 4.70 x 10-9 0.18 
rs7238078 18 T 1.11 0.77 0.83 0.76 1.79 x 10-20 0.38 
rs1077667 19 C 1.16 0.78 0.82 0.80 3.82 x 10-7 3.62 x 10-3 
rs2278442 19 A 1.08 0.65 0.62 0.69 7.01 x 10-5 6.09 x 10-9 
rs8112449 19 G 1.1 0.67 0.70 0.65 1.15 x 10-4 0.03 
rs10411936 19 A 1.16 0.30 0.32 0.34 0.01 7.23 x 10-7 
rs874628 19 A 1.12 0.68 0.71 0.73 3.91 x 10-5 9.26 x 10-12 
rs7255066 19 C 1.1 0.25 0.22 0.24 6.29 x 10-6 0.11 
rs281380 19 G 1.08 0.33 0.39 0.32 6.55 x 10-18 0.17 
rs2762932 20 G 1.15 0.14 0.15 0.17 0.19 3.41 x 10-10 
rs2248359 20 C 1.12 0.59 0.65 0.58 6.96 x 10-13 0.30 
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Table 12: Risk allele frequencies in mainland Scotland, Orkney and Shetland 
Risk allele frequencies (RAF) and Pearson’s chi-squared test p-values for SNPs which have at 
least one significant result when comparing PGRS between populations.  The chi-squared p-
values are shown for two RAF comparisons: Generation Scotland (GS) and ORCADES (ORC); 
Generation Scotland and VIKING (VIK).  Significant results, corrected for multiple testing at 126 
loci over two population comparisons (corrected p-value significance level of <1.98 x 10-4), are 
shown in bold.  Significant p-values from RAF that are higher in Generation Scotland than 
ORCADES or VIKING are highlighted in dark red, and significant p-values from RAF that are 
higher in ORCADES or VIKING than Generation Scotland are highlighted in light blue.  NB: 
RAF values are rounded to 2 decimal places.  This can result in values (such as rs4149584) that 
appear the same due to rounding but give differing p-values between populations. 
 
5.3.2 Can common risk variants differentiate between MS cases and 
controls? 
The common risk variants used in this study were all previously associated with MS 
risk: therefore, as a quality control measure mean PGRS in cases were compared to 
mean PGRS in controls, with the expectation that individuals with MS would have 
significantly higher risk scores than individuals without MS. 
The mean z-scored PGRS probability densities of cases and controls are distinguishable 
in the full pT 0.0005 SNP set, the pT 0.0005 SNP set without rs9271069 and in 
rs9271069 alone (Figure 20).  Within the full pT 0.0005 SNP set, cases across all three 
populations display a small frequency peak in the lower end of the distribution, 
indicating that there is a proportion of cases who have the same or lower mean PGRS as 
controls.  VIKING has a less even distribution of cases, due to small sample size.  When 
rs9271069 is removed from the pT 0.0005 group, the distribution of ORCADES and 
VIKING cases and controls remains similar, however the distribution for Generation 
Scotland significantly changes, with the distribution of cases displaying more individual 
peaks.  When viewing the mean PGRS probability density of rs9271069 alone, the 
distribution of PGRS scores is similar between populations, however Generation 
Scotland has a higher frequency of controls with a raw PGRS equal to 0. 
The confidence intervals for mean PGRS cases and controls do not overlap in any of the 
three population groups for SNP sets pT 0.0005 and pT 0.0005 without rs9271069 
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(Figure 21).  An overlap in confidence intervals is seen between cases and controls in 
PGRS from rs9271069 alone.  However, when mean PGRS scores in cases and controls 
are meta-analysed, there is no overlap in the confidence intervals in any of the SNP sets.  
The largest difference between meta-analysed PGRS is seen in the full pT 0.0005 SNP 
set, with cases having 0.67 (95% CI 0.52, 0.82) standard deviations from the mean 
(compared to pT 0.0005 without rs9271069 and rs9271069 alone, where mean PGRS in 
cases are 0.49 (95% CI 0.33, 0.64) and 0.53 (95% CI 0.35, 0.72) standard deviations 
from the mean, respectively). 
In the full pT 0.0005 SNP set, the ORCADES controls have a PGRS mean 0.08 standard 
deviations above Generation Scotland and 0.02 standard deviations below VIKING.  
When the PGRS of rs9271069 alone are looked at, ORCADES controls have a PGRS of 
0.21 standard deviations higher than Generation Scotland and 0.08 standard deviations 
higher than VIKING.  However, when rs9271069 is taken out of the PGRS calculation, 
ORCADES controls have a mean PGRS score 0.02 standard deviations below 
Generation Scotland and 0.06 standard deviations below VIKING. 
The same pattern is also seen amongst cases; in the full pT 0.0005 SNP set, the 
ORCADES cases have a PGRS score 0.06 standard deviations above Generation 
Scotland and 0.03 standard deviations below VIKING.  In the PGRS of rs9271069 alone, 
ORCADES cases have the highest mean PGRS: 0.30 and 0.19 standard deviations above 
Generation Scotland and VIKING cases, respectively.  However, as seen in the controls, 
when rs9271069 is taken out of the PGRS calculation, ORCADES cases fall to a mean 
PGRS score 0.08 standard deviations below Generation Scotland and 0.13 standard 
deviations below VIKING. (NB: confidence interval estimates have been omitted from 
this paragraph for ease of reading but can be viewed in Figure 21). 
When MS cases and controls are compared within each dataset using two-sided t-tests 
(Table 13), they can be distinguished statistically in each population in the full pT 
0.0005 SNP set (with p-values: Generation Scotland = 5.42 x 10-4; ORCADES = 4.07 x 
10-9; VIKING = 2.93 x 10-3).  When rs9271069 is removed, only Generation Scotland (p-
value 4.22 x 10-3) and ORCADES (p-value 1.03 x 10-5) are statistically different.  When 
rs9271069 is considered alone, only ORCADES cases and controls are statistically 
different (p-value 1.53 x 10-4).  This reflects the number of cases; less cases leads to 




Figure 20: Probability density plots of z-scored polygenic risk scores 
The probability density plots use z-scored polygenic risk scores (PGRS) for MS cases (n = 30) 
and controls in Generation Scotland (n cases = 30, n controls = 8708), ORCADES (n cases = 94, 
n controls = 2120) and VIKING (n cases = 16, n controls = 2158).  Three SNP sets are used for 
comparison: pT 0.0005 (n=126); pT 0.0005 without rs9271069 (n=125); rs9271069 alone (n=1). 
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Figure 21: Forest plots of z-scored polygenic risk scores (PGRS) 
The forest plots use z-scored polygenic risk scores (PGRS) for Multiple Sclerosis cases and 
controls in Generation Scotland, ORCADES and VIKING.  Three SNP sets are used for 
comparison: pT 0.0005 (n=126); pT 0.0005 without rs9271069 (n=125); rs9271069 alone (n=1). 
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SNP set n (SNP) Dataset 




pT 0.0005 126 
GS 30 8708 -3.88 5.42 x 10-4 
ORCADES 94 2120 -6.43 4.07 x 10-9 





GS 30 8708 -3.10 4.22 x 10-3 
ORCADES 94 2120 -4.64 1.03 x 10-5 




GS 30 8708 -2.11 0.04 
ORCADES 94 2120 -3.94 1.53 x 10-4 
VIKING 16 2158 -1.32 0.21 
Table 13: Two-sided t-test results comparing MS cases and controls  
Polygenic risk scores (PGRS) of Multiple Sclerosis cases and controls are compared within three 
datasets (Generation Scotland (GS); ORCADES and VIKING) using three groups of SNP sets (pT 
0.0005, pT 0.0005 without rs9271069 and rs9271069 only).  Significant results, corrected to 
account for 9 tests, are highlighted in bold (corrected p-value significance level of <0.005). 
 
5.3.3 How much variance in MS risk do common risk variants explain? 
A logistic regression model was developed to analyse the quality of the PGRS by 
assessing how much of MS risk variance could be explained by common risk variants.  
The logistic regression model (described in section 5.2.6: Equation 22) predicted 
Multiple Sclerosis status using PGRS, with age, sex and the first two principal 
components included as covariates.  Full results for each model can be found in 
Supplementary Table 4. 
Nagelkerke’s pseudo R2 was calculated to determine how much variance in MS risk 
common risk variants could explain (Figure 22).  Without covariates, PGRS alone 
generally explained less than 5% of variance in MS risk: the full pT 0.0005 SNP set 
explained 3%, followed by pT 0.0005 without rs9271069 with 2% and rs9271069 alone 
with 1% variance explained.  The addition of covariates in the model resulted in a higher 
explanation of variance, with the weighted means of each group increasing by an 
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average of 4% (R2 values for pT 0.0005, pT 0.0005 without rs9271069 and rs9271069 
alone at 8%, 6% and 5% for each SNP set, respectively). 
 
Figure 22: Nagelkerke’s pseudo-R2 results for the prediction of MS risk by PGRS 
Nagelkerke’s pseudo-R2 results are shown for the prediction of Multiple Sclerosis risk in 
Generation Scotland (n cases = 30, n controls = 8708), ORCADES (n cases = 94, n controls = 
2120) and VIKING (n cases = 16, n controls = 2158) using the model MS~PGRS  and the model 
MS~PGRS+age+sex+PC1+PC2. Nagelkerke's pseudo R2 is shown for scores derived using three 
SNP sets - pT 0.0005 (n SNPS = 126), pT 0.0005 without rs9271069 (n SNPs = 125) and 
rs9271069 only (n SNPs = 1). 
 
5.3.4 Can common risk variants predict MS status? 
To determine if common risk variants could predict an individual’s MS status, the 
results from the logistic regression model (described in section 5.2.6: Equation 22) were 
used to calculate a receiver operator curve (ROC) and the area under this curve (AUC).  
The model with covariates was more successful in predicting MS status than just PGRS 
alone (Figure 23).  This was reflected in the AUC values: for using PGRS alone to predict 
MS status, the meta-analysed AUC scores for each SNP group were 0.69 (95% CI 0.65, 
0.74), 0.65 (95% CI 0.60, 0.69) and 0.62 (95% CI 0.57, 0.66) for the full pT 0.0005 
group, pT 0.0005 without rs9271069 and rs9271069 alone (Supplementary Figure 2).  
When covariates were included, these scores increased to 0.74 (95% CI 0.70, 0.79), 0.73 
(95% CI 0.68, 0.77) and 0.70 (95% CI 0.66, 0.75) respectively.  The full pT 0.0005 SNP 




Figure 23: ROC curves for predicting MS status 
ROC curves showing the average predictive performance (the true positive rate and false positive 
rate) of predicting Multiple Sclerosis status using the model MS~PGRS+age+sex+PC1+PC2 and 
the model MS~PGRS for three SNP sets: pT 0.0005 (n SNPS = 126), pT 0.0005 without 
rs9271069 (n SNPs = 125) and rs9271069 only (n SNPs = 1), using three datasets: Generation 
Scotland (n cases = 30, n controls = 8708), ORCADES (n cases = 94, n controls = 2120) and 
VIKING (n cases = 16, n controls = 2158). 
 
5.3.5 How much do common risk variants contribute to excess MS risk in 
the Northern Isles? 
The principal aim of this thesis chapter was to determine how much contribution 
common risk variants made to the excess risk of MS found in the Northern Isles of 
Scotland, particularly Orkney.  Common risk variants were first compared in controls 
between the three population groups to determine if there was a significant difference in 
the overall effect of common risk variants.  Consequently, that difference was quantified 
and the expected effect of common risk variants to excess MS risk in each population 
was calculated.  This was then compared to the observed excess MS risk, with the aim of 
determining how much of the increased prevalence in the Northern Isles could be 
explained by common risk variants.  
Do common risk variants for MS differ between mainland Scotland and the Northern 
Isles? 
To determine the difference in common risk alleles between the three populations, the 
controls from Generation Scotland, ORCADES and VIKING were compared (only 
controls were compared to not bias the results with a high proportion of individuals 
with MS). 
A statistical difference between Generation Scotland and both ORCADES and VIKING 
was seen in the full pT 0.0005 SNP set (p-values 1.97 x 10-5 and 3.16 x 10-5 respectively;  
Table 14).  There was no statistical difference detected between ORCADES and VIKING 
in this SNP set.  When rs9271069 was removed from the SNP set, there was no 
statistical difference detectable between any of the control populations.  When 
rs9271069 was looked at alone, a statistical difference was seen when comparing all 
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populations (p-values for GS / ORCADES: 1.01 x 10-20; GS / VIKING: 7.15 x 10-8; 
ORCADES / VIKING 1.93 x 10-3).  However, when observing the probability density 


















pT 0.0005 126 
GS 8708 ORCADES 2120 -4.27 1.97 x 10-5 
GS 8708 VIKING 2158 -4.17 3.16 x 10-5 





GS 8708 ORCADES 2120 0.26 0.79 
GS 8708 VIKING 2158 -1.87 0.06 




GS 8708 ORCADES 2120 -9.39 1.01 x 10-20 
GS 8708 VIKING 2158 -5.40 7.15 x 10-8 
ORCADES 2120 VIKING 2158 3.10 1.93 x 10-3 
 
Table 14: Comparison of PGRS of MS controls between populations 
Two-sided t-test results comparing polygenic risk scores (PGRS) of Multiple Sclerosis controls 
between Generation Scotland, ORCADES and VIKING, using three groups of SNP sets pT 
0.0005 (n SNPS = 126), pT 0.0005 without rs9271069 (n SNPs = 125) and rs9271069 only (n 
SNPs = 1).  Significant results (with significance corrected to account for 9 tests) are highlighted 







Figure 24: Population comparison of probability density plots of z-scored polygenic 
risk scores for MS controls 
The probability density plots use z-scored polygenic risk scores (PGRS) for Multiple Sclerosis 
controls in Generation Scotland (n controls = 8708), ORCADES (n controls = 2120) and VIKING 
(n controls = 2158).  Three SNP sets are used for comparison: pT 0.0005 (n=126); pT 0.0005 
without rs9271069 (n=125); rs9271069 alone (n=1). 
 
How much excess risk in MS in the Northern Isles is caused by common risk variants? 
To determine the contribution of common risk variants to excess MS risk in the 
Northern Isles, a comparison was made between the calculated expected risk and the 
observed risk seen from MS prevalence data (Table 15).   
The calculated difference between the mean PGRS using the full pT 0.0005 SNP set was 
0.06 (95% CI 0.03, 0.09) between Generation Scotland controls and VIKING controls, 
and 0.05 (95% CI 0.02, 0.08) between Generation Scotland controls and ORCADES 
controls.  Removing rs9271069 from the risk score calculation caused the mean PGRS in 
ORCADES controls to drop 0.01 (95% CI -0.04, 0.01) below Generation Scotland 
controls, however the mean for VIKING controls remained 0.02 (95% CI 0.00, 0.05) 
above Generation Scotland.  Both these values did not significantly differ from 0.  When 
rs9271069 was looked at alone, the calculated difference between the mean PGRS in 
controls of Generation Scotland and VIKING was 0.04 (95% CI 0.02, 0.05) and 
Generation Scotland and ORCADES was 0.06 (95% CI 0.05, 0.07). 
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To calculate the expected MS risk caused by these common risk variants, the mean values 
were multiplied by the logistic regression model (with covariates) beta (see section 5.2.6 
for full methodology). 
Therefore, in Shetland the expected log of odds ratios due to common risk variants is 0.06 
(95% CI 0.03, 0.09), which can be compared to the observed log of odds ratio of 0.71 
(95% CI 0.51, 0.91).  This accounts for 9 cases (95% CI 5, 14) out of 150 observed excess 
cases per 100,000 individuals in Shetland (Figure 25).  The majority of this expected risk 
is from the HLA SNP rs9271069, which contributes a log of odds ratio of 0.04 (95% CI 
0.02, 0.05): equivalent to 6 cases (95% CI 3, 8) per 100,000 individuals. 
In Orkney, all the expected excess risk is due to HLA SNP rs9271069, which contributes 
0.06 (95% CI 0.05, 0.07) out of the observed 1.02 (95% CI 0.83, 1.21) log of odds ratios.  
This accounts for 9 cases (95% CI 8, 11) of the observed 257 excess cases per 100,000 
individuals in Orkney. 
 Generation 
Scotland 
VIKING (95% CI) ORCADES (95% CI) 
Expected excess MS risk due 
to all common risk variants 
0 0.06 (0.03, 0.09) 0.05 (0.02, 0.08) 
Expected excess MS risk due 
to common risk variants 
without HLA SNP rs9271069 
0 0.02 (0.00, 0.05) -0.01 (-0.04, 0.01) 
Expected excess MS risk due 
to HLA SNP rs9271069 
0 0.04 (0.02,0.05) 0.06 (0.05,0.07) 
Observed excess MS risk in 
populations 
0 0.71 (0.51, 0.91) 1.02 (0.83, 1.21) 
Table 15: The contribution of common risk variants to excess MS prevalence in the 
Northern Isles 
Expected and observed excess MS risk (log of odds ratios) in both VIKING (Shetland; n controls 
= 2158) and ORCADES (Orkney; n controls = 2120) when compared to Generation Scotland, (n 
controls = 8708).  Expected log(OR) values were calculated from the logistic regression results 
for the model MS ~ PGRS + age + sex + array + PC1 + PC2 by multiplying it with the mean PGRS 
calculated from the pT 0.0005 SNP set (n = 126) and rs9271069 alone (n=1).  Significant 
differences between either ORCADES or VIKING and Generation Scotland for expected MS risk 
differences (taken from  
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Table 14) are highlighted in bold.  Observed log of odds values were calculated from the 
prevalence data found in the paper by Visser et al (Visser et al., 2012). 
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Figure 25: Excess prevalence of Multiple Sclerosis in the Northern Isles 
Multiple Sclerosis prevalence (per 100,000 individuals) in Mainland Scotland, Shetland and 
Orkney, with data taken from Visser et al (Visser et al., 2012).  Excess prevalence is described as 
any additional prevalence in Orkney and Shetland that is over the baseline mainland Scotland 
prevalence.  Excess prevalence due to common risk variants (not including HLA SNP rs9271069) 
and to HLA SNP rs9271069 alone is highlighted.  These values are calculated as described in 
Methods section 5.2.6. 
 
5.4 Discussion 
Summary of Findings 
Calculating polygenic risk scores for individuals in Orkney, Shetland and mainland 
Scotland allowed for the contribution of common risk variants to excess MS in the 
Northern Isles to be assessed.  Orkney and to a lesser extent Shetland have an 
excessively high prevalence of MS, so it was expected that this could be explained by 
these islands having a higher frequency of common risk variants.  These findings 
suggest that the cumulative risk from common risk variants is not a major contributing 
factor towards the excessively high rates of MS in Orkney or Shetland.  However, a 
small proportion of risk can be attributed to a tag SNP for the HLA-DRB1 haplotype 
HLA-DRB1*1501, the major genetic risk factor for MS. 
As a collective, common risk variants do not make a significant or meaningful 
contribution to the excess of MS in the Northern Isles; any difference found in the risk 
scores when comparing between population groups is due to HLA-DRB1.  The mean 
risk score in Orkney is higher than the risk score in mainland Scotland, conditional on 
the presence of the HLA-DRB1 tag SNP; when this SNP is removed from the risk score 
calculations, no statistical difference between the controls in Orkney, Shetland and 
mainland Scotland is detected.  Upon inclusion of this SNP in the risk score 
calculations, a statistical difference between risk scores in mainland Scotland and the 
Northern Isles populations is detected.  If the Northern Isles had a higher burden of 
common risk variants than mainland Scotland, it would be expected that the statistical 
difference of PGRS scores would be maintained with the removal of the HLA-DRB1 tag 
SNP, which is not the case.  This indicates that without HLA-DRB1, the genetic effect of 
common risk variants as a contributor to excess MS prevalence is very weak and has no 
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meaningful impact on increased prevalence in the Northern Isles.  In 1981, Compston 
found that there were higher frequencies of four common risk variants in Orkney 
(specifically HLA, B7, Dw2 and DR2), and he was the first to suggest that Orkney may 
have generally higher frequencies of common risk variants than mainland Scotland 
(Compston, 1981).  The results here suggest this is not the case, although they do not 
refute the findings made in 1981; several common risk variants such as the large-effect 
HLA-DRB1 variant (which encodes the DR2 serotype studied in 1982) do have higher 
frequencies in Orkney, however as a collective the majority of variants do not have a 
significant impact on differential MS prevalence in the Northern Isles. 
The contribution of HLA-DRB1 
HLA-DRB1 tag SNP caused a significant difference between risk scores in mainland 
Scotland compared to the Northern Isles for two reasons: firstly, it has a large effect 
size, with a previously reported odds ratio of 2.77.  Secondly, the frequency of the risk 
allele is significantly higher in Orkney (RAF = 0.23, p-value = 8 x 10-13) and to a lesser 
extent Shetland (RAF = 0.21, p-value = 2.3 x 10-6) than mainland Scotland (RAF = 0.17).  
This is a novel finding, as the frequency of this risk variant had not been previously 
measured in the Northern Isles.  This frequency is higher than that previously reported 
in European heritage populations: Bahlo et al listed the frequency of this risk allele as 
0.15, based on a combined sample of 4014 control individuals with reported European 
ancestry (Bahlo et al., 2009).  It is possible that the frequency of this allele is higher in 
the Northern Isles populations due to the founders of Orkney and Shetland having 
higher frequencies of the risk allele.  Differing frequencies of single or a small number of 
variants in isolated populations compared to nearby non-isolated populations has been 
noted before in MS studies.  For example, MS prevalence in Sardinia was compared to 
that of mainland Italy, and the findings indicated that higher frequencies of two TNF 
alpha gene variants in Sardinia contributed towards differences in MS prevalence (Wirz 
et al., 2004).  Conversely, the isolated population of the Sami was compared to the main 
Norwegian population, and lower frequencies of IL-10 risk variants between the Sami 
and Norwegians was suggested to contribute to the lower prevalence of MS seen in the 
Sami (Grytten Torkildsen et al., 2008) 
The contribution of the HLA-DRB1 tag SNP, both by itself and with the other common 
risk variants, was quantified to determine the proportion of observed excess MS 
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prevalence that could be explained within the Northern Isles.  A small proportion of 
excess MS in the Northern Isles is explained by all the common risk variants – however 
the majority of this is due to HLA-DRB1.  The observed log of odds risk of MS for a 
Shetland individual in comparison to an individual in mainland Scotland was 0.71 – the 
proportion of log of odds risk that was explained by common risk variants was 0.06 
(0.04 of which was explained by the HLA-DRB1 tag SNP).  In Orkney the observed log 
of odds risk of MS for an Orcadian in comparison to an individual in mainland Scotland 
was 1.03 – the proportion of log of odds risk that was explained by common risk 
variants was 0.05, slightly lower than the 0.06 explained by the HLA-DRB1 tag SNP, as 
the expected risk from common risk variants not including this SNP was actually higher 
in mainland Scotland than Orkney.  Although this proportion of explained excess risk 
appears small, the observed excess of MS risk captures both genetic and environmental 
contributors: considering that the majority of this expected excess in risk is comprised 
of the genetic effect of HLA-DRB1, this is a relatively important finding.  Additionally, 
this is explaining more than is expected based on 3% of variance that is estimated to be 
explained by common risk variants, as indicated by the calculated Nagelkerke’s pseudo 
R2 value. 
Variance explained by common risk variants 
The amount of variance explained by common risk variants is an affirmation of a 
previous study finding from the IMSGC: in 2010, an IMSGC study reported that a 
polygenic risk score calculated from 12,627 SNPs explained roughly 3% of variance in 
MS risk (International Multiple Sclerosis Genetics Consortium, 2010).  However, a 
study using 475,806 SNPs estimated around ~30% of MS risk variance to be 
attributable to common genetic variants (Watson et al., 2012).  This study uses 126 
SNPs, which limits the amount of variance can be explained, although adding an 
additional ~12,500 SNPs does not appear to explain any additional variance.  Three to 
five percent of total MS risk variance is small, however it should not be discounted as 
unimportant, particularly due to the relatively small number of SNPs that contribute to 
this variance percentage. 
Predicting MS using common risk variants  
Although common risk variants explained a small percentage of the variance of Multiple 
Sclerosis, they could possibly be used to predict MS status.  To explore the prediction 
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capabilities of the common risk variants used in this study, the AUC was calculated: 
when using common risk variants alone to predict MS, the full common risk variant set 
had the highest success rate of 0.69 (95% CI 0.65, 0.74).  When the covariates age, sex, 
PC1 and PC2 were included in this, the scores increased to 0.74 (95% CI 0.70, 0.79).  
Similar scores to this have been determined in the past; De Jager et al. in 2009 used 16 
SNPs with a resulting AUC of 0.697, but this decreased to an AUC of 0.635 when 
replicated using smaller sample sizes (De Jager, Chibnik, et al., 2009).  A similar score 
of 0.69 was obtained by Jafari et al. in 2011 using 53 SNPs (Jafari et al., 2011).  
Increasing the number of common risk variants has the potential to increase the 
predictive ability of common risk variants for MS.  
Finding Implications 
The majority of common risk variants, previously suggested to be a large influence on 
the excessively high prevalence in the Northern Isles, have been shown to have a similar 
collective effect size as those on mainland Scotland.  Only the HLA-DRB1 variant has 
been shown to differ between populations.  The implications of this are significant for 
the people of Orkney and Shetland, as MS has a large bearing within the island groups, 
both clinically and socially.  Here, it is not a burden of common risk variants that are 
causing the excess of MS prevalence.  Research on MS in the Northern Isles specifically 
is not commonplace: the findings from this study update the knowledge of MS in the 
Northern Isles, which is important for individuals understanding why MS affects 
Orkney and Shetland so strongly.  Furthermore, communicating the findings of this 
research to individuals in Orkney and Shetland has the potential to stimulate discussion 
generally on what the major risk factors of MS are, and could lead to promotion of 
better lifestyle choices (such as reducing smoking and taking vitamin D supplements) 
that could help in disease prevention. 
Additionally, the findings here suggest research on MS in the Northern Isles should 
focus on other possible risk factors such as exploring the HLA-DRB1 locus in further 
detail in Orkney and Shetland and identifying any possible rare variants which may be 
present.  This is supported by the result that generally, only a small proportion of 
variation in MS is explained by known common risk factors.   
The implications of these findings in a clinical setting are limited, as the common risk 
variants used here would not be an effective choice for targeting for treatment therapies, 
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and they can also not be used to predict MS with high enough accuracy.  Although the 
use of common risk variants for indicating disease status have been used effectively for 
other diseases such as prostate cancer (as discussed in the introduction), a significantly 
larger collection of common risk variants would be needed to produce the same 
practical results. 
Study Limitations 
The number of common risk variants included here could be seen as a limitation.  The 
inclusion of more common risk variants in the risk score calculation may not only 
increase the effectiveness of risk scores to predict MS, but it could also increase the 
proportion of observed log of odds risk that can be explained by common risk variants 
in the Northern Isles.  If more common risk variants were included and the frequencies 
of these happened to differ between mainland Scotland and the Northern Isles, this 
could influence the impact of common risk variants between populations.  The number 
of common variants used was therefore a limitation within this study.  The common risk 
variants included here are informative as they capture a considerable proportion of the 
theoretical polygenic risk score that could be constructed using all MS risk variants, as 
the 126 SNPs used here had relatively high effect sizes.  However, to capture the full 
effect of common risk scores between populations, a larger discovery GWAS providing a 
full list of variants would be needed.  Repeating this analysis with a different discovery 
GWAS would therefore provide a useful addition to the findings in this study. 
Another limitation with this study is the sample size and number of cases within each 
population, particularly within the Northern Isles groups.  However, this remains the 
only cohort that has gathered genetic data from individuals in Orkney and Shetland, 
and as much of this is used as possible.  Further data collection from the Northern Isles 
populations would therefore provide a great aid for clarifying the genetic basis of 
Multiple Sclerosis (as well as providing more information generally about complex 
disease within the islands).  Finally, the risk score in this study is also partially based on 
imputed genotypes; the risk prediction algorithm could be improved if real genotypic 




This study sought to investigate the hypothesis that Orkney, and to a lesser extent, 
Shetland, have an excess of Multiple Sclerosis prevalence due to a higher frequency of 
common risk variants.  Common risk variants as a collective do not make a significant 
or meaningful contribution to the excess of MS in the Northern Isles.  Any significant 
difference seen in PGRS is due to the tag SNP for the HLA-DRB1 locus.  This risk 
variant has a significantly higher frequency in Orkney and, to a lesser extent, Shetland 
than mainland Scotland.  This variant alone contributes 0.04 out of 0.06 of the log of 
odds risk of MS explained by common risk variants in Shetland, and all of the log of 
odds risk of MS explained by common risk variants in Orkney, explaining 0.06 log of 
odds ratios alone.  Although this is a small proportion of the 0.71 observed log of odds 
risk of MS seen in Shetland and 1.03 observed log of odds risk of MS seen in Orkney, the 
common risk variants explain more than what was expected of them, as it was estimated 
that only 3% of variance in MS risk could be explained by common risk variants. 
There is potential for improving both the quality of the risk score in predicting MS and 
the amount of excess risk in the Northern Isles explained by increasing the number of 
variants included in the risk score calculation.  That, along with other improvements 
(such as using genotyped instead of imputed data and increasing the sample size 
through future additional data collection) would allow for an additional follow up study.  
Here, 9 out of 150 excess cases per 100,000 were explained in Shetland and 9 out of 257 
excess cases per 100,000 were explained in Orkney, or about the equivalent of 2 
patients in each archipelago.  Therefore, although these findings explain some of the 
excess MS in the Northern Isles, additional studies focusing on other causes (both 











CHAPTER 6: DISCUSSION AND CONCLUSION 
6.1 Thesis findings 
Chapter 3: Heritability of Multiple Sclerosis in the Northern Isles of Scotland 
The Northern Isles of Scotland has one of the highest rates of Multiple Sclerosis in the 
world.  We sought to understand the existence and extent of any genetic causes.  My 
first finding estimated the SNP heritability in Orkney for MS at 0.31 (95% CI 0.13, 
0.49).  An estimate of SNP heritability for MS in Shetland could not be obtained.  The 
current largest published estimate of SNP heritability for MS, using IMSGC data of 
14,802 MS cases and 26,703 controls estimates SNP heritability as 0.19 (95% CI 0.18, 
0.20) (International Multiple Sclerosis Genetics Consortium et al., 2017).  While 
heritability is a population-specific measure (IMSGC measured it within broadly 
European individuals) and it is possible that Orkney has a significantly higher 
heritability than that calculated by the IMSGC, it is likely that the true estimate of 
heritability in Orkney is much closer to that calculated by IMSGC.  The IMSGC have a 
far larger number of cases resulting in a pinpointed estimate of heritability, while the 
estimate calculated in this thesis completely overlaps their estimate.  Therefore, it is 
most likely that the heritability estimate calculated here is higher than the true 
heritability in Orkney. 
Chapter 4: Genome Wide Association Study of Multiple Sclerosis in the Northern Isles 
of Scotland 
I then considered trying to discover whether there were unique common variants in 
Orkney and Shetland using a GWAS of 112 MS cases and 4223 controls from the 
Northern Isles.  I found 89 SNPs of suggestive significance, largely within six key 
regions of the genome.  The six regions of suggestive significance were defined as having 
two or more SNPs within 1000 kb of one another that were below the suggestive 
significance threshold: these were found on chromosomes 2, 6, 12 and three regions on 
chromosome 18.  As these SNPs did not reach the genome-wide significance level, it is 
important to determine if these results are real (either causative or in LD with a 
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causative SNP) or caused by chance.  Within the literature, only one SNP (chromosome 
6 SNP rs9268154) was previously associated with Multiple Sclerosis: in the 2018 
IMSGC results (which used 32,367 MS cases and 36,012 controls) it has a listed p-value 
of 0 and it is also in moderate LD with HLA-DRB1*1501 (r2 = 0.65) (International 
Multiple Sclerosis Genetics Consortium et al., 2018).  The other five regions identified 
do not contain SNPs that are associated with MS, and the top SNP of each region has 
reported p-values in the 2018 IMSGC study ranging from 0.06 to 0.68.  Based on this, it 
is likely that these regions appeared as suggestively significant due to chance.  However, 
as four of the five regions lay in regions implicated in immune system functioning or 
have some previous link to an MS-related pathway, they are promising candidates for 
further studies in the Northern Isles of Scotland.  
Chapter 5: Polygenic risk score study of Multiple Sclerosis in the Northern Isles of 
Scotland 
Thirdly, I wanted to determine if the Northern Isles, by chance, have a higher frequency 
of common risk variants for MS.  I found that a tag SNP for HLA-DRB1*1501 
(OR=2.77), rs9271069, had a significantly higher frequency in Orkney (RAF=0.23) and 
Shetland (RAF=0.21) than mainland Scotland (RAF=0.17), with respective p-values of 8 
x 10-13 and 2.3 x 10-6.  Frequencies for this SNP reported in other cohorts appears to be 
similar to that in mainland Scotland or lower.  TOPMed (n=125,568) and TwinsUK 
(n=3708) both report the frequency as 0.14, while 1000Genomes (n=5008) reports the 
frequency at 0.15 (Moayyeri et al., 2013; The 1000 Genomes Project Consortium, 2015; 
National Center for Biotechnology Information, 2017).  The significantly higher 
frequency of this SNP in the Northern Isles in comparison to both mainland Scotland 
and the general European population suggests that it plays an important role in the 
prevalence of MS in the Northern Isles. 
When the polygenic risk scores from common MS risk variants were compared between 
controls from mainland Scotland and controls from Orkney and Shetland, a significant 
difference was found between populations (p-values 1.97 x 10-5 and 3.16 x 10-5 
respectively).  However, upon removal of the HLA-DRB1*1501 tag SNP, rs9271069, 
from the polygenic risk score calculation, the statistical difference between populations 
disappeared.  Any significant difference between mainland Scotland and Orkney / 
Shetland was caused by rs9271069.  This was confirmed when rs9271069 was examined 
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alone, with a significant difference in the risk score from rs9271069 alone found 
between all population comparisons (Generation Scotland and ORCADES: 1.01 x 10-20; 
Generation Scotland and VIKING: 7.15 x 10-8; ORCADES and VIKING 1.93 x 10-3).   
When quantified, the contribution of rs9271069 in Shetland equates to causing 6 cases 
(95% CI 3, 8) out of 150 observed excess cases per 100,000 individuals.  In Orkney, 
rs9271069 accounts for 9 cases (95% CI 8, 11) of the observed 257 excess cases per 
100,000 individuals.  This is approximately 4% of excess cases in both populations 
attributable to one SNP. 
A study comparing polygenic MS risk scores of two control groups has not currently been 
published.  However, in a 2016 study of polygenic risk scores, 103 common MS risk 
variants were compared between 452 multiplex family cases and sporadic cases 
(Mescheriakova et al., 2016).  Between the two groups of MS cases, a significant 
difference (p-value <0.0001) in risk scores was only found when the HLA-DRB1*1501 
locus was included in the risk score calculation.  This study concluded that familial cases 
had a higher HLA-DRB1*1501 allele frequency, leading to a greater burden of risk.  it is 
possible that Orkney and Shetland have higher burdens of the HLA-DRB1*1501 allele due 
to the strong family structures present within these population isolates, that is in turn 
causing an increase in the burden of MS.   
In general, I found that the polygenic risk scores calculated with the 127 most strongly 
associated MS risk variants explained 3% of variance.  This is approximately in line with 
previous research: 12,627 SNPs were able to account for approximately 3% of variance 
in an early IMSGC study (International Multiple Sclerosis Genetics Consortium, 2010).  
It would be expected that having 127 SNPs as opposed to 12,627 would result in a lower 
percentage of variance explained.  However, the estimate of variance calculated in my 
results is increased by the higher frequency of the HLA-DRB1*1501 SNP in the Northern 
Isles populations, which accounts for 1% of the 3% of explained variance.   
Finally, I determined the predictive capacity of the polygenic risk scores for MS status as 
having an AUC score of 0.69 (95% CI 0.65, 0.74).  This is generally in line with the scores 
previously published in literature.  The 2016 study using 452 MS cases with 103 common 
risk variants estimated the AUC to be 0.72 (95% CI 0.69, 0.75) which overlaps with the 
results produced here (Mescheriakova et al., 2016).  Another 2016 study calculated the 
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predictive AUC using 78 cases, 121 unaffected siblings and 103 controls with 110 
previously associated SNPs to produce an AUC of 0.82 (95% CI 0.75, 0.88) (Dobson et 
al., 2016).  This risk score appears relatively high, and the study notes that it is close to 
approaching the 0.85 AUC cut-off which is acceptable for clinically predicting a disease 
(Wilson et al., 1998).  However, that cut-off is based on more common, treatable 
diseases such as cardiovascular disease.  Multiple Sclerosis is a (relatively) rare, 
heterogenous disease, and while it is useful to see to what degree risk scores could aid in 
prediction, a higher number of additional common variants or the incorporation of 
environmental factors into prediction models will be required to improve risk 
prediction.  
 
6.2 What is causing the excessive prevalence of MS in the 
Northern Isles? 
The Northern Isles have a high prevalence of MS and determining if predominantly 
environmental or genetic factors, or a mixture of both, are causing this is essential to 
disease understanding and formulating strategies for prevention in the region.  Many 
environmental factors have been implicated generally in MS risk and development, 
including geographic region (specifically latitude), vitamin D levels, Epstein-Barr virus 
infection, smoking, obesity and gut microbiota.  Most of these have been investigated 
within Orkney.   The conventional environmental factors (such as vitamin D, latitude, 
vitamin D and smoking) do not appear to be explaining the excess prevalence, even if 
they contribute to individual risk. 
Both the conventional genetic and environmental risk factors appear to be within 
normal bounds in the Northern Isles.  This leads to ask the question: what is causing the 
excessive prevalence within this region?  Logically, some factor, either genetic, 
environmental or both, differs in a way that is unique to the Northern Isles. 
Latitude 
MS rates increase as you move further from the equator, and we know that the Northern 
Isles have a high MS rate for their given latitude.  Other regions on the same latitude 
(59°- 60°N) have substantially lower rates of MS: Rogaland, Norway – 176 per 100,000, 
South Estonia – 51 per 100,000, the majority of Russian territories - range from 30 to 
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70 per 100,000, across Canada – 260 per 100,000 (Gross, Kokk and Kaasik, 1993; 
Grytten, Torkildsen and Myhr, 2015; Widdifield et al., 2015; Boyko et al., 2016).  In my 
opinion, the cause of the high rates of MS in the Northern Isles would not be due to an 
environmental factor that varies by latitude.  If an environmental factor - either known 
to researchers or as yet unmeasured – that varied with latitude contributed to the excess 
of MS in Orkney and Shetland, the rates of MS would be more comparable to 
geographic locations of a similar latitude.  As it stands, the prevalence of MS in the 
Northern Isles is much higher than locations of similar latitude, and so the cause of the 
excess is likely another factor.  This is supported by the finding that vitamin D was not 
found to contribute to the excess of MS in the Northern Isles. 
Population demographics 
Women are more likely than men to develop MS.  If the Northern Isles had a higher 
population of women than men, this may explain some of the excess.  However, the 
ratio of men to women in Orkney (49.7:50.3) and Shetland (50.9:49.1) is comparable to 
the ratio found across Scotland (49:51) (National Records of Scotland, 2018), with 
Shetland being the only location in Scotland to have more men than women.  Therefore, 
it is unlikely that the excess rate of MS is linked to gender. 
In terms of population demographics, Orkney and Shetland do have higher numbers of 
the population aged 30 and above (70% and 66%) compared to mainland Scotland 
(65%).  Orkney also has more people above the age of 80 (6%) than mainland Scotland 
(5%), although Shetland has less (4%) (National Records of Scotland, 2019).  A greater 
percentage of the population above the age of onset of MS, combined with a population 
that appears to live longer, would lead to a higher prevalence of MS if the incidence 
rates were the same between Orkney and mainland Scotland.  However, I do not think 
that the 5% higher increase in over-30s would equate to such a large difference in MS 
prevalence, although it may contribute a small number of cases per 100,000 
individuals. 
Viral exposure 
Epstein-Barr virus is known to associate with MS, primarily due to links between 
infectious mononucleosis and evidence from seroepidemiological studies.  Other viruses 
have also been implicated in MS (for example, human herpesvirus 6) and it may be 
possible that an unknown virus or other infectious agent has contributed (or continues 
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to contribute) to MS risk (Virtanen and Jacobson, 2012).  Evidence for viral agents 
causing an increase in disease prevalence have previously been suggested in the 
Northern Isles.  During the Second World War, a cluster of leukaemia occurred in 
children in Orkney and Shetland; the death rate for this disease was three times higher 
during a period where 60,000 British troops vastly outnumbered the local populace.  It 
was suggested that this disease cluster was caused by an infectious, probably viral, agent 
brought from the British troops (Kinlen and Balkwill, 2001).  Clusters of disease can 
often occur when isolated rural communities are exposed to a significant influx of 
outsiders.  Is it possible that this WW2 occupation began a similar epidemic of MS in 
the Northern Isles?  If Northern Isles children were exposed to an unfamiliar virus, this 
may have increased the risk of developing MS at a later age.  Exposure to environmental 
factors during childhood are key for influencing risk of developing MS, as has been 
shown with migration studies: the incidence of developing MS has been shown to 
correlate with the risk of developing MS within the region of childhood residence 
(Compston and Coles, 2008).  An individual who resides in a low-risk region but 
migrates to a high-risk region during adulthood will retain their low risk of developing 
MS (Gale and Martyn, no date).  However, an individual who migrates from a low to 
high risk region during childhood (under 15 years of age) will acquire the high risk of 
their new host country (Gale and Martyn, no date).  Therefore, individuals may have 
exposed children in the Northern Isles to a viral burden which, 30-40 years later, 
manifested in a higher prevalence of MS.  This theory would be difficult to prove, given 
the extended time frame between childhood and the onset of development. It also 
appears that later cohorts of children continue to develop MS.  Nevertheless, an 
infectious agent may contribute somewhat to the excess of MS cases in the islands. 
Obesity 
Obesity has been shown to influence MS and is a risk factor for the disease: a Mendelian 
Randomisation study showed that an increase of 1 standard deviation in BMI increased 
the odds of developing MS by 41% (95% CI 20, 66) (Mokry et al., 2016).  The exact 
mechanisms for how obesity increases the risk of MS is unclear, but it is possibly 
because individuals who are classed as overweight have a reduction in the amount of 
testosterone produced.  Low testosterone has previously been associated with cognitive 
decline in MS, and in animal models testosterone seems to be protective against 
synaptic preservation by crossing the blood brain barrier to affect neuronal cells (Bove 
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et al., 2015).  Additionally, individuals who are overweight generally have an increase in 
their immune response and potentially neuroinflammatory activity, as the body 
produces more proinflammatory mediators within fat tissues (Lumeng, Bodzin and 
Saltiel, 2007). 
Orkney has the highest percentage of individuals who are classed as overweight and 
obese for any location in Scotland at 73% (95% CI 68, 78), while Shetland comes close 
with 71% (95% CI 64, 77).  For comparison, the Scottish average is 65% (95% CI 64, 66) 
(Scottish Government, 2018).  The higher levels of individuals classed as overweight 
and obese in Orkney and Shetland is likely to be reflected in a higher disease burden of 
MS, and I believe a reduction in the number of cases in the Northern Isles would occur 
if many islanders retained a BMI below 25 (not including BMI increases due to muscle 
mass).  Given the difference in percentage between obesity levels in mainland Scotland 
and Orkney in particular, I think it is likely this contributes a small amount to the excess 
burden of MS.  
Gut microbiota  
Much attention has recently been given to gut microbiota and its role in Multiple 
Sclerosis (Cekanaviciute et al., 2017; Chu et al., 2018; Kirby and Ochoa-Repáraz, 2018; 
Mowry and Glenn, 2018).  The gut microbiome is incredibly complex in both the way it 
impacts our cellular and immune system functioning, and the way it is influenced by 
external factors. 
It is possible to theorise that the people of the Northern Isles may have a different gut 
microbiome composition to individuals in mainland Scotland, and it may be influencing 
the risk of MS.  Gut microbiota in patients with MS differs from healthy individuals, 
with some microbiota found in MS cases associating with promoting inflammatory 
cytokines and general inflammation (Kirby and Ochoa-Repáraz, 2018).  Loss of function 
of T regulatory cells and modulation of immune-mediated demyelination have also been 
reported as a result of changes to gut microbiome composition (Umeton et al., 2018).   
The gut microbiome is unique to each individual, but individuals from the same 
geographic region will generally have a more similar microbiome than individuals from 
different geographic regions.  The geographic scale to which this extends has yet to be 
clarified, but it has been noted when comparing individuals from different countries 
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(Yatsunenko et al., 2012).  The gut microbiome is certainly influenced by the place of 
residence, along with diet and lifestyle factors (Chu et al., 2018).  If individuals in the 
Northern Isles have a specific factor which influences their gut microbiome enough for 
it to be significantly different from that in mainland Scotland, this may be enough to 
influence disease risk.  However, two gut bacteria significantly associated with MS, 
Akkermansia muciniphila and Acinetobacter calcoaceticus (Cekanaviciute et al., 2017), 
are unlikely to play a role in causing an increase in MS in the Northern Isles.  
Akkermansia muciniphila has been found to decrease with obesity; as individuals in 
Orkney are significantly more obese than individuals on mainland Scotland, it is 
unlikely that they have higher levels of this bacteria.  Additionally, I do not believe the 
evidence for Acinetobacter calcoaceticus is strong enough to conclude it is a causal 
factor in the development of MS; it is an opportunistic bacterium found in patients with 
multiple underlying conditions, and so its presence is quite likely a consequence of MS.  
Additionally, much of the research carried out on gut bacteria is with a small sample 
size from a specific population group (for example, (Umeton et al., 2018) which had 
samples from 42 cases).  It would be interesting to investigate the composition of gut 
microbiota in the Northern Isles in comparison to that of mainland Scotland, as it has 
the potential to reveal interesting information about the gut microbiome and its relation 
to MS risk.  However, a study of this nature would have more success on focusing on 
population differences (Northern Isles vs mainland Scotland) rather than trying to 
determine if specific bacteria were causing MS in the Northern Isles.  With a disease 
such as Multiple Sclerosis, it is difficult to determine if gut bacteria are the cause rather 
than the consequence of developing MS.  Other studies in the literature, for example, 
Kirby & Ochoa-Repáraz (2018), have found a difference between cases and controls for 
microbiome content within a population group but were unable to specify if the 
difference was cause or effect. 
However, based on the current rather slim evidence, I do not think it is likely that gut 
microbiota play a significant role in determining MS risk in Orkney and Shetland.  
Although this remains to be investigated in future studies, I do not believe this should 
be given high priority in comparison to other potential areas of investigation such as 
rare genetic variants. 
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Hygiene hypothesis 
To determine why the Northern Isles has such a high prevalence of MS, it can often be 
useful to look at other population isolates with similarly high frequencies.  One of these 
is the island of Sardinia, which has an overall prevalence of 247.6 per 100,000 
individuals (Pugliatti, Sotgiu and Rosati, 2002; Sotgiu et al., 2004), much higher than 
the surrounding low latitude and high vitamin D Mediterranean populations.  The 
hygiene hypothesis was a theory proposed to help explain the high MS risk in this 
region.  Within this population, the incidence rate of MS has increased substantially 
over the past forty years (Sotgiu et al., 2003) and the hygiene hypothesis was proposed 
to explain this.  Post-World War II, a distinct lifestyle change (which included a malaria 
eradication campaign) left a population which had evolved to combat a multitude of 
parasites and pathogens with no need for such immunogenic mutations, leaving the 
Sardinian population prone to autoimmune diseases, where the immune system attacks 
the self (Sotgiu et al., 2003).  This is unlikely to have happened in the Northern Isles.  
While it may be possible that the Northern Isles have undergone a lifestyle change in 
regards to increased use of antibiotics, this is i) not comparable to Sardinia given the 
lesser range of dangerous pathogens such as mosquito-borne diseases and ii) would 
likely not be so different from the rest of mainland Scotland and so would not explain 
why the prevalence differs between the two populations.  Therefore, although this 
theory may help explain MS prevalence in Sardinia, I do not think it applies to the 
Northern Isles. 
Unique or unmeasured environmental factor 
Over 400 environmental risk factors have been examined in Multiple Sclerosis.  These 
include exposure to environmental agents, traumatic events and accidents, 
vaccinations, surgeries, comorbidities and infectious, musculoskeletal and biochemical 
biomarkers (Belbasis et al., 2015).  It has been noted that many environmental risk 
factors appear to show differential association dependent on geographical region 
(Ramagopalan et al., 2010).  The Northern Isles may have a region-specific 
environmental factor that has not currently been measured.  A similar study looking at 
geo-environmental exposures was conducted in South-West Sardinia (Monti et al., 
2016), an area which has a high prevalence of MS at 210 individuals per 100,000 (Cocco 
et al., 2011).  The study used geochemical data for heavy metals, along with UV 
exposure and urbanization data for all municipalities in the region.   
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They found an association between MS distribution and copper (Cu) levels; where for a 
50 ppm increase in Cu concentrations, the adjusted odds of MS were 2.2 times higher 
(95% CI 1.3, 4.0, p = 0.006).  Additionally, one village had a particularly high 
prevalence of MS (431 per 100,000) and one village had a particularly low prevalence of 
MS (46 per 100,000).  The high prevalence village was associated with a high value of 
Cu (64.12±18.44 ppm) while the low prevalence village was associated with a low value 
of Cu (10.24±18.26 ppm).  The study group hypothesized that environmental factors, 
such as Cu levels, along with the expression of genetic risk factors based on a specific 
environmental trigger may cause the geographical differences seen between regions in 
South West Sardinia.  A similar study would be able to be carried out in the Northern 
Isles using data, if available, for environmental factors which have not previously been 
looked at, such as heavy metal data on the islands, and compare the results to mainland 
Scotland.  Heavy metal data has been collected in Orkney and it has been noted that it 
has a higher concentration of heavy metals (Curtis and Simpson, 2001), as well as high 
concentrations of Uranium in the red sandstone (Smith and Great Britain. Environment 
Agency., 2003), as well as possibly radon gas, however the extent of this and their 
contribution, if any, to MS, is unknown.  
Additionally, it may be possible that it is a completely unknown and unmeasured 
environmental factor that is unique to the Northern Isles.  If this is the case, patterns in 
case data as time progresses may present more evidence to support this.  
X chromosome 
There has been some discussion over the involvement of the X chromosome in MS risk, 
given that the ratio of MS is three times higher in women than men (a ratio which is 
maintained within the Northern Isles).  To date, only one variant has been identified as 
genome-wide significant (rs2807267) on the X chromosome, and with an odds ratio of 
1.07 this would not explain differences by sex.  It is very unlikely that the X chromosome 
of people in the Northern Isles has some significant and unique involvement in the 
excess of MS in the region, given the lack of evidence for genetic involvement of the sex 
chromosomes in general.  Additionally, significant involvement of the X chromosomes 
has the potential to skew the ratio of men to women on the islands, which as it stands, 
does not differ from the ratio found for MS worldwide. 
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Gene-gene interactions 
Gene-gene interactions have been shown to contribute a small amount of risk for MS.  
Principally, interactions between haplotypes HLA-DQA1*01:01-HLA-DRB1*15:01 and 
HLA-DQB1*03:01-HLA-DQB1*03:02 have been shown in a large-scale study with 
17,465 cases and 30,385 controls (Moutsianas et al., 2015).  The increased frequency of 
HLA-DRB1*1501 in the Northern Isles may lead to a slight increase in such interactive 
effects.  Outside the HLA region, a study recently found an MS-associated IL7R variant 
interacted with an unknown, non-MS related variant in DDX39B (Galarza-Muñoz et al., 
2017).  This interaction increased the risk of MS by almost three times due to the over 
production of the protein sIL7R which increased MS risk.  It may be possible that a 
unique gene-gene interaction similar to this exists in the Northern Isles.  If a variant 
that is rare elsewhere but common in the Northern Isles region interacts with another 
variant to produce an effect on an immunological or pro-inflammatory pathway, it may 
increase the risk of MS in a way that would not be seen in mainland Scotland if the 
interactive variant was of low frequency.  The network of immune cells implicated in 
Multiple Sclerosis involves a vast array of molecules and cell types, including cytokines, 
signaling molecules and antigen receptors, whose interactions can lead to an almost 
infinite variation of functional outcomes, including redundancy which is often the case 
with MHC interactive effects.  This complex system gives rise for many opportunities for 
gene-gene interaction to occur and this in turn has the potential to be unique to a 
population that differs in allele frequencies. Additionally, gene interactions may occur 
even in the absence of statically significant individual main effects (Motsinger et al., 
2007), and so an undetected common variant that is unique to the Northern Isles may 
have an interactive effect that contributes to a higher rate of MS in the region.  
Disruption in immunological and pro-inflammatory pathways due to gene-gene 
interactions has previously been linked to some cases of familial MS, and so it is not 
difficult to imagine a similar scenario occurring in the Northern Isles (Vilariño-Güell et 
al., 2019).  
However, there is no known MS hotspot which has, to date, been explained by gene-
gene interactive effects.  Although it’s understood that interactive effects do contribute a 
small proportion to MS risk, this contribution is limited.  Thus, while it is possible that 
unique gene-gene interactions exist on Orkney, these would likely not be enough to 
explain such a high proportion of excess prevalence. 
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Detecting gene-gene interactions within the Northern Isles would be very difficult, given 
the limited sample size.  To detect interactions between genes, a much larger sample 
size is needed than simply to find individual effects.  For example, in the very basic 
scenario of examining the interaction between two SNPs, with three genotype 
combinations each, these gives 9 genotype combinations: increasing the number of 
SNPs in each interaction term leads to exponentially bigger results.  If any interactive 
effects do exist in the Northern Isles, these would therefore be very difficult to detect. 
Gene-environment interactions 
Much evidence has been presented to support the effect of interactions between genetics 
and environmental factors in MS.  For vitamin D, the vitamin D response element 
(VDRE) is found in the promotor region for HLA-DRB1; thus it is very likely that the 
expression of HLA-DRB1 is controlled by vitamin D (Ramagopalan, Maugeri, et al., 
2009).  In EBV, an interaction between increased Epstein–Barr nuclear antigen 1 titres 
and HLA variants has been found to increase MS susceptibility (De Jager, Chibnik, et 
al., 2009).  Tobacco smoke exposure has been associated with greater MS risk, with 42 
NAT1 variants showing evidence for interaction (Napier et al., 2016).  Heavy metal 
exposure has been identified as interacting with MS variants in 5 genes examined in a 
study of 217 cases, including VDR, TNF-α, TNF-β,  MbP and APOE (Napier et al., 2016).  
Overweight individuals with a BMI of >27 kg/m2 who had 1 or 2 HLA-DRB1*15 risk 
variants were reported to have a seven-fold increased risk of MS in comparison with 
individuals who had no HLA-DRB1*15 risk variants and a BMI less than 27 kg/m2 
(Gianfrancesco and Barcellos, 2016).  These studies were conducted at least 200 
individuals and suggest the presence of interaction between MS risk variants and the 
most influential environmental factors.  It is therefore very likely that similar 
interactions exist in the Northern Isles, but to what degree these are affecting the MS 
prevalence is unknown.  It is my suggestion that the increased frequency of the HLA-
DRB1*1501 variant combined with a high rate of overweight individuals will lead to a 
greater contribution of interactive effects to MS prevalence than in mainland Scotland.  
Investigating this is challenging due to the small sample size of cases, but prioritisation 
of specific environmental factors such as obesity would allow for a more streamlined 
approach.  If gene-environment interactions were found to be significant MS risk 
factors in the Northern Isles, this would help effective strategies for MS prevention to be 
designed. 
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It may be the case that gene-environment interactions are not contributing to the excess 
prevalence in the Northern Isles.  While gene-environment interactions may explain hot 
spots in other diseases, such as chronic kidney disease (Friedman, 2018), interactions 
have not previously explained any MS hotspots.  However, Orkney is unique in terms of 
its combination of genetic and environmental factors, and I think it is likely that some, 
even if it is a small amount, of the excess prevalence could be explained gene-
environment interactions (particularly involving obesity). 
Comorbidities 
Often, individuals who develop MS acquire other immune-mediated inflammatory 
diseases or have close family members that do (Nielsen et al., 2008).  This can be due to 
diseases sharing similar pathways, with overlapping genetics or environmental risk 
factors (Sawcer et al., 2011).  A high prevalence of MS may mean that there is a high 
prevalence of an associated disease; if so, this may give an indication as to the reason 
why MS is so high in the islands.   
Multiple diseases have been associated with MS, however not every disease has a 
measured prevalence in Orkney and/or Shetland.  Of diseases previously associated 
with MS, rheumatoid arthritis, Crohn’s disease and diabetes each have an estimated 
prevalence for the Northern Isles.  For rheumatoid arthritis, the Northern Isles do have 
a slightly higher prevalence (747 per 100,000 individuals compared to mainland 
Scotland's 708 per 100,000 individuals), however it does not show the same excess in 
case numbers that found in Multiple Sclerosis (Scottish Public Health Record, 2012).  
Crohn’s disease had a slightly lower prevalence in the Northern Isles (136 per 100,000) 
than North-Eastern Scotland (147 per 100,000), although this was measured during the 
1980s and prevalence rates may have changed since this time (Kyle, 1992).  Diabetes 
was also at a slightly lower prevalence in the Northern Isles (4700 and 4800 per 100,00 
in Orkney and Shetland) compared to mainland Scotland (5400 per 100,000) (NHS 
Scotland, 2016). 
Although this only gives a picture of three diseases, they are some of the most strongly 
associated with MS.  Additionally, both Orkney and Shetland are very community-based 
populations, and as such it is more obvious when a disease is at a particularly high 
prevalence.  Multiple Sclerosis remains the principal disease of focus on the islands as 
so many residents are aware of its high prevalence due to local knowledge alone.  There 
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has not been a similar disease noted by residents for its high prevalence.  Although it 
would be useful to record the prevalence of other diseases specifically as island-specific 
prevalence rates, local knowledge should not be discounted as an indicator of disease 
spread.   
As it does not appear that any other disease has such a high prevalence to the Northern 
Isles when compared to nearby regions (such as mainland Scotland), it suggests that the 
disease mechanism that is causing the excess prevalence in the Northern Isles is specific 
to Multiple Sclerosis.  This insinuates that the cause of the excess prevalence on the 
islands are population-specific, but also disease-specific.  If an environmental factor was 
solely to cause excess prevalence, it would likely have some effect on other, related 
diseases.  For example: an excess of heavy metals would not just cause an increase in 
Multiple Sclerosis on the islands, but also other diseases, for which the risk is also 
increased by heavy metal exposure.  Additionally, it is likely not one factor that is shared 
between multiple diseases that is causing MS.  It is more likely that it is a combination 
of factors – some may be shared with other diseases, but not all – or an entirely MS-
specific factor, such as rare genetic susceptibility variants. 
Epigenetics 
Epigenetics is the study of phenotypic changes caused by the modification of gene 
expression by alterations to the genome that do not change the nucleotide code, for 
example histone acetylation and DNA methylation (Petronis, 2010).  A recent study 
found significant variation of DNA methylation within human groups in a single 
continent (Giuliani et al., 2016).  The variation in each group was shaped by 
environmental factors such as nutrients, UVA exposure and pathogen load, with 
ecological niches influencing an individual’s DNA methylation profile.  The geographical 
scale over which this variation extends (for example, mainland Scotland verses the 
Northern Isles) has yet to be seen.  Several MS-associated environmental factors, such 
as vitamin D, dietary factors, smoking, EBV infection and UV radiation have been 
shown to alter DNA at an epigenetic level (Rito et al., 2018).  If these factors can change 
DNA methylation and cause other epigenetic changes, and they differ at a local level, it 
may be possible that there is a different epigenetic profile for individuals living in the 
Northern Isles as opposed to mainland Scotland.  This would be further affected by the 
potential inheritance of epigenetic factors (Perez and Lehner, 2019); as the Northern 
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Isles was more isolated in the past, it may lead to a greater difference in environmental 
factors influencing epigenetics when compared to mainland Scotland.   
However, there are two key questions when considering epigenetics as a cause of MS.  
Firstly, are environmental factors different enough in the Northern Isles to cause a 
change in epigenetic profiles between two population groups?  Factors such as EBV 
infection, smoking and vitamin D have been shown not to differ between these 
populations.  It may be possible that a difference in diet in general (given the higher rate 
of obesity in the Northern Isles) or an unknown or unmeasured environmental factor 
may cause a significant difference, but this has not been quantified. 
Secondly, if a significant different in environmental factors is seen between populations, 
how much will this contribute to the variation of Multiple Sclerosis?  The potential 
difference in epigenetics between mainland Scotland and the Northern Isles relies on 
not only there being a significant difference between key environmental factors, but for 
that difference to be great enough to have an influential effect on epigenetic changes 
that is enough to influence MS risk.  Although it is known that environmental factors for 
MS can influence epigenetics, there has not been any specific quantification of how 
much variation in risk this results in. 
I think that although diet or some unmeasured environment factor has the potential to 
cause a slight difference in epigenetics, I do not think that this will significantly impact 
the prevalence of MS in the Northern Isles.  I certainly doubt that it is the reason for 
excess prevalence in the region.  However, on a broader scale, it may be interesting to 
study the difference in epigenetic patterns between these and other populations, and 
how, if at all, this contributes to disease variation. 
Rare variants 
Possibly the most likely contributor towards the excess risk of MS in the Northern Isles 
are rare genetic variants: variants with a frequency of less than 0.01 that are usually not 
captured by SNP-array genotyping technology.  Much evidence has been presented in 
recent years to support the influence of rare variants in MS risk, particularly amongst 
family groups.  For example, whole exome sequencing on 127 individuals from 26 
multiplex families identified 28 novel genes with rare variants that had segregated 
completely with the disease in at least two families (Haines et al., 2013).  Another recent 
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study identified 9 rare variants within 6 genes that were all present within one multi-
incident family (Traboulsee et al., 2017).  Even within a single family there may be more 
than one variant that is increasing MS risk.  Another study identified a rare three-
variant haplotype in purinergic receptor genes P2RX4 and P2RX7 within a multi-
incident family (Sadovnick et al., 2017); the rare variants were found to segregate in six 
family members diagnosed with MS.  These three studies are examples of rare variants 
identified which likely cause MS, and there are other studies that have identified other 
rare variants associating with MS (Harding and Robertson, 2019).  Within the Northern 
Isles, it is possible that there are one or more rare variants, possibly segregating within 
families, that are associated with Multiple Sclerosis.  Rare variants of interest will have 
large effect sizes and are likely to be causal in MS, with obvious functional 
consequences.  Therefore, these have the potential to explain a larger proportion of the 
excess cases of MS found in the islands. 
Isolated populations such as the Northern Isles have generally experienced bottlenecks 
and genetic drift, and so by chance rare variants can increase in frequency.  A 2017 
study (which included Orkney) empirically showed that isolated populations were 
enriched for rare functional variants (Xue et al., 2017).  Enrichment of rare variants has 
been the source of high disease rates in other population isolates, for example high 
schizophrenia risk within a Finnish population isolate was attributed to rare variants 
(Pietiläinen et al., no date).  It is possible that the Northern Isles may have multiple rare 
variants and in combination they may explain a considerable proportion of variance for 
MS.  Common variants contribute only a relatively small proportion to the overall 
heritability of MS, and so other types of variants, particularly rare variants, should be 
prioritised for future research. However, by their very nature rare variants are going to 
be extremely difficult to pin down in a population where there is a very low limit to the 
total number of patients that can ever be collected without waiting impractically long 
for cases to accrue, and hence limits on statistical power. 
 
6.3 Strengths, limitations, implications and future work 
6.3.1 Strengths of using ORCADES and VIKING 
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This thesis used the ORCADES and VIKING cohorts, which sample population isolates; 
with this comes both positive and negative characteristics for data use.  Population 
isolates have the potential to reveal key insights into causative alleles.  Alleles which 
may be at a rare or low frequency in the general population may have drifted to higher 
frequencies due to, for example, the founders of the populations having higher 
frequencies of these alleles by chance.  This can allow their detection, which otherwise 
may have been missed.  Population isolates can also have a unique profile of rare 
variants, which has the potential to reveal insights into disease pathways which would 
otherwise be undiscovered. 
ORCADES and VIKING were created with the aim of discovering genes and variants 
that contribute to common, complex diseases.  Although both datasets are relatively 
small, they sample a substantial proportion of the island populations and are the only 
genetic resources available for the unique Northern Isles populations, and so should be 
utilised fully.  Both cohorts have rich phenotyping and genotyping and are an excellent 
resource for the population isolates of Orkney and Shetland in the Northern Isles of 
Scotland.  Additionally, all participants have ancestry from either Orkney or Shetland 
and therefore have enhanced kinship information with recorded pedigrees.  This can be 
exceedingly useful for data analysis as pairwise relationships can be informative within 
genetic analyses. 
 
6.3.2 Limitations of using ORCADES and VIKING 
Sample Size 
Sample size is fundamental for every statistical study.  An adequate sample size is 
required to detect an effect within a sampled population group; if a sample size is too 
low, it will lead to Type II errors.  Conversely, if a sample size is too high, it is adding 
unnecessary additional costs to data collection.  Generally, an effective sample size is 
one that is defined as the minimum number of samples needed to achieve adequate 
statistical power.  Statistical power can be defined as the probability that a null 
hypothesis is rejected when the alternative hypothesis is true. An adequate statistical 
power of 80% is typically used; using power to this level avoids false negative 
associations while retaining cost effectiveness in data collection (Hong and Park, 2012).  
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Power can be affected by multiple factors, with different study designs resulting in 
different statistical power estimates.  For example, dominant models require a lower 
sample size than additive models, common diseases and common SNPs with stronger 
effect sizes also require lower sample sizes, particularly when considering variants with 
high levels of LD.  Increasing the number of controls per case until a ratio of 1:4 has 
been reached will also allow an increase in power.  Hong and Park (2012) calculated 
that a GWAS testing a single SNP will require 248 cases, while testing 500,000 SNPs 
requires 1206 cases, under an assumption of 1:1 case/control ratio, complete LD, 5% 
MAF, 5% disease prevalence and an OR of 2 (Hong and Park, 2012). 
Within this study, the principal limiting factor was sample size.  Multiple sclerosis in 
particular has many variants of small to moderate effect (OR 1.02 - 1.2).  Therefore, 
larger sample sizes will inherently be needed to achieve the power needed to detect 
these common variants of smaller effect.  The inadequate sample size was particularly 
evident within this thesis in both the heritability analysis and GWAS. Case numbers 
were not a limiting factor within the key analysis in Chapter 5, as the principal 
comparison of polygenic risk scores to determine if there were a difference in common 
allele frequencies in mainland Scotland and the Northern Isles was only conducted on 
control individuals.   
In Chapter 3, an accurate heritability estimate was unable to be obtained for VIKING 
(15 cases and 2090 controls), and the heritability estimate for ORCADES (97 cases and 
2118 controls) had had a confidence interval spanning 0.1 to 0.5.  With estimating SNP 
heritability, increasing sample size allows the estimate to approach the true SNP-
heritability of the population.  Compared to the IMSGC estimate (14,802 cases and 
26,703 controls), whose confidence interval spanned 0.18-0.20, the effect of large 
sample size is apparent.  Under the assumption of a trait heritability of 0.2 (on the 
liability scale), an additional 560 ORCADES cases and 595 VIKING cases would be 
needed to achieve an adequate statistical power in each SNP heritability analysis 
(Visscher et al., 2014). 
Within the GWAS, this study was unable to find any statistically significant SNPs with 
112 cases and 4,208 controls for the Northern Isles.  GWAS in particular requires a 
stringent p-value threshold.  Within one association, the observed signal is statistically 
significant if the p-value is lower than the predetermined 0.05 required to reject the null 
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hypothesis.  However, when testing a large number of SNPs, this p-value is corrected for 
multiple comparison to reduce false positive results.  Therefore, a significantly larger 
sample size is needed to achieve enough power for discovery (Klein, 2007).  Specifically 
for this study, 698 additional samples would be required to detect variants to genome-
wide significance level, with the assumption of the disease allele frequency equal to 0.5 
and a genotype relative risk of 1.5 (Menashe, Rosenberg and Chen, 2008). 
The ORCADES and VIKING dataset are limited in what they can achieve in terms of 
variant discovery when using traditional methods such as GWAS.  A relatively small 
population (approximately 22,000 individuals in Orkney and 23,000 individuals in 
Shetland) will yield small numbers of MS cases, despite the high rates of MS in the 
islands.  This in turn results in reduced power and therefore the likelihood of discovery 
of disease contributors is low, particularly when comparing these studies to the huge 
cohort studies conducted by IMSGC. 
Unfortunately, it is not possible to increase the case numbers within ORCADES and 
VIKING, and so these cohorts must be maximised with novel, and often relatively 
expensive, methods of analysis (such as WGS) to gain new knowledge of variants.  
Although the analyses conducted in this study were unlikely to prove fruitful given the 
low power, it was still important to conduct this research.  Heritability, GWAS and 
PGRS analyses had not previously been performed for the Northern Isles, and so it was 
important to conduct these even given the small possibility that significant results 
would be found. 
The use of common reference panels for imputation 
Within this study, a GWAS was performed on an imputed dataset.  In the absence of 
whole genome sequencing, imputation provides a cost-effective solution for enriching 
genotyped datasets.  It is based on haplotype sharing between individuals and can be 
carried out using a framework of common variants from a SNP array and a collection of 
haplotypes in a reference panel.  The reference panels most often used for imputation, 
common reference panels, are composed of a large number of individuals of European 
ancestry.  However, several factors will influence the quality and success of imputation 
and the genomic coverage of variants, including haplotype structure, the presence of 
population-specific variants, and differing allele frequencies (Marchini and Howie, 
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2010).  Thus, a one-size-fits-all approach to common reference panels may not be 
appropriate for unique populations, such as population isolates. 
Within population isolates, common risk variants can generally be imputed with good 
accuracy.  However, any rare or unique variants which are specific to the population 
would be difficult, if not impossible, to impute.  To resolve this, a population-specific 
reference panel can be designed to produce higher quality imputation results that are 
more accurate and that provide more genomic coverage and give a better enrichment of 
variants.  By capturing rare variation more effectively, downstream analyses would be 
more likely to identify these rare variants with success.  Had a population-specific 
reference panel been available for the Northern Isles dataset, it is possible that the 
GWAS would identify variants to statistical significance or bring more truly causal 
variants to suggestive significance.  Population isolates are an excellent resource for 
identifying unique and rare variants which contribute to a disease, and so a population-
specific reference panel is a powerful strategy for achieving higher genomic coverage, 
higher imputation accuracy and a better estimation of allele frequencies. 
Linkage disequilibrium 
It is important to consider how much linkage disequilibrium exists within a population, 
and how this may influence genetic analyses.  Longer stretches of LD means longer 
haplotypes, which helps imputation and facilitates GWAS in identifying an associated 
region of the genome with a trait (Hatzikotoulas, Gilly and Zeggini, 2014).  However, 
having longer LD blocks adds extraneous markers to a possible causal variant, which 
may hinder efforts to isolate the causative variant from other variants that are in 
complete LD with them (Kristiansson, Naukkarinen and Peltonen, 2008).  Therefore, 
longer LD blocks that may help to initially identify a locus also lead to a lesser 
resolution in defining causal variants within a wider associated area.  This is important 
to discuss in relation to population isolates, as younger isolates tend to have LD that 
exists over slightly longer genomic regions. LD is influenced by many factors, including 
recombination, population size and population structure, and this leads to regions of LD 
in older populations tending to be shorter than LD regions in younger populations.  
Although this was not a particular issue within this study (as no statistically significant 
variants were identified through GWAS), it is an important point to note within 
population isolates that can cause issues with analyses further on from GWAS. 
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6.3.3 Implications of this research 
The research in this thesis has several implications for future MS research.  Firstly, I 
showed that common risk variants do not appear to cause the geographic hotspot.  This 
may help researchers looking to find the cause of high rates of MS in other regions, with 
the suggestion that it may not be due to common variants (particularly because known 
common risk variants also appear to contribute less than 5% to disease variance, and 
also tend to be found at similar frequencies across populations).  Additionally, several 
potential common variants which may contribute to MS risk have been highlighted.  If 
these are later proven to be real associations, they have the potential to be informative 
of novel pathways of disease, which in turn could lead to new drug treatments.   
However, one of the primary reasons of conducting the research in this study, aside 
from adding to the current knowledge on MS, was to pass the findings on to the Orkney 
and Shetland communities.  There is much speculation within the public sphere in the 
Northern Isles regarding the cause of the excess of MS cases.  It is therefore important 
for these individuals to know that they do not carry an unusual burden of common risk 
variants.  These variants, although important in determining MS risk, are not placing an 
additional burden on the people of the Northern Isles in comparison to those in 
mainland Scotland.  The strongest known variant, HLA-DRB1*1501, appears to be at a 
slightly higher frequency in Orkney and Shetland; individuals on the islands could 
potentially take an at-home genetic test to determine if they have the risk alleles for this 
variant, although this advice may be excessive given the small proportion it contributes 
to developing MS. 
Public health information 
Communicating the findings of past, current and future studies of MS research in an 
effective way to the public is essential to avoid misconceptions about MS cause and 
prevention.  For example, in a previous study by Weiss et al, it was found that low blood 
plasma vitamin D levels were not causing an excess of MS cases in the region.  This does 
not mean that vitamin D deficit is not important in influencing MS risk, but only that it 
is not causing additional cases of MS in the region than would be expected.  It is 
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important for individuals of the public to know that it is still important to keep vitamin 
D intake at adequate levels to prevent increased risk of disease. 
It is particularly important to convey to individuals who live in the Northern Isles that 
although previous studies indicate that environmental factors do not appear to 
contribute to the excess risk of MS on the islands, the influence on the environment on 
disease risk and development is still important.  Many residents are aware of the high 
rates of MS, and caution should be made before publicising that environmental factors 
such as vitamin D are not contributory to the excess risk, as they still contribute to the 
general level of risk.  Any healthcare on the island should not take emphasis away from 
the importance of diet and healthy lifestyle choices.  
In general, it is hoped that the findings of this research are communicated to individuals 
in the Northern Isles with the intent of starting discussion on the risk factors of MS in 
general, with the goal of encouraging better lifestyle choices.  Although the 
environmental risk factors are no more significant in causing MS than mainland 
Scotland, they should still be targeted for improvement.  Emphasis should be made to 
reduce the rate of overweight and obese individuals on the islands, given the high 
percentage of individuals who are classed as overweight.  This would not only lower the 
risk of MS for individuals in the island, but many other overweight-associated health 
conditions. 
 
6.3.4 Future research 
This study has found that common risk variants as a collective, do not make a 
meaningful contribution to the excess of MS in the Northern Isles.  However, a small 
proportion of the excess risk is due to the strongest known common variant, HLA-
DRB1*1501.  Yet, the majority of the excess risk in the Northern Isles remains 
unexplained. 
The findings of this research are limited in answering this question, however it is 
possible that the excess rates are caused by an unlucky combination of multiple 
environmental and genetic factors: a higher frequency of the HLA-DRB1*1501 variant, 
strong rare variants which are confined to several family lines within the Northern Isles, 
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higher obesity levels and gene-environment interactions.  There may also be unknown 
environmental factors which contribute to an increased risk, such as heavy metal 
toxicity or an infectious agent. 
Given that there are most likely multiple contributors to the excess rate of MS, there are 
numerous avenues to which future research could be directed. 
The most obvious of these appears to be a targeted search for rare variants.  Rare 
variants are often enriched in population isolates due to founder effect and genetic drift 
and can have strong effects on disease risk.  Recent MS studies have also provided 
further evidence that multiplex families often have one or more rare variants.  Multiple 
Sclerosis is a heterogenous disease, and as such it is likely that individuals have causal 
variants of different frequencies contributing towards the disease.  Identifying rare 
variants, even if they are unique to the Northern Isles, will contribute to the full 
spectrum of known variants on MS and provide a greater understanding to disease 
mechanisms.  Additionally, if the discovered variants have a high effect on MS risk, 
measuring them in a clinical setting could lead to personalised medicine for individuals 
with the highest genetic risk.   
It is suggested that rare variant research should use whole genome sequencing to scan 
multiplex families to potentially identify causal rare and low frequency variants.  It is 
possible that there are private variants found only within specific families – if a variant 
is not observed in large collections of genomic data (e.g. gnomAD) and only exists 
within a family, the only way to detect it is through WGS.  There have been substantial 
decreases in the cost of sequencing, as well as increases in the throughput, which have 
made it more favourable to carry out WGS at a larger scale.  Additionally, an alternative 
to whole genome sequencing is whole exome sequencing, which only sequences coding 
regions of the genome.  Although this method does not capture variation in non-coding 
regions, it is more cost effective.  Using whole genome or exome sequencing within the 
Shetland and Orkney populations would be particularly useful as the pedigree 
information held for these populations would allow information gained to be 
extrapolated across the related individuals in the cohorts.   
Specific recommendations 
A primary focus of future research on multiple sclerosis in the Northern Isles should be 
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on rare variants.  It is recommended that the most cost-effective solution for effectively 
detecting these variants is to whole-genome sequence individuals in ORCADES 
(primarily) and VIKING to a low depth.  This would capture variants in non-coding 
regions but would have more power than sequencing less individuals at a higher depth 
(Li et al., 2011).  This strategy has proven successful for improving power to detect rare 
variants (Holm et al., 2011).  In the samples that have been sequenced, variants can be 
phased with long-range haplotype phasing and then imputed back into the sample set.  
This is similar to using the sequenced group as a population-specific reference panel for 
imputation.  In terms of specific analyses to detect rare variants, it is suggested that a 
gene-based burden testing approach should be used (Guo et al., 2018).  This takes 
sequence data to look at the number of individuals carrying rare variants in each gene 
and comparing them between MS cases and controls.  By combining multiple rare 
variants across a candidate gene, it overcomes the power issue faced when considering 
rare variants alone.  WGS would (in theory) be able to detect Orkney and Shetland 
specific rare variants, although power will always be limited by the low absolute 
numbers of cases, overall and in any particular kindred.   
  
6.3.5 Summary 
Multiple Sclerosis is a multifactorial disease of autoimmune origin which is increasingly 
common at higher latitudes, including Scotland.  It has previously been shown that the 
Northern Isles of Scotland have the highest prevalence of MS in the world. Various risk 
factors, both genetic and environmental, are implicated in MS, but the reasons for the 
peak in Orkney and Shetland are not well understood.  This thesis sought to better 
understand these very high rates through several approaches using the data of the 
Northern Isles Multiple Sclerosis study, Orkney Complex Disease Study and the Viking 
Health Study - Shetland.  
As well as shining a light on the very high rates this thesis set out to contribute the 
findings to the general understanding of MS as well as in the communities of Orkney 
and Shetland.  Firstly, the SNP heritability in Orkney for MS was estimated at 0.31 (95% 
CI 0.13, 0.49), while an estimate for Shetland could not be obtained due to low case 
numbers.  Secondly, a GWAS identified 89 SNPs of suggestive significance, largely 
 166 
within six key regions of the genome; four of the six regions were implicated in immune 
system functioning or have some previous link to an MS-related pathway and so may be 
useful for further study, while one was in the known HLA region. 
Thirdly, a tag SNP for the most strongly associated MS risk variant, HLA-DRB1*1501, 
was found to have a significantly higher frequency in Orkney (0.23) and Shetland (0.21) 
than mainland Scotland (0.17).  This SNP equates to causing 6 cases (95% CI 3, 8) out of 
150 observed excess cases per 100,000 individuals in Shetland and 9 cases (95% CI 8, 11) 
of the observed 257 excess cases per 100,000 individuals in Orkney.  This SNP therefore 
explains approximately 4% of the excess cases found in both populations. 
Finally, common risk variants in general (not including the HLA-DRB1*1501 tag SNP) 
were not found to differ between mainland Scotland and Orkney and Shetland.  Overall, 
they explained 3% of the variance of MS risk in the Northern Isles; the HLA-DRB1*1501 
SNP accounted for 1% of this.   
The results in this study have shown that common variants do not dominate the excess 
MS risk in Orkney and Shetland and have provided several suggestive candidate 
variants for follow up studies.  A small part of the picture of MS in the Northern Isles 
has been painted here, but much remains to be elucidated about the disease.  It is likely 
that variants of multiple frequencies likely contribute to the genetic architecture of MS, 
rather than one sole contributor.   
It is known that environmental factors have a strong influence of MS, and here I have 
shown that genetics make at least a small contribution to the excess rates of MS in this 
region.  
However, the cause of the excess MS prevalence in the Northern Isles remains mostly 
unexplained and is still a case for investigation.  Based on previous findings as well as 
the findings in this thesis, I think that the excess prevalence of MS can likely be 
attributed to several factors.  The biggest proportion of excess cases is likely caused by 
rare variants with strong effects.  Smaller contributions will also be made from the high 
rates of overweight and obesity found in the islands: being obese raises risk of MS, but 
also has interactive effects with genetic variants, further increasing disease risk.  A 
higher frequency of HLA-DRB1*1501 is causing a small number of cases, but I think that 
there may be further gene-environment interactive effects from this variant that 
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contribute to MS risk.  I also think it would be worth investigating heavy metal levels 
within the Northern Isles, as heavy metals have been associated with other MS hotspots. 
 
6.3.6 Conclusion 
Genetic studies of Multiple Sclerosis have progressed immensely over the past few 
years.  MS has changed from an unknown and untreatable disease to a more 
manageable condition which we now understand with greater clarity. Genetic studies of 
MS indicate that the immune system is the primary source of MS pathology, with 
variants of numerous frequencies influencing disease risk along with multiple 
environmental factors.  Identifying additional variants and determining their function 
and interactions with the environment will give us new information to leverage as novel 
targets for therapy, prevention and personalised healthcare. 
A major goal for MS research is developing precision medicine for the disease with 
personalised treatments tailored towards sub-populations with unique causative 
profiles.  This could prove particularly useful for communities such as the Northern 
Isles, who likely have a unique risk profile and would benefit greatly from personalised 
healthcare strategies.   
Researching MS has the potential to bring to light new surprises, leading to a changing 
understanding of the disease with each new discovery made.  The future of MS research 
in the Northern Isles and beyond will lie in new methods to discover and explore the 
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Aetiology The cause(s) of a disease or condition 
Epidemiology The study of health and disease determinants and distributions 
Incidence rate The number of new cases that develop in a population within a specific time-period 
Inflammatory disease 
A group of diseases which result from an individual’s 
immune system attacking the body’s own cells or 
tissues 
Prevalence rate The number of cases present in a population at a specific point in time 
 
Genetic vocabulary 
Additive genetic effects When the combined effects of alleles are equal to the sum of their individual effects 
Allele One form of a given gene 
Allelic Dosage The estimated number of copies of each allele 
Batch effects Variation introduced to samples due to laboratory handling procedures 
Call rate The number of SNPs on a chip receiving a genotype call divided by the total number of SNPs 
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Candidate gene study A study that evaluates genetic variation in a specific region of genes, chosen using prior knowledge 
Causal variant 
A variant that has a causal effect on a trait (as opposed 
to a variant that is only associated with a trait due to 
LD) 
Common variant A variant with a population frequency greater than 5% 
Complex disease A disease influenced by a combination of environmental factors and multiple genes 
Copy number variation 
Where sections of the genome are repeated, with the 
number of repeats varying between individuals in a 
population 
Deletion A type of DNA mutation where part of a DNA sequence is lost during DNA replication 
Disease risk factor Any attribute or exposure that increases an individual’s likelihood of developing a disease 
DNA strand 
DNA is double-stranded; for a reference chromosome, 
one of these strands is deemed the forward or plus 
strand, while the complimentary strand is deemed the 
reverse or minus strand 
Dominance  Where an allele at one gene masks the contribution of another allele at the same gene 
Effect size The affect size of an allele is the magnitude of the effect on the phenotype 
Enhancer region A short stretch of DNA which increases the likelihood of transcription of a nearby gene 
Epigenetics The study of heritable changes within the phenotype that are not caused by DNA sequence alterations 
Epistasis 
Interactions between genes where the effect of one 
gene is dependent on the presence of one or more 
modifier genes 
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Exon A region of DNA or RNA that codes for a protein or peptide sequence 
Exon splicing A process where introns are removed, and exons are joined together 
Fine-mapping 
A method used to determine the causal variant, by 
taking evidence of association from a GWAS to identify 
and subsequently explore regions of interest for 
independent effects on the trait 
Gene 
A region of DNA which can influence one or more 
phenotypes and can be transferred from parent to 
offspring 
Gene expression The process where information from a gene is used to synthesize a gene product 
Genetic bottleneck A sharp decline in the size of a population due to an extreme event(s) such as famine or genocide 
Genetic drift The change in frequency of an allele in a population due to random sampling 
Genetic variant An alteration in a common DNA sequence; includes SNPs and insertions/deletions 
Genome The full set of genetic material present in an organism or cell 
Genome-wide association 
study (GWAS) 
A method used to detect associations between a trait of 
interest and genetic variants in a population sample 
Genotype The genetic composition of an organism, or more specifically the set of alleles carried by an organism 
Genotyping platforms Equipment designed to carry out genotyping, for example array technologies 
Haplotype A group of alleles that tend to always occur together and are likely inherited together  
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Haplotype reference 
consortium A large reference panel of human haplotypes 
Hardy-Weinberg 
equilibrium 
An equation that can be used to calculate genetic 
variation of a population at equilibrium.  The principal 
of the HWE states that the genetic variation (allele 
frequencies) within a population will remain constant 
between generations in the absence of disrupting 
factors 
Heritability 
The proportion of variance of a trait within a 
population at a specific time that is due to genetic 
variation between individuals 
Heterozygosity The possession of two different alleles of a gene by an individual 
High throughput 
technologies 
Refers to sequencing techniques which allows large 
amounts of DNA to be sequenced at once 
Homozygosity The possession of two identical alleles of a gene by an individual 
Human leukocyte antigen 
complex 
A gene complex that encodes the major 
histocompatibility complex in humans 
Identity by descent 
Identical segments of DNA which are shared by two or 
more people that have been inherited from a common 
ancestor 
Identity by state Identical segments of DNA which is shared by two or more people that do not have a common ancestor 
Imputation The statistical inference to determine unobserved genotypes 
Inbreeding The production of offspring from mating closely genetically related individuals 
Insertion A type of DNA mutation where one or more nucleotide base pairs are inserted into a DNA sequence 
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Intragenic A stretch of DNA sequence that is positioned between genes 
Intron A region of DNA or RNA within a gene that does not code for a protein 
Inversion A type of DNA mutation where a segment of a chromosome is reversed end to end 
Jackpot effect 
Where the frequency of a rare variant is increased in a 
population or group by chance due to population 
events 
Linkage disequilibrium The non-random association between alleles at separate loci 
Linkage study 
A family-based study used to map a trait to a specific 
location in the genome through the identification of 
segments of DNA that co-segregate with the trait 
through families 
Locus A location on a chromosome 
Low frequency variant A variant with a minor allele frequency between 0.5% and 5% 
Major histocompatibility 
complex 
A gene complex that codes for cell surface proteins, 
necessary for the acquired immune system to 
recognise foreign molecules 
Marker A DNA sequence whose locus on the genome is known 
Mendelian disease Diseases caused by mutations found in one gene 
Mendelian randomisation 
Where genetic variants are used as instrumental 
variables to determine if a modifiable exposure is 
causally related to a specific trait. 
Monogenic disease A disease caused by a single defective gene 
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Mutation 
A permanent alteration of the DNA sequence of a gene, 
caused by altering a single nucleotide or the deletion, 
insertion or rearrangement of DNA segments 
Non-synonymous mutation A change in the DNA sequence that changes an amino acid within a protein 
Oligogenic disease A disease which is caused by a small number of genes 
Parent-of-origin effect 
When the phenotypic effect of an allele depends on 
whether it is inherited from an individual’s father or 
mother 
Phasing Assigning alleles to maternal and paternal chromosomes 
Phenotype An observable physical property in an organism resulting from both its genotype and environment 
Pleiotropic When one gene influences more than one phenotypic trait 
Polygenic risk score A genetic risk score based on genetic loci and their associated weights 
Polygenic trait A trait controlled by more than one gene 
Population stratification 
The presence of systematic differences in allele 
frequencies between groups within a population, for 
example due to different ancestries 
Population structure 
The presence of subpopulations within a population 
which can have differences to the main population, e.g. 
in allele frequency 
Promotor region A region of DNA that leads to the start of transcription of a specific gene 
Protein isoforms 
Very similar proteins that originate from the same 
gene but have differences in structure and function 
due to genetic differences 
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Proxy variant A variant which represents another, usually due to very high LD between the two variants 
Rare variant A variant with a minor allele frequency below 0.5%  
Recessive  
Relating to a trait controlled by genes which are 
expressed only when the variant is inherited from both 
parents 
Recombination rate 
The rate at which recombination happens; the process 
where DNA is broken and recombined to create new 
allele combinations 
Recurrence rate The risk that offspring will be affected by a disease or trait given a specific set of relatives 
Reference allele The allele that is found in the reference genome; not necessarily the major allele 
Relatedness coefficient A measure of the degree of consanguinity between two individuals; double the kinship coefficient 
Reproductive fitness The reproductive success of an individual; a quantitative representation of selection 
Risk allele The allele which confers a risk of developing a trait, usually a disease 
Single nucleotide 
polymorphism 
A single substitution of a nucleotide within a DNA 
sequence 
SNP array 
A group of microscopic DNA spots attached to a 
surface, designed to detect single nucleotide 
polymorphisms within individuals 
Splicing The process of removing introns and joining exons together in messenger RNA 
Strand flip Changing the strand (plus or minus) of a SNP  
Synonymous mutation A change in the DNA sequence that codes for an amino acid, but the amino acid is not changed 
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Tag SNP A SNP that exists in a region of high LD that is used to represent a specific haplotype 
Transcription The process by which DNA is copied into RNA by RNA polymerase; it is the first stage of gene expression 
Translation The process of translating a sequence of mRNA to amino acids to synthesise proteins 
Translocation 
The movement of a segment of chromosome from one 
position to another (either on the same or different 
chromosome) 
Whole-genome sequencing The process of determining an organism’s complete DNA sequence 
Winner's curse 
The tendency for initial studies of a trait to 
overestimate the effect size of some variants, the very 
fact it was found in that study generates an upward 
bias in the estimate.  
 
Mathematical vocabulary 
Area under the curve (AUC) 
The area under a curve; when used in relation to a 
ROC curve, it can be used as a method of evaluating a 
model’s performance, with a high AUC value 
corresponding to a better predictive ability of the 
model 
Association test A study used to determine if a genetic variant is associated with a specific trait 
Beta The resulting coefficient from a model fit; gives an indication of effect size 
Chi-squared statistic  A measurement for how expectation of data compares to observed data 
 217 
Confounding 
Occurs when a variable influences both the 
independent and dependent variable to cause a 
spurious association 
Correlation coefficient A number between -1 and 1 that describes a linear dependence between two variables 
Covariate A variable that may be predictive of the outcome of a study, or may be a confounding or interacting variable 
Fixed effects model 
A model where the independent variables are constant, 
with only the dependent variable changing in response 
to differing levels of independent variables 
Genetic relationship matrix 
(GRM) 
A matrix of genetic pairwise relationships for a group 
of individuals, where genetic relationships are 




A statistical method used to estimate SNP heritability 
GRAMMAR+ Residuals 
Residuals (the difference between an observed value 
and its estimated value) produced using the genome 
wide rapid association using mixed model and 
regression 
Incidence matrix A matrix containing relationship-values between two classes of objects 
Kinship coefficient 
The probability that a pair of randomly sampled alleles 
from two individuals are identical and from the same 
ancestor; a measure of relatedness 
Kinship matrix A matrix containing kinship coefficient values for a group of individuals 
Liability 
In the context of genetics, liability describes the 
collective contribution of genetic and environmental 
factors in developing a trait (usually a disease) 
Linear fixed effects model A linear regression model that only uses fixed effects 
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Linear mixed effects model A linear regression model that uses both fixed and random effects 
Linear regression 
A predictive analysis that models the relationship 
between a dependent variable and one or more 
independent variables using a linear approach 
Linkage disequilibrium 
score regression (LDSR) 
A statistical approach to quantify the contribution of 
polygenic effects and confounding factors using GWAS 
summary statistics 
Log likelihood 
The natural logarithm of the likelihood; used to 
determine optimal values for the coefficients estimated 
by a model 
Logistic regression 
A predictive analysis that models the relationship 
between a dependent variable and one or more 
independent variables where the dependent variable is 
binary  
Logit transformation A method to transform sigmoid distributions into a linear distribution 
Meta-analysis Pooling data from multiple independent studies on a trait to determine an overall effect 
Nagelkerke’s pseudo r2 
A metric used to determine the goodness-of-fit of a 
model by comparing the improvement of the full 
model compared to the intercept model 
Normal cumulative 
distribution 
A function that shows the area under the probability 
density function from minus infinity to x, the 
distribution of random variable X; it is a logistic 
distribution 
Normal probability density 
function 
A function that describes a probability distribution for 
a continuous random variable, where the AUC for a 
given interval on the x-axis is the probability of the 
random variable occurring 
Null model 
A model generated with random samples under a 
specific distribution where some elements are 
constant, and some can vary stochastically; for 
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example, the null model for Y = ô + ö1õ + ú would be Y 
= ô + ú, where ô + ú would be equal to the mean of Y 
Odds ratio 
A measurement of the strength of association between 
two events A and B; it is the ratio of the odds of B 
occurring in the presence of A and the odds of B 
occurring in the absence of A; a value above 1 indicates 
A and B are positively correlated, a value below 1 
indicates A and B are negatively correlated, and a value 
of 1 indicates A and B are independent 
Power The probability of a test to reject a false null hypothesis 
Principal component 
analysis 
A method that converts a group of observations which 
may be correlated into linearly uncorrelated variables 
(called principal components); the first component 
accounts for as much variability in the data as possible, 
and every subsequent component has the highest 
variance under the constraints of the preceding 
components; it can be used to visualise genetic 
distance and relatedness  
p-value The probability of finding observed results when the null hypothesis of a study is true 
Quantile-Quantile (Q-Q) 
plot 
A probability plot that compares the quantiles from 
two distributions (with the x and y axis corresponding 
to the two distributions); if the points lie 
approximately along y=x, the distributions are deemed 
similar 
Random effects model A model where the model parameters are random variables 
Rare variant burden test A test that combines rare variant information within a single region into a summary dose variable  
Receiver Operator 
Characteristic (ROC) curve 
A curve which plots the true positive rate (sensitivity) 
against the false positive rate (specificity) of a binary 
classifier model to determine its diagnostic ability 
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Significance threshold 
A threshold chosen for a specific test; corresponds to 
an appropriate probability of committing a type I error 
(or registering a false positive) 
Standard deviation 
A measure used to quantify the dispersion of a set of 
data values; a high standard deviation indicates that 
data points are spread out over a wide range of values 
Two-sample t-test A statistical test that is used to test the difference between two population means 
Type I error / False Positive When the null hypothesis is true, but is rejected 
Type II error / False 
Negative When the null hypothesis is false, but is not rejected 
Vector A quantity that has both direction and magnitude; they remain invariant to the coordinate system 




A subsystem of the immune system made up of 
specialized cells and processes that destroy pathogens 
or prevent pathogen growth; it creates an 
immunological memory after an initial pathogen 
response 
Antibody 
A protein produced in response to the presence of an 
antigen; antibodies attach to antigens to help remove 
pathogens from the body 
Antibody effector function 
The action of an antibody to destroy or neutralise a 
pathogen, for example antigens can block pathogen 
action or activate other parts of the immune system  
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Antigen 
A foreign or toxic substance which can produce an 
immune response, particularly via increasing antibody 
production 
Astrocyte 
Star-shaped non-neuronal cells found in the brain and 
spinal cord; a large variety exist and help in CNS 
functioning 
Autoreactive Acting against the organism that produced it 
Axon The nerve fibre for a neuron that conducts electrical impulses away from the neuron body 
B cell 
A white blood cell which is part of the adaptive 
immune system; can bind to specific antigens to 
initiate an antibody response, as well as present 
antigens and secrete cytokines 
Blood brain barrier A semi-permeable barrier that separates circulating blood from the brain and CNS fluid 
Bystander signal 
A bystander signal can occur in cytokines and cause 
bystander T cell activation, which enables T cells to 
bypass some control checkpoints 
Cation A positively charged ion 
Cell-mediated immunity 
Part of the immune system which does not involve 
antibodies; it can include the activation of phagocytes, 
release of cytokines and activation of antigen-specific 
cytotoxic T cells 
Chemokine A small signalling molecule secreted by cells that function to attract immune cells to an infection site 
Chromatin A combination of protein, RNA and DNA which together make up the chromosomes of an organism 
Complement system A biochemical cascade that helps antibodies to remove or mark pathogens 
Cortical tissue The outer layer of the cerebrum in the brain 
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Cytokines 
A large group of substances which are secreted by 
immune cells to induce an effect in another cell; 
includes interleukin, interferons and growth factors 
Cytotoxic T cells 
Also known as CD8+ T cells, these cells function to kill 
damaged or infected cells, as well as cancer cells; they 
express T cell receptors which can recognise antigens 
and produce an immune response 
Dendritic cells 
Antigen presenting cells – they process antigen 
material and present it on their surface to attract T 
cells 
Differentiation The process by which a cell develops to become more specialised and perform a specific function 
DNA methylation 
The addition of methyl groups to a DNA molecule to 
change the activity of that DNA, for example to repress 
gene transcription 
Enzyme A protein that acts as a biological catalyst 
Experimental autoimmune 
encephalomyelitis  
An animal model for brain inflammation that is very 
similar to Multiple Sclerosis; it is an inflammatory 
demyelinating disease of the CNS 
Helper T cell Also known as CD4+ T cells, they help activate B cells, macrophages and cytotoxic T cells 
Hematopoietic stem cells Stem cells that give rise to blood cells; occurs in the bone marrow 
Humoral immunity 
Part of the immune system that is mediated by 
macromolecules found in extracellular fluids, for 
example secreted antibodies 
IgG antibodies 
The most common type of antibody in blood 
circulation, it is produced and released by plasma B 
cells 
Immunoglobulin An antibody that attaches to the B cell membrane 
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Innate immune system 
Non-specific defence mechanisms within the immune 
system to remove pathogens and toxic substances, 
including physical barriers (for example, the skin), 
inflammation and white blood cell activity 
Interferons Signalling proteins that are produced in response to viral infection 
Interleukin-1 family (IL-1) A group of cytokines that help regulate immune and inflammatory responses 
Leukocyte 
Also known as a white blood cell, leukocytes circulate 
primarily in the blood and help counteract toxic 
substances, pathogens and disease 
Lymphocytes 
A type of white blood cell that is essential for immune 
responses; the two main types of lymphocytes are B 
cells and T cells 
Lymphoid organ Organs or parts of tissues in which lymphocytes can differentiate and proliferate 
Macrophages A large white blood cell which can phagocytose or 'eat' particles, for example bacteria and viruses 
Metabolites A molecule essential to or formed in the metabolic process, for example amino acids 
MHC class I molecules Found on the surface of all nucleated cells; act to display peptide fragments to cytotoxic T cells 
MHC class II molecules 
Found on the surface of professional antigen 
presenting cells such as dendritic cells; act to display 
antigens to initiate an immune response 
Microglia Non-neuronal cells that function as macrophages in the CNS 
Monoclonal A monoclonal cell is produced from a single ancestral cell – it is a clone of the original cell 
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Monocytes 
A type of white blood cell that can help destroy 
pathogens and can differentiate into macrophages and 
dendritic cells 
Myelin sheath An insulating cover that wraps around an axon, it helps increase the speed of nerve impulses 
Naive T cells A mature T cell that has not yet encountered an antigen 
Natural killer (NK) cells 
A type of white blood cell and part of the innate 
immune system, NK cells reject both virally infected 
cells and tumour cells; similar to cytotoxic T cells, 
except NK cells cannot recognise antigens 
Oligoclonal bands 
Bands of immunoglobulins that can be seen when an 
individual’s cerebrospinal fluid or blood serum is 
analysed; can be used to diagnose disease such as MS 
Oligodendrocytes A non-neuronal cell that myelinates CNS axons 
Peptide  A molecule containing two or more amino acids, they are shorter in amino acid chain length than proteins 
Phagocytes A type of cell that can engulf and absorb pathogens and other particles 
Plasma B cells Also called effector B cells, these B cells secrete antibodies in response to antigen presentation 
Post-translational histone 
modification 
A method of regulating gene expression; the genome is 
organised into active euchromatin (where DNA can be 
transcribed) or inactive heterochromatin (where DNA 
is less accessible for transcription) 
Proinflammatory The opposite of anti-inflammatory; the act of increasing inflammation and making a disease worse 
Proliferation  The rapid increase in number of a substance, such as a cell 
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Regulatory T cells 
A subgroup of T cells that help regulate the immune 
system, prevent autoimmune disease, and maintain 
tolerance to self-antigens 
Remyelination 
The process of forming oligodendrocytes to create new 
myelin sheaths around demyelinated axons within the 
CNS 
T cells 
A lymphocyte which possesses specific cell-surface 
antigen receptors, they function to recognise foreign 
tissues and infected cells and directs the immune 
system in response; produced in the thymus 



































(A1) SE P Info 
. 1_145044288 1 145044288 C T 0.09 0.15 0.03 4.44 x 10-8 0.50 
rs34584371 2_153037808 2 153037808 A G 0.12 0.08 0.02 4.01 x 10-6 0.99 
rs72932144 2_177553322 2 177553322 T C 0.32 0.06 0.01 5.30 x 10-7 1.00 
rs11691194 2_177553829 2 177553829 A G 0.32 0.06 0.01 4.06 x 10-7 1.00 
rs955972 2_177555937 2 177555937 A G 0.34 0.05 0.01 1.48 x 10-6 1.00 
rs955973 2_177556099 2 177556099 G A 0.42 0.05 0.01 6.74 x 10-7 0.99 
rs17786781 2_177556469 2 177556469 G A 0.32 0.06 0.01 4.10 x 10-7 1.00 
rs2885628 2_177561074 2 177561074 T A 0.33 0.05 0.01 1.43 x 10-6 1.00 
rs10207615 2_177561365 2 177561365 A C 0.32 0.06 0.01 3.13 x 10-7 1.00 
rs13413215 2_177563646 2 177563646 T A 0.32 0.06 0.01 3.04 x 10-7 1.00 
rs72929573 2_177568452 2 177568452 A G 0.32 0.06 0.01 1.67 x 10-7 0.99 
rs1398972 2_177569251 2 177569251 C G 0.32 0.06 0.01 1.49 x 10-7 0.99 
rs72929579 2_177570137 2 177570137 A C 0.32 0.06 0.01 1.51 x 10-7 0.99 
rs6433609 2_177572596 2 177572596 T C 0.32 0.06 0.01 1.85 x 10-7 0.99 
rs113441701 2_177572715 2 177572715 A G 0.32 0.06 0.01 1.80 x 10-7 0.99 
rs72929586 2_177573625 2 177573625 T C 0.32 0.06 0.01 1.50 x 10-7 0.99 
rs7635898 3_55408967 3 55408967 C A 0.09 0.09 0.02 3.87 x 10-6 0.84 
rs816545 3_156092170 3 156092170 T C 0.05 0.11 0.02 5.42 x 10-6 0.93 
rs73221623 3_196370840 3 196370840 T C 0.10 0.08 0.02 4.43 x 10-6 0.97 
. 6_32237926 6 32237926 C T 0.78 -0.06 0.01 9.60 x 10-6 1.00 
. 6_32245370 6 32245370 G A 0.78 -0.06 0.01 9.65 x 10-6 1.00 
. 6_32259527 6 32259527 A G 0.78 -0.06 0.01 9.75 x 10-6 1.00 
rs9268154 6_32266021 6 32266021 A T 0.78 -0.06 0.01 9.65 x 10-6 1.00 
rs9268155 6_32266310 6 32266310 C T 0.78 -0.06 0.01 9.68 x 10-6 1.00 
. 6_32279938 6 32279938 G A 0.78 -0.06 0.01 9.50 x 10-6 1.00 
. 6_32289390 6 32289390 C A 0.78 -0.06 0.01 9.34 x 10-6 1.00 
. 6_32300809 6 32300809 G A 0.78 -0.06 0.01 6.95 x 10-6 1.00 
. 6_32305979 6 32305979 T G 0.78 -0.06 0.01 6.33 x 10-6 1.00 
. 6_32316016 6 32316016 G T 0.78 -0.06 0.01 6.93 x 10-6 1.00 
. 6_32318610 6 32318610 A G 0.78 -0.06 0.01 7.37 x 10-6 1.00 
. 6_32320153 6 32320153 A G 0.78 -0.06 0.01 7.02 x 10-6 1.00 
. 6_32336187 6 32336187 C T 0.78 -0.06 0.01 6.83 x 10-6 1.00 
. 6_32336495 6 32336495 A T 0.78 -0.06 0.01 7.18 x 10-6 1.00 
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. 6_32392906 6 32392906 A C 0.79 -0.06 0.01 9.69 x 10-6 1.00 
. 6_32393235 6 32393235 C G 0.79 -0.06 0.01 9.71 x 10-6 1.00 
. 6_32397309 6 32397309 G A 0.74 -0.06 0.01 6.32 x 10-6 1.00 
. 6_32397784 6 32397784 A G 0.74 -0.06 0.01 6.27 x 10-6 1.00 
. 6_32398748 6 32398748 A C 0.74 -0.06 0.01 6.29 x 10-6 1.00 
. 6_32399159 6 32399159 C T 0.74 -0.06 0.01 6.27 x 10-6 1.00 
. 6_32402686 6 32402686 T C 0.74 -0.06 0.01 6.31 x 10-6 1.00 
. 6_32406473 6 32406473 G A 0.74 -0.06 0.01 7.46 x 10-6 1.00 
. 6_32406704 6 32406704 G T 0.74 -0.06 0.01 7.32 x 10-6 1.00 
. 6_32409058 6 32409058 C T 0.80 -0.06 0.01 5.91 x 10-6 0.99 
. 6_32411726 6 32411726 A G 0.75 -0.06 0.01 3.89 x 10-6 1.00 
. 6_32412580 6 32412580 C T 0.75 -0.06 0.01 5.90 x 10-6 1.00 
. 6_32415109 6 32415109 G T 0.75 -0.06 0.01 4.11 x 10-6 1.00 
rs12209200 6_57217336 6 57217336 T C 0.08 0.10 0.02 1.03 x 10-6 0.84 
rs4720446 7_4982335 7 4982335 C G 0.88 -0.07 0.02 7.56 x 10-6 0.98 
rs10965046 9_21518275 9 21518275 G A 0.14 0.07 0.02 7.92 x 10-6 0.98 
rs76585251 9_24750193 9 24750193 T G 0.07 0.10 0.02 2.20 x 10-6 0.95 
rs78870428 10_25662804 10 25662804 G A 0.10 0.09 0.02 6.60 x 10-6 0.86 
rs117374511 10_134496477 10 134496477 T C 0.06 0.10 0.02 6.97 x 10-6 0.91 
rs2268134 12_13997305 12 13997305 G T 0.09 0.08 0.02 7.22 x 10-6 1.00 
rs11055642 12_13999533 12 13999533 C T 0.09 0.08 0.02 7.18 x 10-6 1.00 
rs4280084 12_13999655 12 13999655 C T 0.09 0.08 0.02 7.03 x 10-6 1.00 
rs1861787 12_14000568 12 14000568 T G 0.09 0.09 0.02 6.07 x 10-6 1.00 
rs1861788 12_14000592 12 14000592 G A 0.13 0.08 0.02 1.45 x 10-6 1.00 
rs71459105 12_14001448 12 14001448 T C 0.09 0.08 0.02 6.11 x 10-6 1.00 
rs71459107 12_14003283 12 14003283 A G 0.13 0.07 0.02 5.50 x 10-6 1.00 
rs11055646 12_14005719 12 14005719 C T 0.13 0.08 0.02 5.62 x 10-7 1.00 
rs2268138 12_14007212 12 14007212 C A 0.09 0.09 0.02 2.40 x 10-6 1.00 
rs7297313 12_14008506 12 14008506 C A 0.13 0.08 0.02 5.83 x 10-7 1.00 
rs11055654 12_14022098 12 14022098 A G 0.09 0.08 0.02 7.69 x 10-6 1.00 
rs11055660 12_14029371 12 14029371 G A 0.14 0.07 0.02 5.45 x 10-6 0.99 
rs73162646 12_130464398 12 130464398 C T 0.13 0.08 0.02 1.52 x 10-6 0.99 
rs8008067 14_72941207 14 72941207 A G 0.07 0.10 0.02 2.39 x 10-6 0.88 
rs8041424 15_97359414 15 97359414 T C 0.06 0.11 0.02 1.86 x 10-6 0.95 
rs1604686 15_97385210 15 97385210 G A 0.09 0.09 0.02 6.43 x 10-6 0.95 
rs7199663 16_86608899 16 86608899 C A 0.16 0.07 0.01 1.90 x 10-6 0.95 
rs62048038 16_88727961 16 88727961 A T 0.08 0.09 0.02 4.79 x 10-6 0.92 
. 17_70738077 17 70738077 A G 0.75 -0.06 0.01 6.43 x 10-6 0.99 
rs62092559 18_19975654 18 19975654 G C 0.06 0.11 0.02 1.47 x 10-6 0.95 
rs112519464 18_19977947 18 19977947 A T 0.05 0.11 0.02 2.18 x 10-6 0.97 
rs34069471 18_19982454 18 19982454 C A 0.05 0.12 0.02 4.70 x 10-7 0.97 
rs62094163 18_19984094 18 19984094 T C 0.05 0.12 0.02 9.83 x 10-7 0.97 
rs73401039 18_19988535 18 19988535 T C 0.05 0.11 0.02 3.08 x 10-6 0.99 
rs73401040 18_19989378 18 19989378 T C 0.05 0.11 0.02 4.06 x 10-6 0.99 
rs1893251 18_19991432 18 19991432 T C 0.05 0.12 0.02 2.92 x 10-7 0.98 
rs17602961 18_36627629 18 36627629 A C 0.05 0.11 0.02 5.27 x 10-6 0.99 
rs1396651 18_36646561 18 36646561 A G 0.06 0.11 0.02 5.77 x 10-6 0.99 
rs1509215 18_36646764 18 36646764 T C 0.05 0.11 0.02 5.30 x 10-6 0.99 
rs77249263 18_36663604 18 36663604 G A 0.06 0.11 0.02 5.94 x 10-6 0.99 
rs62096323 18_56304224 18 56304224 G C 0.10 0.08 0.02 4.15 x 10-6 0.97 
rs55704994 18_56307599 18 56307599 T G 0.10 0.08 0.02 4.79 x 10-6 0.97 
rs10221425 18_56317005 18 56317005 T C 0.14 0.07 0.02 5.65 x 10-6 0.98 
rs62094974 18_56318728 18 56318728 A G 0.14 0.07 0.02 5.48 x 10-6 0.98 
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rs11872221 18_56319582 18 56319582 T A 0.14 0.07 0.02 4.88 x 10-6 0.98 
rs75479243 19_2739091 19 2739091 T C 0.08 0.10 0.02 9.17 x 10-6 0.85 
rs28752178 22_36833819 22 36833819 C T 0.11 0.08 0.02 2.62 x 10-6 0.99 
Supplementary Table 1: Results from GWAS in MS in ORCADES/VIKING dataset, 
where SNP p-value < 1 x 10-5 
Results from a GWAS of MS on the ORCADES/VIKING dataset (cases: 112, controls: 4223). Only 
SNPs which have passed the suggestive threshold of 1 x 10-5 are included.  However, it should be 
noted that only one of these SNPs passed the genome-wide significance threshold (SNPID 
chr1_145044288), and so beta values should be read with caution.  The RSID is the Reference 
SNP cluster ID.  SNPID is the chromosome number and base pair number, which is used to 
identify a SNP if an RSID has not been assigned, for example.  Chr is the chromosome the SNP is 
located on.  Position is the base pair position the SNP can be found at.  A1 is the reference allele, 
and A0 is the non-reference allele.  Freq is the frequency of the A1 allele within the dataset.  Beta 
is the effect size estimate.  SE is the standard error of the effect size estimate.  The p-value is the 
calculated probability or level of significance of the effect estimate.  The Info measure describes 
the information within the imputed genotypes relative to the information that would be 
presented if only the allele frequencies were known – for example, an info measure of 1 would 
denote that all genotypes are completely certain, whereas an info score of 0 would denote that 
the genotype probabilities are completely uncertain (Purcell et al., 2007). 
 
   












(95% CI) SD Min Max Statistic p-value 
A GS 127 8708 7.20 
(7.19 - 7.21) 
0.60 4.88 9.58 30 7.60 
(7.39 - 7.81) 
0.56 6.31 8.75 -3.86 5.74 x 10-4 
OR 127 2118 7.24 
(7.21 - 7.27) 
0.61 5.19 9.29 94 7.63 
(7.51 - 7.75) 
0.58 5.82 9.31 -6.35 5.86 x 10-9 
VIK 127 2156 7.26 
(7.23 - 7.28) 
0.62 5.30 9.56 16 7.66 
(7.42 - 7.89) 
0.45 6.58 8.52 -3.51 3.05 x 10-3 
B GS 126 8708 7.17 
(7.16 - 7.18) 
0.60 4.84 9.50 30 7.57 
(7.36 - 7.77) 
0.56 6.31 8.75 -3.88 5.42 x 10-4 
OR 126 2118 7.21 
(7.19 - 7.24) 
0.61 5.15 9.28 94 7.60 
(7.49 - 7.72) 
0.57 5.82 9.28 -6.43 4.07 x 10-9 
VIK 126 2156 7.23 
(7.20 - 7.26) 
0.62 5.26 9.52 16 7.62 
(7.39 - 7.86) 
0.44 6.58 8.48 -3.53 2.93 x 10-3 
C GS 101 8708 6.29 
(6.28 - 6.30) 
0.54 4.39 8.55 30 6.69 
(6.50 - 6.87) 
0.50 5.20 7.54 -4.35 1.52 x 10-4 
OR 101 2118 6.36 
(6.33 - 6.38) 
0.55 4.40 8.34 94 6.70 
(6.60 - 6.80) 
0.48 5.34 7.79 -6.66 1.30 x 10-9 
VIK 101 2156 6.33 
(6.31 - 6.36) 
0.55 4.76 8.12 16 6.69 
(6.40 - 6.98) 
0.55 5.59 7.56 -2.57 2.13 x 10-2 
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D GS 61 8708 4.32 
(4.31 - 4.33) 
0.44 2.90 6.05 30 4.63 
(4.46 - 4.80) 
0.45 3.65 5.60 -3.82 6.54 x 10-4 
OR 61 2118 4.38 
(4.36 - 4.40) 
0.46 3.11 5.89 94 4.66 
(4.56 - 4.76) 
0.47 3.61 5.62 -5.62 1.67 x 10-7 
VIK 61 2156 4.37 
(4.35 - 4.39) 
0.47 3.18 5.93 16 4.67 
(4.43 - 4.91) 
0.46 3.97 5.28 -2.61 1.96 x 10-2 
 
Supplementary Table 2: Polygenic risk score p-value threshold group descriptive 
statistics 
Descriptive statistics for the polygenic risk scores at the four different p-value threshold (pT) 
groups: pT A = 0.05; pT B = 0.0005; pT C = 0.000005; pT D = 0.00000005, for the three 
population groups (pop = population; OR = ORCADES; VIK = VIKING; GS = Generation 
Scotland).  Two-sample t-test statistics for comparing the mean values of cases and controls is 
also included. 
 
RSID CHR BP RA OR 
OR 
p-Value 
RAF GS/ORCADES GS/VIKING 
GS ORC VIK χ2 p-value χ2 p-value 
rs4648356 1 2709164 C 1.16 1.00 x 10-14 0.67 0.68 0.70 2.02 0.16 16.49 4.89 x 10-5 
rs912961 1 10356848 G 1.34 3.00 x 10-10 0.33 0.32 0.35 4.04 0.04 6.22 0.01 
rs233100 1 85772009 G 1.09 1.00 x 10-6 0.56 0.56 0.55 0.04 0.84 2.08 0.15 
rs11810217 1 93148377 A 1.15 5.80 x 10-15 0.27 0.26 0.24 1.86 0.17 15.37 8.86 x 10-5 
rs12048904 1 101331536 A 1.1 4.00 x 10-8 0.38 0.38 0.37 0.03 0.86 1.38 0.24 
rs11581062 1 101407519 G 1.13 2.50 x 10-10 0.30 0.28 0.30 8.26 4.06 x 10-3 0.19 0.66 
rs1335532 1 117100957 A 1.2 6.86 x 10-22 0.86 0.86 0.88 0.00 0.99 6.01 0.01 
rs3761959 1 157669278 G 1.1 2.90 x 10-6 0.53 0.53 0.53 0.24 0.62 0.16 0.69 
rs1323292 1 192541021 A 1.12 2.30 x 10-8 0.82 0.81 0.79 4.20 0.04 32.43 1.23 x 10-8 
rs7522462 1 200881595 G 1.11 1.90 x 10-9 0.70 0.68 0.66 8.44 3.66 x 10-3 25.42 4.61 x 10-7 
rs6718520 2 43325570 A 1.17 3.00 x 10-8 0.46 0.40 0.47 55.88 7.72 x 10-14 2.27 0.13 
rs12466022 2 43359061 C 1.1 6.20 x 10-10 0.72 0.71 0.74 2.53 0.11 5.66 0.02 
rs7592560 2 68647001 A 1.1 5.10 x 10-11 0.54 0.58 0.57 15.87 6.79 x 10-5 7.34 0.01 
rs17174870 2 112665201 G 1.1 1.30 x 10-8 0.74 0.74 0.71 0.00 0.98 24.13 9.00 x 10-7 
rs882300 2 136976255 C 1.19 1.00 x 10-7 0.53 0.51 0.50 4.77 0.03 17.44 2.97 x 10-5 
rs281783 2 200751582 A 1.11 0.00018 0.80 0.81 0.80 4.81 0.03 0.14 0.71 
rs10201872 2 231106724 A 1.13 1.80 x 10-10 0.17 0.16 0.14 3.57 0.06 21.77 3.08 x 10-6 
rs9821630 3 16970938 G 1.09 3.90 x 10-6 0.28 0.30 0.25 9.75 1.79 x 10-3 14.32 1.55 x 10-4 
rs11129295 3 27788780 T 1.11 1.20 x 10-9 0.35 0.42 0.37 85.49 2.33 x 10-20 5.35 0.02 
rs669607 3 28071444 C 1.13 1.90 x 10-15 0.47 0.43 0.43 29.77 4.86 x 10-8 24.60 7.04 x 10-7 
rs1500710 3 56914065 A 1.09 5.20 x 10-5 0.58 0.53 0.58 45.36 1.64 x 10-11 0.01 0.92 
rs771767 3 101748638 A 1.12 8.60 x 10-9 0.26 0.26 0.26 0.18 0.67 0.80 0.37 
rs9657904 3 105586714 T 1.4 2.00 x 10-10 0.79 0.75 0.75 31.24 2.28 x 10-8 33.85 5.95 x 10-9 
rs2293370 3 119219934 G 1.16 2.70 x 10-9 0.81 0.79 0.82 10.51 1.19 x 10-3 5.78 0.02 
rs4285028 3 121660664 A 1.11 1.80 x 10-8 0.74 0.73 0.75 1.22 0.27 2.88 0.09 
rs4308217 3 121793187 C 1.1 5.70 x 10-8 0.68 0.65 0.65 8.45 3.65 x 10-3 7.56 0.01 
rs9282641 3 121796768 G 1.2 1.00 x 10-11 0.92 0.92 0.91 0.35 0.56 5.06 0.02 
rs4680534 3 159698945 C 1.12 6.00 x 10-6 0.34 0.34 0.35 0.00 0.97 0.62 0.43 
rs2243123 3 159709651 C 1.09 7.20 x 10-6 0.28 0.27 0.30 5.73 0.02 5.75 0.02 
rs10936599 3 169492101 C 1.1 7.00 x 10-7 0.76 0.74 0.75 8.93 2.80 x 10-3 0.52 0.47 
rs228614 4 103578637 G 1.09 1.40 x 10-7 0.54 0.59 0.54 29.15 6.71 x 10-8 0.21 0.65 
rs6821894 4 186571441 T 1.08 9.20 x 10-5 0.62 0.59 0.60 17.36 3.09 x 10-5 7.22 0.01 
rs6897932 5 35874575 C 1.12 1.08 x 10-18 0.72 0.69 0.74 12.80 3.47 x 10-4 9.75 1.80 x 10-3 
rs350058 5 40211802 A 1.14 1.00 x 10-4 0.08 0.09 0.07 11.22 8.10 x 10-4 3.68 0.06 
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rs4613763 5 40392728 C 1.21 2.50 x 10-16 0.13 0.15 0.14 12.13 4.95 x 10-f04 9.21 2.41 x 10-3 
rs9292777 5 40437948 T 1.19 1.00 x 10-9 0.59 0.58 0.59 3.49 0.06 0.17 0.68 
rs756699 5 133446575 A 1.12 6.20 x 10-7 0.88 0.88 0.88 0.60 0.44 0.02 0.88 
rs6879677 5 140954954 A 1.08 0.00054 0.40 0.36 0.37 20.80 5.11 x 10-6 8.46 3.64 x 10-3 
rs1062158 5 141523000 A 1.09 2.30 x 10-6 0.62 0.59 0.65 13.43 2.48 x 10-4 14.86 1.16 x 10-4 
rs2546890 5 158759900 A 1.11 2.33 x 10-17 0.51 0.53 0.54 1.92 0.17 10.33 1.31 x 10-3 
rs10866713 5 158918894 A 1.17 7.00 x 10-7 0.21 0.20 0.18 5.18 0.02 22.10 2.59 x 10-6 
rs4075958 5 176784512 A 1.11 4.90 x 10-7 0.25 0.25 0.27 0.00 0.99 6.57 0.01 
rs11755724 6 7118990 A 1.08 2.60 x 10-6 0.36 0.34 0.35 8.24 4.10 x 10-3 0.64 0.43 
rs9260119 6 29910189 A 1.21 1.00 x 10-11 0.45 0.42 0.43 13.86 1.97 x 10-4 7.00 0.01 
rs9271069 6 32575700 A 2.77 < 1 x 10-50 0.17 0.23 0.21 103.00 3.36 x 10-24 44.93 2.05 x 10-11 
rs854917 6 90127390 A 1.09 0.00017 0.73 0.75 0.73 8.27 4.03 x 10-3 0.48 0.49 
rs12212193 6 90996769 G 1.09 3.80 x 10-8 0.45 0.53 0.47 97.45 5.53 x 10-23 3.88 0.05 
rs11962089 6 105612220 G 0.69 8.00 x 10-6 0.11 0.11 0.08 0.60 0.44 38.82 4.65 x 10-10 
rs802734 6 128278798 A 1.1 5.50 x 10-9 0.67 0.65 0.63 8.20 4.19 x 10-3 29.00 7.24 x 10-8 
rs9399141 6 135495574 C 1.12 1.60 x 10-6 0.23 0.22 0.26 2.16 0.14 12.56 3.94 x 10-4 
rs11154801 6 135739355 A 1.15 1.00 x 10-13 0.36 0.36 0.36 0.02 0.89 0.32 0.57 
rs17066096 6 137452908 G 1.14 6.00 x 10-13 0.24 0.28 0.28 37.87 7.58 x 10-10 28.79 8.07 x 10-8 
rs13192841 6 137967214 A 1.1 1.30 x 10-8 0.29 0.29 0.28 1.01 0.32 2.87 0.09 
rs1738074 6 159465977 C 1.14 1.56 x 10-20 0.55 0.53 0.54 4.46 0.03 0.85 0.36 
rs6952809 7 2448493 A 1.08 3.60 x 10-6 0.31 0.30 0.30 2.63 0.10 2.32 0.13 
rs1843938 7 3113034 A 1.09 1.10 x 10-5 0.44 0.46 0.42 2.81 0.09 9.81 1.73 x 10-3 
rs2214543 7 10796892 G 1.09 0.00016 0.74 0.75 0.73 4.04 0.04 0.07 0.79 
rs2066992 7 22768249 C 1.18 6.30 x 10-5 0.95 0.97 0.95 31.44 2.05 x 10-8 0.02 0.89 
rs11984075 7 37436854 G 1.13 1.10 x 10-5 0.11 0.10 0.11 4.82 0.03 0.42 0.52 
rs7789940 7 75951230 G 1.87 6.00 x 10-6 0.30 0.27 0.30 12.13 4.96 x 10-4 0.00 0.99 
rs354033 7 149289464 G 1.1 4.70 x 10-9 0.74 0.78 0.79 37.44 9.43 x 10-10 57.01 4.33 x 10-14 
rs6986386 8 9421789 A 1.09 1.60 x 10-5 0.23 0.24 0.23 0.88 0.35 0.44 0.51 
rs1520333 8 79401038 G 1.11 1.60 x 10-7 0.24 0.23 0.25 1.48 0.22 4.05 0.04 
rs4410871 8 128815029 G 1.11 7.70 x 10-9 0.70 0.70 0.72 0.05 0.82 9.37 2.21 x 10-3 
rs2019960 8 129192271 C 1.1 5.20 x 10-9 0.23 0.23 0.20 0.20 0.65 14.06 1.77 x 10-4 
rs6984045 8 131092413 C 1.59 2.00 x 10-6 0.03 0.04 0.03 6.89 0.01 2.34 0.13 
rs2150702 9 5893861 G 1.16 3.00 x 10-8 0.49 0.54 0.53 30.07 4.18 x 10-8 20.87 4.92 x 10-6 
rs290986 9 93563536 A 1.12 9.10 x 10-7 0.80 0.80 0.78 0.00 1.00 10.63 1.11 x 10-3 
rs10984447 9 121984553 A 1.17 8.00 x 10-6 0.74 0.74 0.74 0.01 0.91 0.06 0.80 
rs3780792 9 136835343 G 1.6 1.00 x 10-6 0.33 0.34 0.36 2.09 0.15 15.70 7.43 x 10-5 
rs12722489 10 6102012 C 1.24 6.41 x 10-15 0.84 0.82 0.80 3.63 0.06 41.40 1.24 x 10-10 
rs7090512 10 6110829 C 1.19 4.60 x 10-20 0.28 0.30 0.29 8.62 3.32 x 10-3 5.07 0.02 
rs793108 10 31415106 A 1.09 2.60 x 10-6 0.49 0.54 0.45 44.97 2.00 x 10-11 14.97 1.09 x 10-4 
rs2503875 10 43814049 A 1.66 2.00 x 10-7 0.29 0.29 0.27 0.84 0.36 2.21 0.14 
rs7912269 10 78727604 A 1.16 1.40 x 10-5 0.94 0.94 0.96 3.14 0.08 41.92 9.53 x 10-11 
rs1250550 10 81060317 A 1.1 6.30 x 10-9 0.36 0.36 0.36 0.31 0.58 0.60 0.44 
rs7923837 10 94481917 G 1.1 4.90 x 10-9 0.62 0.66 0.64 26.39 2.80 x 10-7 6.46 0.01 
rs17824933 11 60760612 G 1.18 4.00 x 10-9 0.23 0.22 0.24 4.36 0.04 2.01 0.16 
rs650258 11 60832282 C 1.12 2.00 x 10-11 0.64 0.66 0.61 5.21 0.02 17.21 3.35 x 10-5 
rs694739 11 64097233 A 1.08 0.00014 0.62 0.62 0.56 0.10 0.75 51.29 7.96 x 10-13 
rs4409785 11 95311422 G 1.11 6.30 x 10-7 0.19 0.22 0.14 29.83 4.72 x 10-8 55.00 1.20 x 10-13 
rs491111 11 116238034 G 1.08 0.00048 0.65 0.65 0.65 0.43 0.51 0.12 0.73 
rs630923 11 118754353 C 1.11 2.80 x 10-7 0.84 0.83 0.85 4.78 0.03 1.74 0.19 
rs7941030 11 122522375 C 1.09 1.60 x 10-5 0.39 0.38 0.41 1.94 0.16 6.92 0.01 
rs1800693 12 6440009 C 1.14 6.42 x 10-23 0.40 0.38 0.38 11.12 8.54 x 10-4 8.78 3.04 x 10-3 
rs4149584 12 6442643 T 1.58 5.00 x 10-6 0.02 0.02 0.02 4.71 0.03 0.00 1.00 
rs10466829 12 9876091 A 1.09 1.40 x 10-8 0.50 0.46 0.51 27.72 1.40 x 10-7 1.28 0.26 
rs703842 12 58162739 A 1.23 5.00 x 10-11 0.66 0.68 0.65 6.67 0.01 1.15 0.28 
rs1790100 12 123656725 G 1.11 7.00 x 10-7 0.21 0.20 0.21 1.03 0.31 0.00 0.95 
rs17594362 13 42139245 T 1.12 3.70 x 10-6 0.12 0.12 0.09 0.74 0.39 25.18 5.23 x 10-7 
rs806321 13 50841323 T 1.09 5.00 x 10-7 0.53 0.55 0.56 6.53 0.01 10.45 1.23 x 10-3 
rs9596270 13 50842440 T 1.35 7.00 x 10-7 0.93 0.90 0.92 64.84 8.14 x 10-16 9.73 1.81 x 10-3 
rs4902647 14 69254191 C 1.11 9.30 x 10-12 0.53 0.54 0.54 2.04 0.15 0.74 0.39 
rs2300603 14 76005557 T 1.11 2.00 x 10-8 0.76 0.73 0.71 20.94 4.75 x 10-6 48.62 3.11 x 10-12 
rs2119704 14 88487689 C 1.27 2.20 x 10-10 0.93 0.93 0.93 0.14 0.71 0.27 0.60 
rs449295 16 1074443 A 1.12 8.40 x 10-8 0.17 0.19 0.16 7.42 0.01 1.80 0.18 
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rs7200786 16 11177801 A 1.15 8.50 x 10-17 0.44 0.44 0.45 0.02 0.89 2.08 0.15 
rs7191700 16 11406803 C 1.15 6.00 x 10-7 0.66 0.68 0.67 3.97 0.05 1.23 0.27 
rs11864333 16 11475576 A 1.09 3.60 x 10-5 0.50 0.54 0.53 24.88 6.11 x 10-7 14.62 1.31 x 10-4 
rs8049603 16 23067260 T 1.19 1.00 x 10-6 0.23 0.21 0.23 9.02 2.68 x 10-3 0.00 0.98 
rs386965 16 79652541 G 1.09 3.90 x 10-6 0.21 0.21 0.27 0.14 0.70 74.54 5.93 x 10-18 
rs13333054 16 86011033 A 1.12 1.30 x 10-8 0.24 0.25 0.26 1.03 0.31 7.01 0.01 
rs17445836 16 86017663 G 1.25 4.00 x 10-9 0.77 0.76 0.79 1.13 0.29 15.59 7.88 x 10-5 
rs2293152 17 40481529 C 1.22 4.00 x 10-8 0.60 0.60 0.62 0.05 0.82 10.42 1.25 x 10-3 
rs9891119 17 40507980 C 1.1 1.80 x 10-10 0.35 0.33 0.39 5.92 0.01 26.49 2.65 x 10-7 
rs1373089 17 44915265 A 1.08 4.00 x 10-5 0.49 0.54 0.52 39.19 3.84 x 10-10 15.24 9.49 x 10-5 
rs8070463 17 45768836 T 1.15 1.00 x 10-7 0.46 0.48 0.45 4.29 0.04 3.07 0.08 
rs180515 17 58024275 G 1.11 8.80 x 10-8 0.36 0.36 0.36 1.23 0.27 0.01 0.94 
rs8081176 17 78283987 C 1.09 1.50 x 10-5 0.31 0.33 0.34 6.86 0.01 15.75 7.22 x 10-5 
rs12456021 18 56213390 A 1.1 3.60 x 10-6 0.19 0.23 0.18 34.31 4.70 x 10-9 1.83 0.18 
rs7238078 18 56384192 T 1.11 2.50 x 10-9 0.77 0.83 0.76 86.01 1.79 x 10-20 0.76 0.38 
rs1077667 19 6668972 C 1.16 9.40 x 10-14 0.78 0.82 0.80 25.78 3.82 x 10-7 8.47 3.62 x 10-3 
rs2278442 19 10444826 A 1.08 0.00012 0.65 0.62 0.69 15.81 7.01 x 10-5 33.81 6.09 x 10-9 
rs8112449 19 10520064 G 1.1 1.20 x 10-6 0.67 0.70 0.65 14.87 1.15 x 10-4 4.92 0.03 
rs10411936 19 16548375 A 1.16 2.00 x 10-7 0.30 0.32 0.34 6.85 0.01 24.55 7.23 x 10-7 
rs874628 19 18304700 A 1.12 1.30 x 10-8 0.68 0.71 0.73 16.92 3.91 x 10-5 46.48 9.26 x 10-12 
rs7255066 19 45146103 C 1.1 1.20 x 10-6 0.25 0.22 0.24 20.40 6.29 x 10-6 2.58 0.11 
rs6509314 19 47696626 T 1.1 4.60 x 10-7 0.70 0.70 0.68 0.21 0.65 6.92 0.01 
rs281380 19 49214470 G 1.08 1.90 x 10-6 0.33 0.39 0.32 74.35 6.55 x 10-18 1.87 0.17 
rs2303759 19 49869051 G 1.11 5.20 x 10-9 0.24 0.23 0.23 1.40 0.24 0.50 0.48 
rs6074022 20 44740196 C 1.17 3.56 x 10-12 0.25 0.27 0.26 8.05 4.54 x 10-3 0.26 0.61 
rs2762932 20 52768391 G 1.15 8.10 x 10-7 0.14 0.15 0.17 1.73 0.19 39.42 3.41 x 10-10 
rs2248359 20 52791518 C 1.12 2.50 x 10-11 0.59 0.65 0.58 51.56 6.96 x 10-13 1.05 0.30 
rs6062314 20 62409713 T 1.18 1.30 x 10-7 0.92 0.91 0.93 1.84 0.18 8.58 3.39 x 10-3 
rs2283792 22 22131125 C 1.09 4.70 x 10-9 0.51 0.52 0.51 0.74 0.39 0.01 0.93 
rs2072711 22 37268555 A 1.12 6.30 x 10-5 0.17 0.15 0.16 11.16 8.34 x 10-4 4.78 0.03 
rs140522 22 50971266 T 1.09 1.70 x 10-8 0.32 0.33 0.29 1.08 0.30 13.72 2.12 x 10-4 
 
Supplementary Table 3: Risk allele frequencies in mainland Scotland, Orkney and 
Shetland  
Risk allele frequencies (RAF) and Pearson’s chi-squared test values (with corresponding p-
values) for all (n=126) variants included in the PGRS calculation.  The chi-squared p-values are 
shown for two RAF comparisons between population controls: Generation Scotland (GS) and 
ORCADES (ORC); Generation Scotland and VIKING (VIK).  Significant results, corrected for 
multiple testing at 126 loci over two population comparisons (corrected p-value significance level 
of <1.98 x 10-4), are shown in bold.  Significant p-values from RAF that are higher in Generation 
Scotland than ORCADES or VIKING are highlighted in dark red, and significant p-values from 
RAF that are higher in ORCADES or VIKING than Generation Scotland are highlighted in light 
blue.  NB: RAF values are rounded to 2 decimal places.  This can result in values (such as 
rs4149584) that appear the same due to rounding but give differing p-values between 
populations. 
 
     95% CI 
A. pT 0.0005 ORCADES Beta SE Z score p-value Lower Upper 
(Intercept) -9.49 1.63 -5.82 5.82 x 10-9 -12.69 -6.30 
 232 
PGRS 1.14 0.21 5.49 4.14 x 10-8 0.74 1.55 
Age -0.01 0.01 -1.65 0.10 -0.03 0.00 
Sex -0.67 0.27 -2.48 0.01 -1.20 -0.14 
PC1 -1.81 6.41 -0.28 0.78 -14.37 10.76 
PC2 -10.73 11.60 -0.93 0.36 -33.47 12.01 
 
     95% CI 
B. pT 0.0005 VIKING Beta SE Z score p-value Lower Upper 
(Intercept) -14.32 3.68 -3.89 0.00 -21.54 -7.10 
PGRS 0.90 0.43 2.09 0.04 0.06 1.75 
Age 0.03 0.02 1.65 0.10 -0.01 0.07 
Sex 0.86 0.67 1.29 0.20 -0.45 2.16 
PC1 1.52 47.27 0.03 0.97 -91.13 94.17 
PC2 58.31 32.81 1.78 0.08 -5.99 122.61 
 
     95% CI 
C. pT 0.0005 GS Beta SE Z score p-value Lower Upper 
(Intercept) -14.20 2.43 -5.85 5.01 x 10-9 -18.96 -9.44 
PGRS 1.04 0.31 3.40 0.00 0.44 1.64 
Age 0.02 0.01 1.75 0.08 0.00 0.05 
Sex -1.20 0.49 -2.43 0.02 -2.16 -0.23 
PC1 6.62 21.32 0.31 0.76 -35.17 48.41 
PC2 -47.06 23.24 -2.02 0.04 -92.61 -1.50 
       
     95% CI 
D. pT 0.0005 ORCADES Beta SE Z score p-value Lower Upper 
(Intercept) -10.13 1.55 -6.55 5.93 x 10-11 -13.17 -7.10 
PGRS 1.10 0.20 5.40 6.61 x 10-8 0.70 1.50 
 
     95% CI 
E. pT 0.0005 VIKING Beta SE Z score p-value Lower Upper 
(Intercept) -10.70 3.26 -3.29 0.00 -17.09 -4.32 
PGRS 0.93 0.43 2.18 0.03 0.09 1.77 
 
     95% CI 
F. pT 0.0005 GS Beta SE Z score p-value Lower Upper 
(Intercept) -12.99 2.26 -5.75 9.17 x 10-9 -17.43 -8.56 
PGRS 1.00 0.30 3.34 0.00 0.41 1.58 
 
     95% CI 
G. pT 0.0005 without 
rs9271069 ORCADES 
Beta SE Z score p-value Lower Upper 
(Intercept) -8.10 1.74 -4.65 3.29 x 10-6 -11.52 -4.69 
PGRS 1.01 0.24 4.24 2.20 x 10-5 0.54 1.48 
Age -0.01 0.01 -1.79 0.07 -0.03 0.00 
Sex -0.65 0.27 -2.44 0.01 -1.17 -0.13 
PC1 -3.74 6.20 -0.60 0.55 -15.89 8.41 
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PC2 -8.55 11.16 -0.77 0.44 -30.42 13.32 
 
     95% CI 
H. pT 0.0005 without 
rs9271069 VIKING 
Beta SE Z score p-value Lower Upper 
(Intercept) -13.77 4.03 -3.42 6.38 x 10-4 -21.68 -5.87 
PGRS 0.86 0.51 1.70 0.09 -0.13 1.85 
Age 0.03 0.02 1.63 0.10 -0.01 0.07 
Sex 0.88 0.66 1.33 0.18 -0.42 2.18 
PC1 -1.35 45.89 -0.03 0.98 -91.29 88.60 
PC2 56.53 31.45 1.80 0.07 -5.11 118.16 
 
     95% CI 
I. pT 0.0005 without 
rs9271069 GS 
Beta SE Z score p-value Lower Upper 
(Intercept) -13.60 2.67 -5.09 3.53 x 10-7 -18.83 -8.36 
PGRS 1.00 0.35 2.81 4.99 x 10-3 0.30 1.69 
Age 0.02 0.01 1.69 0.09 0.00 0.05 
Sex -1.19 0.49 -2.42 0.02 -2.16 -0.23 
PC1 7.15 21.27 0.34 0.74 -34.54 48.84 




     95% CI 
K. pT 0.0005 without 
rs9271069 VIKING 
Beta SE Z score p-value Lower Upper 
(Intercept) -10.16 3.67 -2.76 5.71 x 10-3 -17.36 -2.95 
PGRS 0.89 0.50 1.76 0.08 -0.10 1.88 
 
     95% CI 
L. pT 0.0005 without 
rs9271069 GS 
Beta SE Z score p-value Lower Upper 
(Intercept) -12.42 2.52 -4.92 8.54 x 10-7 -17.37 -7.48 
PGRS 0.95 0.35 2.74 6.17 x 10-3 0.27 1.63 
 
     95% CI 
M. rs9271069 alone 
ORCADES 
Beta SE Z score p-value Lower Upper 
(Intercept) -1.47 0.47 -3.16 1.56 x 10-3 -2.39 -0.56 
PGRS 1.43 0.36 3.93 8.36 x 10-5 0.72 2.14 
     95% CI 
J. pT 0.0005 without 
rs9271069 ORCADES 
Beta SE Z score p-value Lower Upper 
(Intercept) -8.68 1.67 -5.20 2.01 x 10-7 -11.95 -5.41 
PGRS 0.95 0.23 4.09 4.27 x 10-5 0.49 1.40 
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Age -0.01 0.01 -1.58 0.11 -0.03 0.00 
Sex -0.61 0.27 -2.30 2.14 x 10-2 -1.13 -0.09 
PC1 -0.42 6.27 -0.07 0.95 -12.70 11.87 
PC2 -10.60 11.21 -0.95 0.34 -32.57 11.36 
 
     95% CI 
N. rs9271069 alone 
VIKING 
Beta SE Z score p-value Lower Upper 
(Intercept) -7.95 1.76 -4.51 6.39 x 10-6 -11.41 -4.50 
PGRS 1.07 0.84 1.27 0.20 -0.58 2.72 
Age 0.03 0.02 1.62 0.11 -0.01 0.07 
Sex 0.85 0.66 1.29 0.20 -0.45 2.15 
PC1 -7.83 44.25 -0.18 0.86 -94.55 78.89 
PC2 56.26 30.93 1.82 0.07 -4.36 116.89 
 
     95% CI 
O. rs9271069 alone GS Beta SE Z score p-value Lower Upper 
(Intercept) -6.79 0.72 -9.43 < 2 x 10-16 -8.20 -5.38 
PGRS 1.13 0.58 1.96 0.05 0.00 2.27 
Age 0.02 0.01 1.73 0.08 0.00 0.05 
Sex -1.17 0.49 -2.38 0.02 -2.14 -0.21 
PC1 5.33 21.35 0.25 0.80 -36.51 47.18 
PC2 -45.33 22.99 -1.97 0.05 -90.40 -0.27 
 
     95% CI 
P. rs9271069 alone 
ORCADES 
Beta SE Z score p-value Lower Upper 
(Intercept) -2.36 0.17 -13.81 < 2 x 10-16 -2.69 -2.02 
PGRS 1.41 0.35 3.98 7.00 x 10-5 0.71 2.10 
 
 
     95% CI 
Q. rs9271069 alone 
VIKING 
Beta SE Z score p-value Lower Upper 
(Intercept) -4.11 0.38 -10.86 < 2 x 10-16 -4.85 -3.37 
PGRS 1.14 0.82 1.40 0.16 -0.46 2.74 
 
 
     95% CI 
R. rs9271069 alone GS Beta SE Z score p-value Lower Upper 
(Intercept) -5.92 0.25 -23.96 < 2 x 10-16 -6.40 -5.44 
PGRS 1.15 0.58 1.99 0.05 0.02 2.29 
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Supplementary Table 4: Logistic regression results for predicting MS risk 
Logistic regression results for the model MS ~ PGRS + age + sex + PC1 + PC2 (letters A, B, C, G, 
H, I, M, N, O) and the model MS ~ PGRS (letters D, E, F, J, K, L, P, Q, R), using PGRS calculated 
from three SNP sets: pT 0.0005 (n SNPS = 126), pT 0.0005 without rs9271069 (n SNPs = 125) 
and rs9271069 only (n SNPs = 1), using three datasets: Generation Scotland (n cases = 30, n 
controls = 8708), ORCADES (n cases = 94, n controls = 2120) and VIKING (n cases = 16, n 




Supplementary Figure 1: Meta-analysed beta scores from MS risk prediction 
models 
Meta-analysed beta values for Generation Scotland (n cases = 30, n controls = 8708), ORCADES 
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(n cases = 94, n controls = 2120) and VIKING (n cases = 16, n controls = 2158) using beta values 
produced from the model MS~PGRS+age+sex+PC1+PC2, using three different SNP sets - pT 
0.0005 (n SNPS = 126), pT 0.0005 without rs9271069 (n SNPs = 125) and rs9271069 only (n 





Supplementary Figure 2: Meta-analysed AUC values 
Meta-analysed area under the curve (AUC) values for Generation Scotland (n cases = 30, n 
controls = 8708), ORCADES (n cases = 94, n controls = 2120) and VIKING (n cases = 16, n 
controls = 2158) using the model MS~PGRS+age+sex+PC1+PC2 and the model MS~PGRS. AUC 
values were calculated in three different SNP sets - pT 0.0005 (n SNPS = 126), pT 0.0005 
without rs9271069 (n SNPs = 125) and rs9271069 only (n SNPs = 1). 
 
